(19) World Intellectual Property Organization International Bureau



(43) International Publication Date 13 March 2003 (13.03.2003)

PCT

(10) International Publication Number WO 03/020923 A1

- (51) International Patent Classification7: C12N 9/24, 9/42
- (21) International Application Number: PCT/IB02/03797
- (22) International Filing Date: 30 August 2002 (30.08.2002)
- (25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

0121387.5

4 September 2001 (04.09.2001) GF

- (71) Applicant (for all designated States except US): DANISCO A/S [DK/DK]; Langebrogade 1, P.O. Box 17, Langebrogade 1, DK-1001 Copenhagen K (DK).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): SIBBESEN, Ole [DK/DK]; Værebrovej 117B, DK-2880 Bagsværd (DK). SØRENSEN, Jens, Frisbæk [DK/DK]; Nordvestpassagen 93, DK-2800 Aarhus (DK).
- (74) Agents: WILLIAMS, Aylsa et al.; D Young & Co, 21 New Fetter Lane, London EC4A 1DA (GB).

- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: XYLANASE VARIANTS

(57) Abstract: The present invention relates to a variant xylanase polypeptide, or fragment thereof having xylanase activity, comprising one or more amino acid modifications such that the polypeptide or fragment thereof has an altered sensitivity to a xylanase inhibitor and has an altered thermo-sensitivity as compared with the parent xylanase enzyme.

-1-

XYLANASE VARIANTS

Field of the invention

5

10

15

20

25

The present invention relates to mutant xylanase enzymes having an altered sensitivity to xylanase inhibitors as well as altered thermo-sensitivity. The present invention also relates to the use of these mutant enzymes in processing plant materials.

Background to the invention

For many years, endo-β-1,4-xylanases (EC 3.2.1.8) (referred to herein as xylanases) have been used for the modification of complex carbohydrates derived from plant cell wall material. It is well known in the art that the functionality of different xylanases (derived from different microorganisms or plants) differs enormously, as a function of pH and temperature. Based on these characteristics, different xylanases have been chosen for different industrial applications. Xylanases selected for the baking industry tend to be mesophilic regarding thermostability and temperature optima. Thus, they have activity at dough processing temperatures (typically 20-40°C) and they are inactivated during baking. In the feed industry, xylanases with different temperature characteristics are preferred. Optimally, xylanases for use in the feed industry are thermostable to retain activity after heat treatment and pelleting. Furthermore, it has recently been demonstrated, that inhibitors of xylanases may influence the functionality and efficiency of xylanases. However, combining these characteristics in variant polypeptides in not reported, and may be used to obtain tailored and more efficient xylanases.

30

Summary of the invention

The present invention relates to more useful xylanases and methods for obtaining same.

15

25

30

The data presented herein show that xylanase inhibitors dictate the functionality and efficiency of the xylanases currently used in, for example, wheat based systems. Furthermore, it is also shown that changing the xylanases sensitivity towards xylanase inhibitors, can be combined with changed thermo-sensitivity of the xylanase. Such a combination makes it possible to tailor a xylanase with the right functionality and thermo-sensitivity

Furthermore, we have gone on to design and test a series of xylanases modified by sitedirected mutagenesis to demonstrate that xylanases can be produced that have a reduced sensitivity to xylanase inhibitors present in plant material and changes thermosensitivity.

In this context, thermo-sensitivity means the xylanases' thermostability and/or temperature optimum. Both characteristics known to persons skilled in the art.

In particular, we have identified a number of residues in family 11 xylanases which influence the degree of inhibition of the xylanase and a number of residues which influence the thermo-sensitivity.

Thus, it will be possible to produce variant xylanases having a modified (for example reduced) sensitivity to xylanase inhibitors and hence altered functionality and a modified thermo-sensitivity.

Altering the functionality, for example thermo-sensitivity and inhibitor sensitivity of a xylanase, will, for example, allow a reduction in the amount of xylanase required in a number of applications such as animal feed, starch production, bakery, flour separation (wetmilling), and paper and pulp production. In addition or alternatively, altering the functionality of a xylanase may make it possible to ensure that xylanase activity is inactivated at moderate, desirable temperatures, without using costly and often highly detrimental temperature elevations in the material processed.

-3-

The present invention provides a method of altering the sensitivity of a xylanase polypeptide to an inhibitor and of altering the thermo-sensitivity of said xylanase polypeptide, which method comprises modifying, preferably modifying one or more amino acid residues of, a parent xylanase polypeptide to provide a variant xylanase polypeptide, and testing the sensitivity of said variant xylanase polypeptide to a xylanase inhibitor compared with the parent xylanase enzyme and testing the thermosensitivity of said variant xylanase polypeptide compared with the parent xylanase enzyme and, optionally, selecting a variant xylanase polypeptide having an altered sensitivity to a xylanase inhibitor and an altered thermo-sensitivity compared with the parent xylanase enzyme.

5

The present invention further provides a variant xylanase polypeptide, or fragment thereof having xylanase activity, comprising one or more amino acid modifications such that the polypeptide or fragment thereof has an altered sensitivity to a xylanase inhibitor compared with a parent enzyme and has an altered thermo-sensitivity as compared with a parent enzyme.

10

15

20

25

The term "parent enzyme" as used herein means an xylanase enzyme from which the variant xylanase enzyme is derived or derivable. With respect to the term "derivable", the variant need not necessarily be derived from the parent enzyme. Instead, the variant could be prepared, for example, by use of recombinant DNA techniques that utilise nucleotide sequence(s) encoding said variant xylanase sequence - i.e. here the nucleotide sequence(s) are similar to mutated nucleotide sequence(s) but they are not prepared by mutation of the parent nucleotide sequence(s). The variant may even be prepared by chemically modifying a parent enzyme. For some embodiments the parent enzyme is the wild type enzyme. The term "wild type" is a term of art understood by skilled persons and includes a phenotype that is characteristic of most of the members of a species occurring naturally and contrasting with the phenotype of a mutant. Thus, in the present context, the wild type enzyme may be a form of the enzyme naturally found in most members of the relevant species. Generally, the relevant wild type enzyme in relation to the variant polypeptides of the invention is the most closely

for the particular mutant xylanases described in the examples, the corresponding wild type enzyme is the wild type Bacillus subtilis xylanase A, more specifically the wild type B. subtilis xylanase A published by Paice et al., 1986 and shown as SEQ ID No.

1. However, where a particular wild type sequence has been used as the basis for producing a variant polypeptide of the invention, this will be the corresponding wild type sequence regardless of the existence of another wild type sequence that is more closely related in terms of amino acid sequence homology. The parent may even be a naturally occurring mutant of the wild type. In a highly preferred aspect the polypeptide of the present invention is prepared by mutating (e.g. by use of biological and/or chemical techniques) a parent enzyme. For some embodiments, preferably the variant polypeptide is derived from a family 11 xylanase.

By way of example, the *B. subtilis* amino acid sequence for xylanase A is shown as SEQ ID No. 1. With respect to this sequence, the amino acid residues giving altered xylanase inhibitor sensitivity may be one or more of:

D11, G12, G13, I15, N17, N29, S31, N32, G34, Y113, N114, D119, G120, D121, R122, T123, T124 and Q175

In a further aspect, with respect to the *B. subtilis* amino acid sequence of xylanse A as shown in SEQ ID No. 1, the amino acid residues giving altered xylanase inhibitor sensitivity may be one or more of:

30

20

The mutations giving altered thermo-sensitivity may be the mutations mentioned below or combinations thereof in respect of the *B. subtilis* amino acid sequence for xylanase A as shown in SEO ID No. 1:

S2A, N8Y, I15M, S22P, N29T, S31Q, T44V, F48N, T50V, V57I, A59E, N61S, S74N, P75A, P90A, T93N, K99N, T111M, D121T, T123Q, T126Q, Y128F, A142V, T143S, T147S, K154R, H156K, N163S, M169L, S179R.

By choosing an appropriate combination of mutations, for example from the lists above, a xylanase with a desired inhibitor sensitivity and thermo-sensitivity can be obtained. Thus, the inhibitor sensitivity and thermo-sensitivity of the xylanase can be individually controlled.

Thus, preferably a variant xylanase polypeptide, or fragment thereof having xylanase activity according to the present invention has an amino acid modification at any one or more of the amino acid residues: 2, 8, 11, 12, 13, 15, 17, 22, 29, 31, 32, 34, 44, 48, 50, 57, 59, 61, 74, 75, 90, 93, 99, 111, 113, 114, 119, 120, 121, 122, 123, 124, 126, 128, 142, 143, 147, 154, 156, 163, 169, 175 and 179, or combinations thereof, based on the amino acid numbering of *B. subtilis* xylanase shown as SEQ ID No. 1, or the equivalent residues in other homologous xylanase polypeptides.

Preferably a variant xylanase polypeptide, or fragment thereof having xylanase activity according to the present invention has at least one amino acid modification at any one or more of the amino acid residues 11, 12, 13, 15, 17, 29, 31, 32, 34, 113, 114, 119, 120, 121, 122, 123, 124, and 175 together with at least one amino acid modification to any one or more of the amino acid residues 2, 8, 15, 22, 29, 31, 44, 48, 50, 57, 59, 61, 74, 75, 90, 93, 99, 111, 121, 123, 126, 128, 142, 143, 147, 154, 156, 163, 169 and 179 based on the amino acid numbering of *B. subtilis* xylanase shown as SEQ ID No. 1, or the equivalent residues in other homologous xylanase polypeptides.

30

35

5

10

15

20

25

Suitably, a variant xylanase polypeptide, or fragment thereof having xylanase activity according to the present invention may have an amino acid modification at any one or more of amino acid residues: 11, 12, 13, 15, 17, 22, 29, 31, 32, 34, 44, 48, 50, 57, 59, 61, 74, 75, 90, 93, 99, 111, 113, 114, 119, 120, 121, 123, 124, 126, 128, 142, 143, 147, 154, 156, 163, 169 and 179, or combinations thereof, based on the amino acid

numbering of *B. subtilis* xylanase shown as SEQ ID No. 1, or the equivalent residues in other homologous xylanase polypeptides.

Suitably a variant xylanase polypeptide, or fragment thereof having xylanase activity according to the present invention may have at least one amino acid modification at any one or more of the amino acid residues 11, 12, 13, 15, 17, 29, 31, 32, 34, 113, 114, 119, 120, 121, 123 and 124 together with at least one amino acid modification to any one or more of the amino acid residues 15, 22, 29, 31, 44, 48, 50, 57, 59, 61, 74, 75, 90, 93, 99, 111, 121, 123, 126, 128, 142, 143, 147, 154, 156, 163, 169 and 179 based on the amino acid numbering of *B. subtilis* xylanase shown as SEQ ID No. 1, or the equivalent residues in other homologous xylanase polypeptides.

10

15

20

25

30

35

By way of example only, suitable combinations of mutations may include: D11F with one or more of S2A, N8Y, I15M, S22P, N29T, S31Q, T44V, F48N, T50V, V57I, A59E, N61S, S74N, P75A, P90A, T93N, K99N, T111M, D121T, T123Q, T126Q, Y128F, A142V, T143S, T147S, K154R, H156K, N163S, M169L, S179R;

D11F and G13F, with additionally one or more of S2A, N8Y, I15M, S22P, N29T, S31Q, T44V, F48N, T50V, V57I, A59E, N61S, S74N, P75A, P90A, T93N, K99N, T111M, D121T, T123Q, T126Q, Y128F, A142V, T143S, T147S, K154R, H156K, N163S, M169L, S179R;

D11F and G34D, with additionally one or more of S2A, N8Y, I15M, S22P, N29T, S31Q, T44V, F48N, T50V, V57I, A59E, N61S, S74N, P75A, P90A, T93N, K99N, T111M, D121T, T123Q, T126Q, Y128F, A142V, T143S, T147S, K154R, H156K, N163S, M169L, S179R; or

D11F and R122D, with additionally one or more of S2A, N8Y, I15M, S22P, N29T, S31Q, T44V, F48N, T50V, V57I, A59E, N61S, S74N, P75A, P90A, T93N, K99N, T111M, D121T, T123Q, T126Q, Y128F, A142V, T143S, T147S, K154R, H156K, N163S, M169L, S179R.

-7-

5

The present invention further relates to a variant xylanase obtainable by, preferably obtained by, either directly or indirectly the method according to the present invention.

In a further embodiment, the present invention relates to a further variant xylanase prepared from a variant xylanase obtainable by, preferably obtained by, carrying out the method of the present invention.

Preferably, the inhibitor is an inhibitor found naturally in plant tissues. Suitably the inhibitor may be a *Triticum aestivum* xylanse-inhibitor (TAXI). Preferably the sensitivity of the variant xylanase enzyme to the inhibitor is reduced as compared to the parent xylanase enzyme.

Preferably, the thermostability of the variant xylanase enzyme is increased.

Preferably, the thermostability of the variant xylanase enzyme is increased by at least 5%, more preferably by at least 10%, even more preferably by at least 15%, even more preferably by at least 20%, even more preferably by at least 30%, even more preferably by at least 40%, even more preferably by at least 50% relative to the parent enzyme when determined using the "Thermostability assay" detailed hereinbelow.

25

15

Preferably, the thermosensitivity of the variant xylanase is decreased.

Preferably, the thermosensitivity of the variant xylanase enzyme is decreased by at least 5%, more preferably by at least 10%, even more preferably by at least 15%, even more preferably by at least 20%, even more preferably by at least 30%, even more preferably by at least 40%, even more preferably by at least 50% relative to the parent enzyme.

Preferably, the variant xylanases have a reduced sensitivity to xylanase inhibitors.

30

Preferably, the sensitivity of the variant xylanase enzyme to a xylanase inhibitor is reduced by at least 5%, more preferably by at least 10%, even more preferably by at least 15%, even more preferably by at least 20%, even more preferably by at least 30%, even more preferably by at least 40%, even more preferably by at least 50% relative to the parent enzyme when determined using the "Xylanase inhibitor assay" detailed hereinbelow.

The present invention also provides a nucleic acid molecule (a nucleotide sequence) encoding a polypeptide of the invention. Also provided is a vector comprising a nucleic acid of the invention, optionally operably linked to a regulatory sequence capable of directing expression of said nucleic acid in a suitable host cell. A host cell comprising a nucleic acid or a vector of the invention is also provided.

In another aspect the present invention provides a method of making a polypeptide of the invention comprising transforming a host cell with a nucleic acid encoding said polypeptide, culturing the transformed cell and expressing said polypeptide.

Our results show that these variant polypeptides have improved properties that make them suitable for a variety of applications, such as bakery, animal feed, starch production, flour separation (wetmilling) and, paper and pulp production.

25

30

20

15

Accordingly, the present invention also provides the use of a variant polypeptide of the invention in a method of modifying plant materials.

Also provided is the use of a variant polypeptide of the invention in baking. The invention further provides the use of a variant polypeptide of the invention in processing cereals, starch production and animal feed and the use of a variant polypeptide of the invention in processing wood, for example in enhancing the bleaching of wood pulp.

The invention further provides a dough that is obtainable by, preferably obtained by, the use of the variant polypeptide and baked products that are obtained by baking such a dough, and noodle and pasta products prepared in accordance with the invention.

Accordingly, the invention further relates to a method of preparing a flour dough, said method comprising adding to the dough components a variant xylanase in accordance with the present invention.

In a further aspect, there is provided a dough improving composition comprising a variant xylanase according to the present invention.

15

25

10

In the same way that variant xylanases may be used in a variety of processing applications, xylanase inhibitors may be used in a variety of processing applications such as bakery, wood pulp processing and cereal processing.

20 Detailed description of the invention

Although in general any molecular techniques mentioned herein are well known in the art, reference may be made in particular to Sambrook *et al.*, Molecular Cloning, A Laboratory Manual (1989) and Ausubel *et al.*, Short Protocols in Molecular Biology (1999) 4th Ed, John Wiley & Sons, Inc.

A. Variant xylanase polypeptides

Xylanase enzymes have been reported from nearly 100 different organisms, including plants, fungi and bacteria. The xylanase enzymes are classified into several of the more than 40 families of glycosyl hydrolase enzymes. The glycosyl hydrolase enzymes, which include xylanases, mannanases, amylases, β-glucanases, cellulases and other carbohydrases, are classified based on such properties as the sequence of

amino acids, the three dimensional structure and the geometry of the catalytic site (Gilkes, et al., 1991, Microbiol. Reviews 55: 303-315).

Of particular interest for baking applications are the enzymes classified in Family 11. All of these are xylanases and are known as the "Family 11 xylanases". Some publications refer to these synonymously as the Family G xylanases, but the term "Family 11 xylanases" will be used herein to refer to both Family G and Family 11 xylanases.

Table A lists a number of known Family 11 xylanases. Most of them have a molecular mass of about 21,000 Da. Three of the Family 11 xylanases (Clostridium stercorarium XynA, Streptomyces lividans XynB, and Thermomonospora fusca XynA) have a higher molecular mass of 31,000 to 50,000 Da. However, these xylanases have a catalytic core sequence of about 21,000 Da similar to the other Family 11 xylanases. The amino acid sequences of the Family 11 xylanases (or, for the larger enzymes, the catalytic core) show a high degree of similarity, usually with more than 40 % identical amino acids in a proper amino acid alignment. The Family 11 xylanases, which are of bacterial, yeast, or fungal origin, share the same general molecular structure.

Figure 1 shows amino acid sequence alignment data in respect of 51 Family 11.

25 xylanases.

TABLE A - Family 11 xylanases

10

15

20

Aspergillus niger Xyn A	Aspergillus kawachii Xyn C	
Aspergillus tubigensis Xyn A	Bacillus circulans Xyn A	
Bacillus pumilus Xyn A	Bacillus subtilis Xyn A	
Cellulomonas fimi Xyn D	Chainia spp. Xyn	
Clostridium acetobutylicum Xyn B	Clostridium stercorarium Xyn A	

Fibrobacter succinogenes Xyn C	Neocallimastix patriciarum Xyn A	
Nocardiopsis dassonvillei Xyn II	Ruminococcus flavefaciens Xyn A	
Schizophyllum commune Xyn	Streptomyces lividans Xyn B	
Streptomyces lividans Xyn C	Streptomyces sp. No. 36a Xyn	
Streptomyces thermoviolaceus Xyn II	Thermomonospora fusca Xyn A	
Trichoderma harzianum Xyn	Trichoderma reesei Xyn I	
Trichoderma reesei Xyn II	Trichoderma viride Xyn	

5

Variant xylanases of the invention

A variant xylanase polypeptide of the invention is typically obtained by modifying a xylanase polypeptide by substituting, deleting or adding one or more amino acid residues within the amino acid sequence of the xylanase polypeptide. Preferably the modification comprises one or more amino acid substitutions. Modification of polypeptide sequences can be carried out using standard techniques such as site directed mutagenesis. The modification may also occur by chemical techniques – such as chemical modification of one or more amino acid residues.

-15

20

25

10

The starting sequence may be a wild type sequence or a non-naturally occurring sequence, for example a derivative that has already been subjected to protein engineering. The xylanase sequence to be modified may be from any source, for example a bacterial, fungal or plant source. Preferably the xylanase sequence to be modified is that of a Family 11 xylanase, more preferably a Family 11 xylanase selected from Trichoderma reesei xylanase I, Trichoderma reesei xylanase II, Trichoderma harzianum xylanase, Trichoderma viride xylanase, Bacillus circulans xylanase A, Bacillus subtilis xylanase A, Bacillus stearothermophilus xylanase A, Aspergillus niger xylanase A, Aspergillus kawachii xylanase C, Aspergillus tubigensis xylanase A, Streptomyces lividans xylanase B, and Streptomyces lividans xylanase C.

In a particularly preferred embodiment, the xylanase sequence to be modified is the *B. subtilis* xylanase sequence shown as SEQ ID No. 1 or a homologue thereof. Preferably said homologue has at least 40, 50, 60 or 80% homology over at least 50 or 100 amino acid residues as determined using the GCG Wisconsin Bestfit package (University of Wisconsin, U.S.A.; Devereux *et al.*, 1984, Nucleic Acids Research 10 12:387).

Specific modifications that are possible according to the present invention include one or more amino acid substitutions at positions 11, 12, 13, 15, 17, 29, 31, 32, 34, 113, 114, 119, 120, 121, 122, 123, 124 and 175 regarding inhibitor sensitivity and one or more substitutions at positions 2, 8, 15, 22, 29, 31, 44, 48, 50, 57, 59, 61, 74, 75, 90, 93, 99, 111, 121, 123, 126, 128, 142, 143, 147, 154, 156, 163, 169 and 179 regarding thermo-sensitivity, or combinations thereof based on the amino acid numbering of *B. subtilis* xylanase shown as SEQ ID No. 1, or the equivalent residues in other homologous xylanase polypeptides.

20

25

30

35

15

Possible substitutions include one or more of D11 \rightarrow Y, D11 \rightarrow N, D11 \rightarrow F, D11 \rightarrow K, D11 \rightarrow S, D11 \rightarrow W, G12 \rightarrow F, G13 \rightarrow F, I15 \rightarrow K, N17 \rightarrow K, N17 \rightarrow Y, N17 \rightarrow D, N29 \rightarrow K, N29 \rightarrow Y, N29 \rightarrow D, S31 \rightarrow K, S31 \rightarrow Y, S31 \rightarrow D, N32 \rightarrow K, G34 \rightarrow D, G34 \rightarrow F, G34 \rightarrow T, Y113 \rightarrow A, Y113 \rightarrow D, Y113 \rightarrow K, N114 \rightarrow A, N114 \rightarrow D, N114 \rightarrow F, N114 \rightarrow K, D119 \rightarrow K, D119 \rightarrow Y, D119 \rightarrow N, G120 \rightarrow K, G120 \rightarrow D, G120 \rightarrow F, G120 \rightarrow Y, G120 \rightarrow N, D121 \rightarrow N, D121 \rightarrow K, D121 \rightarrow F, D121 \rightarrow A, R122 \rightarrow D, R122 \rightarrow F, R122 \rightarrow A, T123 \rightarrow K, T123 \rightarrow Y, T123 \rightarrow D, T124 \rightarrow K, T124 \rightarrow Y, T124 \rightarrow D, Q175 \rightarrow E, Q175 \rightarrow S and Q175 \rightarrow L regarding inhibitor sensitivity (with reference to the amino acid sequence of *B. subtilis* xylanase) or their equivalents in other homologous xylanase polypeptides and one or more substitutions of S2 \rightarrow A, N8 \rightarrow Y, I15 \rightarrow M, S22 \rightarrow P, N29 \rightarrow T, S31 \rightarrow Q, T44 \rightarrow V, F48 \rightarrow N, T50 \rightarrow V, V57 \rightarrow I, A59 \rightarrow E, N61 \rightarrow S, S74 \rightarrow N, P75 \rightarrow A, P90 \rightarrow A, T93 \rightarrow N, K99 \rightarrow N, T111 \rightarrow M, D121 \rightarrow T, T123 \rightarrow Q, T126 \rightarrow Q, Y128 \rightarrow F, A142 \rightarrow V, T143 \rightarrow S, T147 \rightarrow S, K154 \rightarrow R, H156 \rightarrow K, N163 \rightarrow S, M169 \rightarrow L, S179 \rightarrow R regarding thermo-sensitivity (with reference to the amino acid sequence of *B. subtilis* xylanase) or their equivalents in other homologous xylanase polypeptides and

5 combinations thereof. Further references to specific residues of the *B. subtilis* xylanase shown as SEQ ID No. 1 will also include their equivalents in other homologous xylanase polypeptides.

A combination of mutations may be carried out, for example mutations at two or more,
three or more, four or more, five or more, ten or more, or fifteen or more of the abovementioned residues.

In a further embodiment, the variant polypeptides of the invention may be purified and isolated naturally occurring mutant xylanases. Alternatively, mutant xylanases may be generated by subjecting organisms to mutagens and then screening for individuals comprising mutations in their xylanase genes. Naturally occurring mutants and mutants generated by random mutagenesis may be identified/screened using a variety of techniques such as PCR screening using suitable nucleic acid primers to amplify regions of xylanase genes and sequencing the resulting fragments.

20

15

Thus variant polypeptides of the invention include naturally occurring mutant xylanases (purified and isolated from the organisms in which they occur or obtained recombinantly), mutant xylanases obtained by random mutagenesis and mutant xylanases obtained by site-directed mutagenesis.

25

30

35

Variant polypeptides of the invention may also be subjected to further modifications that do not necessarily affect sensitivity to inhibitors or thermo-sensitivity, including any substitution of, variation of, modification of, replacement of, deletion of or addition of one (or more) amino acids from or to the sequence providing the resultant amino acid sequence retains xylanase activity, preferably having at least substantially the same xylanase activity as the unmodified sequence.

Conservative substitutions may be made, for example according to the Table below. Amino acids in the same block in the second column and preferably in the same line in the third column may be substituted for each other:

-14-

5

ALIPHATIC	Non-polar	GAP
		ILV
	Polar - uncharged	CSTM
		NQ
	Polar - charged	DE
		KR
AROMATIC		HFWY

Polypeptides of the invention also include fragments of the full-length sequences mentioned above having xylanase activity.

- Polypeptides of the invention may further comprise heterologous amino acid sequences, typically at the N-terminus or C-terminus, preferably the N-terminus. Heterologous sequence may include sequences that affect intra or extracellular protein targeting (such as leader sequences).
- Polypeptides of the invention are typically made by recombinant means, for example as described below. However they may also be made by synthetic means using techniques well known to skilled persons such as solid phase synthesis. Polypeptides of the invention may also be produced as fusion proteins, for example to aid in extraction and purification. It may also be convenient to include a proteolytic cleavage site between the fusion protein partner and the protein sequence of interest to allow removal of fusion protein sequences, such as a thrombin cleavage site. Preferably the fusion protein will not hinder the function of the protein sequence of interest.
- The use of appropriate host cells is expected to provide for such post-translational modifications as may be needed to confer optimal biological activity on recombinant expression products of the invention.

-15-

Polypeptides of the invention may be in a substantially isolated form. It will be understood that the protein may be mixed with carriers or diluents which will not interfere with the intended purpose of the protein and still be regarded as substantially isolated. A polypeptide of the invention may also be in a substantially purified form, in which case it will generally comprise the protein in a preparation in which more than 90%, e.g. 95%, 98% or 99% of the protein in the preparation is a polypeptide of the invention.

15

20

25

30

35

Variant polypeptides of the invention have an altered sensitivity to xylanase inhibitors and an altered thermo-sensitivity compared to the parent xylanase sequence - which may be a corresponding wild type xylanase. Preferably, variant polypeptides have reduced sensitivity to xylanase inhibitors and reduced thermo-sensitivity. The term "altered sensitivity to xylanase inhibitors" means that the extent to which the endo-β-1,4-xylanase activity of a variant polypeptide of the invention is inhibited by the xylanase inhibitor is different to that of the parent xylanase enzyme - which may be the corresponding wild type xylanase. Preferably the extent to which the variant polypeptide is inhibited by the inhibitor is less than that of the parent xylanase enzyme - which may be the wild type protein. This may, for example, be due to a change in the three-dimensional structure of the variant polypeptide such that the inhibitor no longer binds with the same affinity as it does to the parent xylanase enzyme - which may be the wild type enzyme. The term "altered thermo-sensitivity" means that the variant polypeptide of the invention has an altered thermostability or temperature optimum determined as described in the methods included below. This may, for example, be due to a change which increases the denaturing temperature of the polypeptide, i.e. that temperature at which the peptide is denatured, compared to the parent xylanase enzyme - which may be the wild type enzyme.

The sensitivity of the variant polypeptides of the invention to xylanase inhibitors can be assayed using the xylanase inhibitor assay described below. A suitable inhibitor for use in the assay is the inhibitor purified from wheat flour in Example 1. Other inhibitors are described below. The thermo-sensitivity of the variant polypeptide of the

-16-

invention may be described using the thermostability and temperature optimum assay described below.

Xylanase assay (Endo-β-1,4-Xylanase activity)

Xylanase samples are diluted in citric acid (0.1 M) - di-sodium-hydrogen phosphate (0.2 M) buffer, pH 5.0, to obtain approx. OD = 0.7 in the final assay. Three dilutions of the sample and an internal standard with a defined activity are thermostated for 5 minutes at 40°C. At time = 5 minutes, 1 Xylazyme tab (crosslinked, dyed xylan substrate) is added to the enzyme solution. At time = 15 minutes (or in some cases longer, depending on the xylanase activity present in the sample) the reaction is terminated, by adding 10 ml of 2% TRIS. The reaction mixture is centrifuged and the OD of the supernatant is measured at 590 nm. Taking into account the dilutions and the amount of xylanase, the activity (TXU, Total-Xylanase-Units) of the sample can be calculated relative to the standard.

20

10

15

Xylanase inhibitors

As used herein, the term "xylanase inhibitor" refers to a compound, typically a protein, whose role is to control the depolymerisation of complex carbohydrates, such as arabinoxylan, found in plant cell walls. These xylanase inhibitors are capable of reducing the activity of naturally occurring xylanase enzymes as well as those of fungal or bacterial origin. Although the presence of xylanase inhibitors have been reported in cereal seeds (see for example McLauchlan et al 1999a; Rouau and Suget 1998) their impact on the efficacy of xylanase enzymes has not been extensively examined.

30

35

25

McLauchlan et al (1999a) disclose the isolation and characterisation of a protein from wheat that binds to and inhibits two family-11 xylanases. Likewise, WO 98/49278 demonstrates the effect of a wheat flour extract on the activity of a group of microbial xylanases all of which are classified as family 11 xylanases. Debyser et al. (1999) also disclose that endoxylanases from Aspergillus niger and Bacillus subtilis, which are both members of the family 11 xylanases were inhibited by a wheat xylanase inhibitor

-17-

called TAXI (*Triticum aestivum* xylanase-inhibitor). McLauchlan *et al* (1999b) teach that extracts from commercial flours such as wheat, barley, rye and maize are capable of inhibiting both family 10 and 11 xylanases.

The xylanase inhibitor may be any suitable xylanase inhibitor. By way of example, the xylanase inhibitor may be the inhibitor described in WO-A-98/49278 and/or the xylanase inhibitor described by Rouau, X. and Surget, A. (1998), McLauchlan, R., et al. (1999b) and/or the xylanase inhibitor described in International Patent Publication No. WO00/39289.

- In some applications, preferably the inhibitor is a TAXI inhibitor. As indicated above, the TAXI inhibitor is disclosed in, for example Debyser et al (1999) and/or WO00/39289. An example TAXI inhibitor may comprise one or more of the amino acid sequences presented as SEQ ID No's 13-19 in WO00/39289.
- The inhibitor may be one or more inhibitors of the same type, for example TAXI. For some applications, the inhibitor may be a mixture of inhibitors of different types, for example TAXI and XIP (Xylanase inhibitor proteins).

Xylanase inhibitor assay

25

30

10

100 μ l of an candidate inhibitor fraction, 250 μ l xylanase solution (containing 12 TXU microbial xylanase/ml) and 650 μ l buffer (0.1 M citric acid - 0.2M di-sodium hydrogen phosphate buffer, pH 5.0) are mixed. The mixture is thermostated for 5 minutes at 40.0°C. At time = 5 minutes one Xylazyme tab is added. At time = 15 minutes the reaction is terminated by adding 10 ml 2% TRIS. The reaction mixture is centrifuged (3500 g, 10 minutes, room temperature) and the supernatant is measured at 590 nm. The inhibition is calculated as residual activity compared to the blank. The blank is prepared the same way, except that the 100 μ l inhibitor is substituted with 100 μ l buffer (0.1 M citric acid - 0.2 M di-sodium hydrogen phosphate buffer, pH 5.0).

5 Specific xylanase inhibitor

As indicated, a xylanase inhibitor that may be used in accordance with the present invention is the xylanase inhibitor described in International Patent Publication No. WO00/39289.

10

This endogenous endo- β -1,4-xylanase inhibitor is obtainable from wheat flour. The inhibitor is a di-peptide, having a MW of about 40 kDa (as measured by SDS-PAGE or mass spectrometry) and a pI of about 8 to about 9.5.

Sequence analysis to date has revealed the that the inhibitor has at least one or more of the sequences presented as SEQ ID No. 2, SEQ ID No. 3, SEQ ID No 4, SEQ ID No. 5, SEQ ID No. 6, SEQ ID No. 7 and/or SEQ ID No. 8.

These inhibitors described in the prior art may also be used in assays to determine the sensitivity of a variant polypeptide of the invention to xylanase inhibitors. They may also be used as described below to modulate the functionality of a xylanase.

Thermostability assay

Solutions of the variant polypeptide are incubated for 10 to 240 minutes, preferably 30 to 240 minutes, at temperatures varying from 30 to 80°C, preferably at 50, 55, 60 or 65°C. Hereafter the xylanase solutions are assayed as described in "Xylanase assay" above. Activities as a function of different pre-incubation temperatures are expressed relatively to the highest activity obtained.

30

35

Temperature optimum assay.

Solutions of the variant polypeptides are assayed as described in "Xylanase assay", except for the temperature. Instead of only assaying the xylanase variants at 40°C, the xylanases may be incubated and assayed at one or more of the following temperatures:

-19-

30, 40, 50, 60 and 70°C. Hereby it is possible to determine a temperature optimum for the xylanase variants.

Polynucleotides

Polynucleotides of the invention comprise nucleic acid sequences encoding the variant polypeptide sequences of the invention. It will be understood by a skilled person that numerous different polynucleotides can encode the same polypeptide as a result of the degeneracy of the genetic code. In addition, it is to be understood that skilled persons may, using routine techniques, make nucleotide substitutions that do not affect the polypeptide sequence encoded by the polynucleotides of the invention to reflect the codon usage of any particular host organism in which the polypeptides of the invention are to be expressed.

Polynucleotides of the invention may comprise DNA or RNA. They may be single-stranded or double-stranded. They may also be polynucleotides which include within them synthetic or modified nucleotides. A number of different types of modification to oligonucleotides are known in the art. These include methylphosphonate and phosphorothioate backbones, addition of acridine or polylysine chains at the 3' and/or 5' ends of the molecule. For the purposes of the present invention, it is to be understood that the polynucleotides described herein may be modified by any method available in the art. Such modifications may be carried out in order to enhance the *in vivo* activity or life span of polynucleotides of the invention.

Nucleotide vectors and host cells

30

35

20

25

Polynucleotides of the invention can be incorporated into a recombinant replicable vector. The vector may be used to replicate the nucleic acid in a compatible host cell. Thus in a further embodiment, the invention provides a method of making polynucleotides of the invention by introducing a polynucleotide of the invention into a replicable vector, introducing the vector into a compatible host cell, and growing the

WO 03/020923

-20-

PCT/IB02/03797

host cell under conditions which bring about replication of the vector. The vector may be recovered from the host cell. Suitable host cells include bacteria such as *E. coli*, yeast and fungi.

Preferably, a polynucleotide of the invention in a vector is operably linked to a regulatory sequence which is capable of providing for the expression of the coding sequence by the host cell, i.e. the vector is an expression vector. The term "operably linked" refers to a juxtaposition wherein the components described are in a relationship permitting them to function in their intended manner. A regulatory sequence "operably linked" to a coding sequence is ligated in such a way that expression of the coding sequence is achieved under conditions compatible with the control sequences. The term "regulatory sequences" includes promoters and enhancers and other expression regulation signals.

Enhanced expression of the polynucleotide encoding the polypeptide of the invention may also be achieved by the selection of heterologous regulatory regions, e.g. promoter, secretion leader and terminator regions, which serve to increase expression and, if desired, secretion levels of the protein of interest from the chosen expression host and/or to provide for the inducible control of the expression of the polypeptide of the invention.

25

10

15

20

Aside from the promoter native to the gene encoding the polypeptide of the invention, other promoters may be used to direct expression of the polypeptide of the invention. The promoter may be selected for its efficiency in directing the expression of the polypeptide of the invention in the desired expression host.

30

35

In another embodiment, a constitutive promoter may be selected to direct the expression of the desired polypeptide of the invention. Examples of strong constitutive and/or inducible promoters which are preferred for use in fungal expression hosts are those which are obtainable from the fungal genes for xylanase (xlnA), phytase, ATP-synthetase, subunit 9 (oliC), triose phosphate isomerase (tpi), alcohol

-21-

dehydrogenase (AdhA), α-amylase (amy), amyloglucosidase (AG - from the glaA gene), acetamidase (amdS) and glyceraldehyde-3-phosphate dehydrogenase (gpd) promoters.

Examples of strong yeast promoters are those obtainable from the genes for alcohol dehydrogenase, lactase, 3-phosphoglycerate kinase and triosephosphate isomerase.

Examples of strong bacterial promoters are the α -amylase and SP02 promoters as well as promoters from extracellular protease genes.

15 Hybrid promoters may also be used to improve inducible regulation of the expression construct.

20

25

Often, it is desirable for the polypeptide of the invention to be secreted from the expression host into the culture medium from where the polypeptide of the invention may be more easily recovered. According to the present invention, the polypeptide of the invention's native secretion leader sequence may be used to effect the secretion of the expressed polypeptide of the invention. However, an increase in the expression of the polypeptide of the invention sometimes results in the production of the protein in levels beyond that which the expression host is capable of processing and secreting, creating a bottleneck such that the protein product accumulates within the cell. Accordingly, the present invention also provides heterologous leader sequences to provide for the most efficient secretion of the polypeptide of the invention from the chosen expression host.

According to the present invention, the secretion leader may be selected on the basis of the desired expression host. A heterologous secretion leader may be chosen which is homologous to the other regulatory regions of the expression construct. For example, the leader of the highly secreted amyloglucosidase (AG) protein may be used in combination with the amyloglucosidase (AG) promoter itself, as well as in

-22-

5 combination with other promoters. Hybrid signal sequences may also be used with the context of the present invention.

Examples of preferred heterologous secretion leader sequences are those originating from the fungal amyloglucosidase (AG) gene (glaA - both 18 and 24 amino acid versions e.g. from Aspergillus), the α -factor gene (yeasts e.g. Saccharomyces and Kluyveromyces) or the α -amylase gene (Bacillus).

10

15

20

25

30

35

Such vectors may be transformed into a suitable host cell as described above to provide for expression of a polypeptide of the invention. Thus, in a further aspect the invention provides a process for preparing polypeptides according to the invention which comprises cultivating a host cell transformed or transfected with an expression vector as described above under conditions to provide for expression by the vector of a coding sequence encoding the polypeptides, and recovering the expressed polypeptides. Suitable host cells include, for example, fungal cells, such as Aspergillus and yeast cells, such as yeast cells of the genus Kluyveromyces or Saccharomyces. Other suitable host cells are discussed below.

The vectors may be for example, plasmid, virus or phage vectors provided with an origin of replication, optionally a promoter for the expression of the said polynucleotide and optionally a regulator of the promoter. The vectors may contain one or more selectable marker genes. The most suitable selection systems for industrial micro-organisms are those formed by the group of selection markers which do not require a mutation in the host organism. Examples of fungal selection markers are the genes for acetamidase (amdS), ATP synthetase, subunit 9 (oliC), orotidine-5²-phosphate-decarboxylase (pvrA), phleomycin and benomyl resistance (benA). Examples of non-fungal selection markers are the bacterial G418 resistance gene (this may also be used in yeast, but not in fungi), the ampicillin resistance gene (E. coli), the neomycin resistance gene (Bacillus) and the E. coli uidA gene, coding for β-glucuronidase (GUS). Vectors may be used in vitro, for example for the production of RNA or used to transfect or transform a host cell.

5

A further embodiment of the invention provides host cells transformed or transfected with a polynucleotide of the invention. Preferably said polynucleotide is carried in a vector for the replication and expression of said polynucleotides. The cells will be chosen to be compatible with the said vector and may for example be prokaryotic (for example bacterial), fungal, yeast or plant cells.

Bacteria from the genus *Bacillus* are very suitable as heterologous hosts because of their capability to secrete proteins into the culture medium. Other bacteria suitable as hosts are those from the genera *Streptomyces* and *Pseudomonas*.

15

20

10

Depending on the nature of the polynucleotide encoding the polypeptide of the invention, and/or the desirability for further processing of the expressed protein, eukaryotic hosts such as yeasts or fungi may be preferred. In general, yeast cells are preferred over fungal cells because they are easier to manipulate. However, some proteins are either poorly secreted from the yeast cell, or in some cases are not processed properly (e.g. hyperglycosylation in yeast). In these instances, a fungal host organism should be selected.

25

30

35

A heterologous host may also be chosen wherein the polypeptide of the invention is produced in a form which is substantially free from other xylanases. This may be achieved by choosing a host which does not normally produce such enzymes.

Examples of preferred expression hosts within the scope of the present invention are fungi such as Aspergillus species and Trichoderma species; bacteria such as Bacillus species, Streptomyces species and Pseudomonas species; and yeasts such as Kluyveromyces species and Saccharomyces species.

Particularly preferred expression hosts may be selected from Aspergillus niger, Aspergillus niger var. tubigenis, Aspergillus niger var. awamori, Aspergillus aculeatis, Aspergillus nidulans, Aspergillus oryzae, Trichoderma reesei, Bacillus

subtilis, Bacillus licheniformis, Bacillus amyloliquefaciens, Kluyveromyces lactis,

Lactococcus lactis, Thermomyces (Humicola) lanuginosus, Pichia spp.,

Schizosaccheromyces pombe, Mucor spp. and Saccharomyces cerevisiae.

According to the present invention, the production of the polypeptide of the invention can be effected by the culturing of microbial expression hosts, which have been transformed with one or more polynucleotides of the present invention, in a conventional nutrient fermentation medium.

The fermentation medium can comprise a known culture medium containing a carbon source (e.g. glucose, maltose, molasses, etc.), a nitrogen source (e.g. ammonium sulphate, ammonium nitrate, ammonium chloride, etc.), an organic nitrogen source (e.g. yeast extract, malt extract, peptone, etc.) and inorganic nutrient sources (e.g. phosphate, magnesium, potassium, zinc, iron, etc.). Optionally, an inducer may be added.

20

25

30

35

10

15

The selection of the appropriate medium may be based on the choice of expression hosts and/or based on the regulatory requirements of the expression construct. Such media are well known to those skilled in the art. The medium may, if desired, contain additional components favouring the transformed expression hosts over other potentially contaminating microorganisms.

After fermentation, the cells can be removed from the fermentation broth by means of centrifugation or filtration. After removal of the cells, the variant polypeptide of the invention may then be recovered and, if desired, purified and isolated by conventional means.

Organisms

The term "organism" in relation to the present invention includes any organism that could comprise the nucleotide sequence coding for the variant xylanase protein according

15

20

25

30

35

to the present invention and/or products obtained therefrom, wherein a transcriptional regulatory sequence can allow expression of the nucleotide sequence according to the present invention when present in the organism. Suitable organisms may include a prokaryote, fungus, yeast or a plant. For the xylanase aspect of the present invention, a preferable organism may be a bacterium, preferably of the genus Bacillus, more preferably Bacillus subtilis.

The term "transgenic organism" in relation to the present invention includes any organism that comprises the nucleotide sequence coding for the protein according to the present invention and/or products obtained therefrom, wherein the transcriptional regulatory sequence can allow expression of the nucleotide sequence according to the present invention within the organism. Preferably the nucleotide sequence is incorporated in the genome of the organism.

The term "transgenic organism" does not cover native nucleotide coding sequences in their natural environment when they are under the control of their native promoter which is also in its natural environment.

Therefore, the transgenic organism of the present invention includes an organism comprising any one of, or combinations of, the nucleotide sequence coding for the amino acid sequence according to the present invention, constructs according to the present invention (including combinations thereof), vectors according to the present invention, plasmids according to the present invention, cells according to the present invention, tissues according to the present invention or the products thereof. The transformed cell or organism could prepare acceptable quantities of the desired compound which would be easily retrievable from, the cell or organism.

Transformation of Host Cells/Host Organisms

As indicated earlier, the host organism can be a prokaryotic or a eukaryotic organism. Examples of suitable prokaryotic hosts include *E. coli* and *Bacillus subtilis*. Teachings

WO 03/020923

- on the transformation of prokaryotic hosts is well documented in the art, for example see Sambrook et al (Molecular Cloning: A Laboratory Manual, 2nd edition, 1989, Cold Spring Harbor Laboratory Press) and Ausubel *et al.*, Short Protocols in Molecular Biology (1999), 4th Ed., John Wiley & Sons, Inc.
- 10 If a prokaryotic host is used then the nucleotide sequence may need to be suitably modified before transformation - such as by removal of introns.

As mentioned above, a preferred host organism is of the genus Bacillus, such as *Bacillus* subtilis.

15

20

In another embodiment the transgenic organism can be a yeast. In this regard, yeasts have also been widely used as a vehicle for heterologous gene expression. The species *Saccharomyces cerevisiae* has a long history of industrial use, including its use for heterologous gene expression. Expression of heterologous genes in *Saccharomyces cerevisiae* has been reviewed by Goodey et al (1987, Yeast Biotechnology, D R Berry et al, eds, pp 401-429, Allen and Unwin, London) and by King et al (1989, Molecular and Cell Biology of Yeasts, E F Walton and G T Yarronton, eds, pp 107-133, Blackie, Glasgow).

25 For several reasons Saccharomyces cerevisiae is well suited for heterologous gene expression. First, it is non-pathogenic to humans and it is incapable of producing certain endotoxins. Second, it has a long history of safe use following centuries of commercial exploitation for various purposes. This has led to wide public acceptability. Third, the extensive commercial use and research devoted to the organism has resulted in a wealth of knowledge about the genetics and physiology as well as large-scale fermentation characteristics of Saccharomyces cerevisiae.

A review of the principles of heterologous gene expression in Saccharomyces cerevisiae and secretion of gene products is given by E Hinchcliffe E Kenny (1993, "Yeast as a

-27-

vehicle for the expression of heterologous genes", Yeasts, Vol 5, Anthony H Rose and J Stuart Harrison, eds, 2nd edition, Academic Press Ltd.).

Several types of yeast vectors are available, including integrative vectors, which require recombination with the host genome for their maintenance, and autonomously replicating plasmid vectors.

In order to prepare the transgenic Saccharomyces, expression constructs are prepared by inserting the nucleotide sequence of the present invention into a construct designed for expression in yeast. Several types of constructs used for heterologous expression have been developed. The constructs contain a promoter active in yeast fused to the nucleotide sequence of the present invention, usually a promoter of yeast origin, such as the GAL1 promoter, is used. Usually a signal sequence of yeast origin, such as the sequence encoding the SUC2 signal peptide, is used. A terminator active in yeast ends the expression system.

20

25

30

10

15

For the transformation of yeast several transformation protocols have been developed. For example, a transgenic *Saccharomyces* according to the present invention can be prepared by following the teachings of Hinnen et al (1978, Proceedings of the National Academy of Sciences of the USA 75, 1929); Beggs, J D (1978, Nature, London, 275, 104); and Ito, H et al (1983, J Bacteriology 153, 163-168).

The transformed yeast cells are selected using various selective markers. Among the markers used for transformation are a number of auxotrophic markers such as LEU2,

HIS4 and TRP1, and dominant antibiotic resistance markers such as aminoglycoside

antibiotic markers, e.g. G418.

Another host organism is a plant. The basic principle in the construction of genetically modified plants is to insert genetic information in the plant genome so as to obtain a stable maintenance of the inserted genetic material.

5

10

15

20

25

30

35

A transgenic plant of the invention may be produced from any plant such as the seed-bearing plants (angiosperms), and conifers. Angiosperms include dicotyledons and monocotyledons. Examples of dicotyledonous plants include tobacco, (Nicotiana plumbaginifolia and Nicotiana tabacum), arabidopsis (Arabidopsis thaliana), Brassica napus, Brassica nigra, Datura innoxia, Vicia narbonensis, Vicia faba, pea (Pisum sativum), cauliflower, carnation and lentil (Lens culinaris). Examples of monocotyledonous plants include cereals such as wheat, barley, oats and maize.

Techniques for producing transgenic plants are well known in the art. Typically, either whole plants, cells or protoplasts may be transformed with a suitable nucleic acid construct encoding a zinc finger molecule or target DNA (see above for examples of nucleic acid constructs). There are many methods for introducing transforming DNA constructs into cells, but not all are suitable for delivering DNA to plant cells. Suitable methods include *Agrobacterium* infection (see, among others, Turpen *et al.*, 1993, J. Virol. Methods, 42: 227-239) or direct delivery of DNA such as, for example, by PEG-mediated transformation, by electroporation or by acceleration of DNA coated particles. Acceleration methods are generally preferred and include, for example, microprojectile bombardment. A typical protocol for producing transgenic plants (in particular monocotyledons), taken from U.S. Patent No. 5, 874, 265, is described below.

An example of a method for delivering transforming DNA segments to plant cells is microprojectile bombardment. In this method, non-biological particles may be coated with nucleic acids and delivered into cells by a propelling force. Exemplary particles include those comprised of tungsten, gold, platinum, and the like.

A particular advantage of microprojectile bombardment, in addition to it being an effective means of reproducibly stably transforming both dicotyledons and monocotyledons, is that neither the isolation of protoplasts nor the susceptibility to Agrobacterium infection is required. An illustrative embodiment of a method for

-29-

5 delivering DNA into plant cells by acceleration is a Biolistics Particle Delivery System, which can be used to propel particles coated with DNA through a screen, such as a stainless steel or Nytex screen, onto a filter surface covered with plant cells cultured in suspension. The screen disperses the tungsten-DNA particles so that they are not delivered to the recipient cells in large aggregates. It is believed that without a screen intervening between the projectile apparatus and the cells to be bombarded, the projectiles aggregate and may be too large for attaining a high frequency of transformation. This may be due to damage inflicted on the recipient cells by projectiles that are too large.

For the bombardment, cells in suspension are preferably concentrated on filters. Filters containing the cells to be bombarded are positioned at an appropriate distance below the macroprojectile stopping plate. If desired, one or more screens are also positioned between the gun and the cells to be bombarded. Through the use of techniques set forth herein one may obtain up to 1000 or more clusters of cells transiently expressing a marker gene ("foci") on the bombarded filter. The number of cells in a focus which express the exogenous gene product 48 hours post-bombardment often range from 1 to 10 and average 2 to 3.

After effecting delivery of exogenous DNA to recipient cells by any of the methods discussed above, a preferred step is to identify the transformed cells for further culturing and plant regeneration. This step may include assaying cultures directly for a screenable trait or by exposing the bombarded cultures to a selective agent or agents.

An example of a screenable marker trait is the red pigment produced under the control of the R-locus in maize. This pigment may be detected by culturing cells on a solid support containing nutrient media capable of supporting growth at this stage, incubating the cells at, e.g., 18°C and greater than 180 µE m⁻² s⁻¹, and selecting cells from colonies (visible aggregates of cells) that are pigmented. These cells may be cultured further, either in suspension or on solid media.

25

30

-30-

An exemplary embodiment of methods for identifying transformed cells involves exposing the bombarded cultures to a selective agent, such as a metabolic inhibitor, an antibiotic, herbicide or the like. Cells which have been transformed and have stably integrated a marker gene conferring resistance to the selective agent used, will grow and divide in culture. Sensitive cells will not be amenable to further culturing.

10

15

20

25

30

To use the bar-bialaphos selective system, bombarded cells on filters are resuspended in nonselective liquid medium, cultured (e.g. for one to two weeks) and transferred to filters overlaying solid medium containing from 1-3 mg/l bialaphos. While ranges of 1-3 mg/l will typically be preferred, it is proposed that ranges of 0.1-50 mg/l will find utility in the practice of the invention. The type of filter for use in bombardment is not believed to be particularly crucial, and can comprise any solid, porous, inert support.

Cells that survive the exposure to the selective agent may be cultured in media that supports regeneration of plants. Tissue is maintained on a basic media with hormones for about 2-4 weeks, then transferred to media with no hormones. After 2-4 weeks, shoot development will signal the time to transfer to another media.

Regeneration typically requires a progression of media whose composition has been modified to provide the appropriate nutrients and hormonal signals during sequential developmental stages from the transformed callus to the more mature plant. Developing plantlets are transferred to soil, and hardened, e.g., in an environmentally controlled chamber at about 85% relative humidity, 600 ppm CO₂, and 250 µE m⁻² s⁻¹ of light. Plants are preferably matured either in a growth chamber or greenhouse. Regeneration will typically take about 3-12 weeks. During regeneration, cells are grown on solid media in tissue culture vessels. An illustrative embodiment of such a vessel is a petri dish. Regenerating plants are preferably grown at about 19°C to 28°C. After the regenerating plants have reached the stage of shoot and root development, they may be transferred to a greenhouse for further growth and testing.

- 5 Genomic DNA may be isolated from callus cell lines and plants to determine the presence of the exogenous gene through the use of techniques well known to those skilled in the art such as PCR and/or Southern blotting.
- Several techniques exist for inserting the genetic information, the two main principles being direct introduction of the genetic information and introduction of the genetic information by use of a vector system. A review of the general techniques may be found in articles by Potrykus (Annu Rev Plant Physiol Plant Mol Biol [1991] 42:205-225) and Christou (Agro-Food-Industry Hi-Tech March/April 1994 17-27).
- Thus, in one aspect, the present invention relates to a vector system which carries a construct encoding a variant xylanase polypeptide according to the present invention and which is capable of introducing the construct into the genome of a plant.
- The vector system may comprise one vector, but it can comprise at least two vectors.

 In the case of two vectors, the vector system is normally referred to as a binary vector system. Binary vector systems are described in further detail in Gynheung An et al. (1980), Binary Vectors, Plant Molecular Biology Manual A3, 1-19.
 - One extensively employed system for transformation of plant cells with a given promoter or nucleotide sequence or construct is based on the use of a Ti plasmid from Agrobacterium tumefaciens or a Ri plasmid from Agrobacterium rhizogenes (An et al. (1986), Plant Physiol. 81, 301-305 and Butcher D.N. et al. (1980), Tissue Culture Methods for Plant Pathologists, eds.: D.S. Ingrams and J.P. Helgeson, 203-208).
- 30 Several different Ti and Ri plasmids have been constructed which are suitable for the construction of the plant or plant cell constructs described above.

25

5 B. Uses

In a general sense, a variant xylanase of the invention may be used to alter, for example reduce, the viscosity derived from the presence of hemicellulose or arabinoxylan in a solution or system comprising plant cell wall material. Typically said plant cell wall materials will comprise one or more xylanase inhibitors. Suitably said plant cell wall materials will be processed at a preferred temperature.

Specifically, a variant xylanase of the invention may be used in processing plant materials for use as foodstuffs, such as animal feed, in processing cereals, in starch production, in baking and in the processing of wood pulp to make paper.

The variant xylanase of the present invention may be used in the preparation of a dough and baked products that are obtained by baking such a dough, and in the preparation of noodle and pasta products.

20

15

10

The variant xylanase of the present invention may be used in a dough improving composition comprising.

Preparation of foodstuffs

25

30

A variant xylanase of the invention may be used to process plant materials such as cereals that are used in foodstuffs including animal feed. As used herein, the term "cereal" means any kind of grain used for food and/or any grass producing this grain such as but not limited to any one of wheat, milled wheat, barley, maize, sorghum, rye, oats, triticale and rice or combinations thereof. In one preferred embodiment, the cereal is a wheat cereal.

The xylan in the food and/or feed supplement is modified by contacting the xylan with the variant xylanase of the present invention.

-33-

As used herein, the term "contacting" includes but is not limited to spraying, coating, impregnating or layering the food and/or feed supplement with the variant xylanase enzyme of the present invention.

In one embodiment, the food and/or feed supplement of the present invention may be prepared by mixing the variant xylanase enzyme directly with a food and/or feed supplement. By way of example, the variant xylanase enzyme may be contacted (for example, by spraying) onto a cereal-based food and/or feed supplement such as milled wheat, maize or soya flour.

10

25

30

35

It is also possible to incorporate the variant xylanase enzyme into a second (and different) food and/or feed or drinking water which is then added to the food and/or feed supplement of the present invention. Accordingly, it is not essential that the variant xylanase enzyme provided by the present invention is incorporated into the cereal-based food and/or feed supplement itself, although such incorporation forms a particularly preferred aspect of the present invention.

In one embodiment of the present invention, the food and/or feed supplement may be combined with other food and/or feed components to produce a cereal-based food and/or feed. Such other food and/or feed components may include one or more other (preferably thermostable) enzyme supplements, vitamin food and/or feed supplements, mineral food and/or feed supplements and amino acid food and/or feed supplements. The resulting (combined) food and/or feed supplement comprising possibly several different types of compounds can then be mixed in an appropriate amount with the other food and/or feed components such as cereal and protein supplements to form a human food and/or an animal feed.

In one preferred embodiment, the food and/or feed supplement of the present invention can be prepared by mixing different enzymes having the appropriate activities to produce an enzyme mix. By way of example, a cereal-based food and/or feed supplement formed from e.g. milled wheat or maize may be contacted (e.g. by

WO 03/020923

10

15

20

PCT/IB02/03797

spraying) either simultaneously or sequentially with the xylanase enzyme and other enzymes having appropriate activities. These enzymes may include but are not limited to any one or more of an amylase, a glucoamylase, a mannanase, an a galactosidase, a phytase, a lipase, a galactolipase, a phospholipase, a glucanase, an arabinofuranosidase, a pectinase, a protease, a glucose oxidase, a hexose oxidase and a xylanase. Enzymes having the desired activities may for instance be mixed with the xylanase of the present invention either before contacting these enzymes with a cereal-based food and/or feed supplement or alternatively such enzymes may be contacted simultaneously or sequentially on such a cereal based supplement. The food and/or feed supplement is then in turn mixed with a cereal-based food and/or feed to prepare the final food and/or feed. It is also possible to formulate the food and/or feed supplement as a solution of the individual enzyme activities and then mix this solution with a food and/or feed material prior to processing the food and/or feed supplement into pellets or as a mash.

The variant xylanase of the present invention may be used in combination with other components. Thus, the present invention also relates to combinations.

The combination of the present invention comprises the variant of the present invention and another component which is suitable for animal or human consumption.

Further examples of other suitable components include one or more of: thickeners, gelling agents, emulsifiers, binders, crystal modifiers, sweeteners (including artificial sweeteners), rheology modifiers, stabilisers, anti-oxidants, dyes, enzymes, carriers, vehicles, excipients, diluents, lubricating agents, flavouring agents, colouring matter, suspending agents, disintegrants, granulation binders etc. These other components may be natural. These other components may be prepared by use of chemical and/or enzymatic techniques.

As used herein the term "component suitable for animal or human consumption" means a compound which is or can be added to the composition of the present

-35-

5 invention as a supplement which may be of nutritional benefit, a fibre substitute or have a generally beneficial effect to the consumer.

Bakery products

The present invention provides the use of a variant xylanase polypeptide of the invention in a process for preparing a foodstuff. Typical bakery (baked) products in accordance with the present invention include bread - such as loaves, rolls, buns, pizza bases etc. - pretzels, tortillas, cakes, cookies, biscuits, crackers etc. The preparation of foodstuffs such as bakery products is well known in the art.

15

20

25

30

The present invention advantageously provides a variant xylanase polypeptide capable of improving the properties of flour based doughs and products made from such doughs. This is, in respect of baked products, achieved by providing a method for preparing baked products which have highly desirable characteristics with respect to bread volume, crumb structure and appearance and which additionally have an extended shelf life as reflected in an enhanced softness, i.e. the staling of the baked products is retarded relative to a baked product made without use of the enzyme of the invention. Although it is presently preferred to use the method for the manufacturing of yeast leavened bread products such as bread loaves, rolls or toast bread, the use of the method for any other types of doughs and dough based products such as noodle and pasta products and cakes, the quality of which can be improved by the addition of the enzymes of the invention, is also contemplated.

The present invention further relates to pasta doughs, noodle doughs and cake doughs or batters comprising the variant xylanase polypeptide and finished products made from such doughs or batters.

Starch production

A variant xylanase of the invention may also be used in starch production from plant materials derived from cereals and tubers, such as potatoes.

Processing of wood pulp

A variant xylanase of the invention may also be used in processing wood pulp, for example in the preparation of paper.

The present invention will now be further described with reference to the following examples which are intended to be illustrative only and non-limiting.

20 EXAMPLES

Example 1 - Purification and characterisation of wheat endogenous xylanase inhibitor.

25 2 kg wheat flour (Danish reform, batch 99056) was extracted with water, using a flour:water ratio of 1:2, during 10 minutes of stirring. The soluble endogenous xylanase inhibitor was separated from the flour-water slurry by centrifugation. The extraction and centrifugation was performed at 4°C. The inhibitor was purified from the water extract by the following chromatographic techniques and concentration techniques: HPLC-SEC, HPLC-CIEC, rotary evaporation, HPLC-HIC, HPLC-SEC and rotary evaporation. The xylanase inhibitor could be monitored and quantified during purification, using the following quantification method.

Inhibitor quantification method

1 XIU (Xylanase Inhibitor Unit) is defined as the amount of inhibitor that decreases 1 TXU to 0.5 TXU under the conditions described below.

10

15

The xylanase used in this assay is Bacillus subtilis wild type xylanase.

250 μ l xylanase solution containing 12 TXU/ml, approx. 100 μ l xylanase inhibitor solution and citric acid (0.1 M) - di-sodium-hydrogen phosphate (0.2 M) buffer, pH 5, to react a reaction volume of 1000 μ l is pre-incubated for 5 minutes at 40°C. At t = 5 minutes, 1 Xylazyme (Megazyme, Ireland) tablet is added to the reaction mixture. At t = 15 minutes the reaction is terminated, by addition of 10 ml 2 % TRIS/NaOH, pH 12. The solution is filtered and the absorbency of the supernatant is measured at 590 nm. By choosing several different concentrations of inhibitor in the above assay, it is possible to create a plot of OD versus inhibitor concentration. Using the slope (a) and intercept (b) from this plot and the concentration of the xylanase it is possible to calculate the amount of XIU in a given inhibitor solution (equation 1).

Equation 1

amount of XIU in solution = ((b/2)/-a)/TXU

25

20

From the endogenous xylanase inhibitor purification, the following inhibitor yield was recovered (table 1).

Table 1. Wheat endogenous xylanase inhibitor recovery after purification.

30

Sample	Amount	XIU	XIU, total	Recovery, %
Flour	2000 g	590/g	1.180.000	100
Purified inhibitor	90 ml	4658/ml	419.220	35.5

The inhibitor sample was pure and free from wheat endogenous xylanolytic activities.

5 .

10

15

Example 2 - Site-directed mutagenesis on xylanases.

Specific mutants of *Bacillus subtilis* xylanase may be obtained by site directed mutagenesis of the wild type enzyme, by the use of any of a number of commercially available mutagenesis kits. An example of how to obtain the D11F mutant using the Quick Exchange kit, available from Stratagene Cloning Systems, 11011 North Torrey Pines Road, La Jolla, CA 92037, USA is given below:

The DNA sequence encoding *Bacillus subtilis* xylanase A has been published by Paice et al., 1986.

The sequence of the coding region is as follows, with the sequence encoding the mature part of the protein shown in capitals:

20 catatgtttaagtttaaaaagaatttcttagttggattatcggcagctttaatgagtatt
agcttgttttcggcaaccgcctctgcaGCTAGCACAGACTACTGGCAAAATTGGACTGAT
GGGGGCGGTATAGTAAACGCTGTCAATGGGTCTGGCGGGAATTACAGTGTTAATTGGTCT
AATACCGGAAATTTTGTTGTTGGTAAAGGTTGGACTACAGGTTCGCCATTTAGGACGATA
AACTATAATGCCGGAGTTTGGGCGCCGAATGGCAATGGATATTTAACTTTATATGGTTGG
25 ACGAGATCACCTCTCATAGAATATTATGTAGTGGATTCATGGGGTACTTATAGACCTACT
GGAACGTATAAAGGTACTGTAAAAAGTGATGGGGTACATATGACATATATACAACTACA
CGTTATAACGCACCTTCCATTGATGGCGATCGCACTACTTTTACGCAGTACTGGAGTGTT
CGCCAGTCGAAGAGACCAACCGGAAGCAACGCTACAATCACTTTCAGCAATCATGTGAAC
GCATGGAAGAGCCATGGAATGAATCTGGGCAGTAATTGGGCTTACCAAGTCATGGCGACA
30 GAAGGATATCAAAGTAGTGGAAGTTCTAACGTAACAGTGGGTAA

The part of the gene encoding the mature part of the wild type enzyme may be expressed intracellularly in *E.coli* by methods well known to people skilled in the art of molecular biology. For example:

35

 Generating a copy of the capitalised part of the above described gene by use of the Polymerase Chain Reaction (PCR) with an added Ndel restriction enzyme site

-39-

5 (CATATG) before the GCTAGCACA and an added HindIII restriction site (AAGCTT) after the GTGTGGTAA.

- 2. Inserting the resultant modified copy of the gene by use of the above mentioned enzymes into the expression vector pET24a(+), which can be obtained from Novagen, Inc. 601 Science Drive, Madison, WI 53711, USA.
- 3. Transforming into a suitable E.coli strain and expression by fermentation as described by the vendor of pET24a(+).

Our D11F mutant enzyme may be obtained by using the "Quick Exchange" mutagenesis kit according to the manufacturer, and using the above described *Bacillus* subtilis wild type xylanase-pET24a(+) construct and the following PCR mutagenesis primers:

Sense primer:

CTACTGGCAAAATTGGACTTTTGGAGGAGGTATAGTAAACGCTG

20

25

15

Antisense primer:

CAGCGTTTACTATACCTCCTCCAAAAGTCCAATTTTGCCAGTAG

The mutant enzyme is expressed and purified using the same protocols as for the wild type enzyme.

Example 3 - Inhibition studies of xylanase mutants.

Xylanase mutants expressed in *E. coli* (see Example 2) were fermented and purified (meaning no other xylanolytic activity was present in the purified preparation) using a de-salting step and a cation exchange chromatography step.

These pure xylanase mutant preparations were diluted to 12 TXU/ml using 0.1 M citric acid - 0.2 M di-sodium-hydrogen phosphate, pH 5.0 and used in the following assay.

A stable inhibitor preparation was made according to the protocol described in Example 1. This stable inhibitor preparation is used as stock for all xylanase-xylanase inhibitor studies. Using the inhibitor quantification method described in Example 1, the inhibitor preparation was analysed to contain 126 XIU/ml.

10 Assay

To 250 μl diluted xylanase mutant preparations, are added 0, 10, 25, 50 or 100 μl inhibitor preparation, respectively. To these inhibitor-xylanase mixtures were added 0.1 M citric acid - 0.2 M di-sodium-hydrogen phosphate, pH 5.0 making the end-volume 1000 μl. These reaction mixtures were pre-incubated for 5 minutes at 40°C. Hereafter 1 Xylazyme tablet (Megazyme, Ireland) were added to all inhibitor-xylanase mixtures. After 10 minutes of incubation at 40°C, the reactions were terminated, by adding 10 ml 2% Tris/NaOH, pH 12.0. The mixtures were centrifuged and the liberated blue colour from the substrate was measured at 590 nm.

20

15

The results in respect of one variant xylanase are presented in table 2.

Table 2. Relative inhibition of a xylanase mutant and parent xylanase (here wildtype enzyme) as a function of xylanase inhibitor.

25

	Xyla	nase Inhibit	or (XIU/ml)
0	1,26	3,15	6,3	12,6
	Relativ	e inhibition,	%	
100	77	48	29	23
	101	88	70	50
		0 1,26 Relativ 100 77 100 101	0 1,26 3,15 Relative inhibition, 100 77 48 100 101 88	Relative inhibition, %

From the results in Table 2, it can be seen that the variant xylanase has a changed sensitivity towards the wheat endogenous xylanase inhibitor.

-41-

Other suitable variant xylanases having changed inhibitor sensitivity include those based on *B. subtilis* xylanase with the following mutations:

i)D11F/K99N/T111M/T126Q/Y128F/A142V/T143S/T147S/K154R/H156K/N163S/M 169L/S179R

ii)N32K/K99N/T111M/T126Q/Y128F/A142V/T143S/T147S/K154R/H156K/N163S/

10 M169L/S179R

iii)T123D/N8Y/S22P/N29T/T44V/F48N/T50V/V57I/A59E/N61S/S74N/P75A/P90A/ T93N

Example 4 - Thermostability studies of xylanase mutants.

15

25

Xylanase mutants expressed in *E. coli* (see Example 2) were fermented and purified (meaning no other xylanolytic activity were present in the purified preparation).

The xylanase mutants were analysed according to the "thermostability assay" 20 mentioned above.

Suitable variant xylanases having altered thermostability include those based on *B. subtilis* xylanase with the following mutations:

i)D11F/K99N/T111M/T126Q/Y128F/A142V/T143S/T147S/K154R/H156K/N163S/M 169L/S179R

ii)N32K/K99N/T111M/T126Q/Y128F/A142V/T143S/T147S/K154R/H156K/N163S/ M169L/S179R

iii)T123D/N8Y/S22P/N29T/T44V/F48N/T50V/V57I/A59E/N61S/S74N/P75A/P90A/ T93N

30 iv)D121F/N8Y/S22P/N29T/T44V/F48N/T50V/V57I/A59E/N61S/S74N/P75A/P90A/ T93N

Variant xylanases had an altered thermostability compared to the wild type xylanase.

-42-

5 Example 5. Temperature optimum studies of xylanase mutants.

Xylanase mutants expressed in *E. coli* (see Example 2) were fermented and purified (meaning no other xylanolytic activity were present in the purified preparation).

The xylanase mutants were analysed according to the "temperature optimum assay" mentioned above.

Suitable variant xylanases having altered thermostability include those based on *B. subtilis* xylanase with the following mutations:

- i)D11F/K99N/T111M/T126Q/Y128F/A142V/T143S/T147S/K154R/H156K/N163S/M 169L/S179R
 - ii)N32K/K99N/T111M/T126Q/Y128F/A142V/T143S/T147S/K154R/H156K/N163S/ M169L/S179R
 - iii)T123D/N8Y/S22P/N29T/T44V/F48N/T50V/V57I/A59E/N61S/S74N/P75A/P90A/

20 T93N

iv)D121F/N8Y/S22P/N29T/T44V/F48N/T50V/V57I/A59E/N61S/S74N/P75A/P90A/ T93N

Variant xylanases have changed temperature optima compared to the wild type xylanase.

Example 6. Xylanase variant having changed inhibitor-sensitivity and changed thermo-sensitivity – (A)

A variant of *Bacillus subtilis* 168 xylanase A, with changed inhibitor sensitivity and with altered thermo-sensitivity may be engineered by combining mutation D11F (changing inhibitor sensitivity) with mutations K99N, T111M, T126Q, Y128F, A142V, T143S, T147S, K154R, H156K, N163S, M169L, S179R (changing thermosensitivity).

20

Example 7. Xylanase variant having changed inhibitor-sensitivity and changed thermo-sensitivity – (B)

A variant of *Bacillus subtilis* 168 xylanase A, with changed inhibitor sensitivity and with altered thermo-sensitivity may be engineered by combining mutation N32K (changing inhibitor sensitivity) with mutations K99N, T111M, T126Q, Y128F, A142V, T143S, T147S, K154R, H156K, N163S, M169L, S179R (changing thermosensitivity).

Example 8. Xylanase variant having changed inhibitor-sensitivity and changed thermo-sensitivity – (C).

A variant of *Bacillus subtilis* 168 xylanase A, with changed inhibitor sensitivity and with altered thermo sensitivity may be engineered by combining mutation T123D (changing inhibitor sensitivity) with mutations N8Y, S22P, N29T, T44V, F48N, T50V, V57I, A59E, N61S, S74N, P75A, P90A, T93N (changing thermo-sensitivity).

Example 9. Xylanase variant having changed inhibitor-sensitivity and changed thermo-sensitivity – (D).

A variant of *Bacillus subtilis* 168 xylanase A, with changed inhibitor sensitivity and with altered thermo sensitivity may be engineered by combining mutation D121F (changing inhibitor sensitivity) with mutations N8Y, S22P, N29T, T44V, F48N, T50V, V57I, A59E, N61S, S74N, P75A, P90A, T93N (changing thermo-sensitivity).

30 Example 10. Inhibition studies of xylanase variants

B. subtilis xylanase mutants were obtained by site directed mutagenesis of the wild type enzyme (see example 2). The following variants were used in this example:

5 S2A/N8Y/I15M/S22P/N29T/S31Q/T44V/F48N/T50V/V57I/A59E/N61S/S74N/P75A/ D121F

-44-

Mut 2:

WO 03/020923

S2A/N8Y/I15M/S22P/N29T/S31Q/T44V/F48N/T50V/V57I/A59E/N61S/S74N/P75A/ T123D

10

20

These mutants were expressed in *E. coli* (see Example 2), fermented and purified (meaning no other xylanolytic activity was present in the purified preparation) using a de-salting step and a cation exchange chromatography step.

These pure xylanase mutant preparations were evaluated for inhibitor sensitivity, using the "Xylanase inhibitor assay" mentioned previously.

A stable inhibitor preparation was made according to the protocol described in Example 1. This stable inhibitor preparation was used as stock for all xylanase-xylanase inhibitor studies. Using the "inhibitor quantification method" described in example 1, the inhibitor preparation was analysed to contain 126 XIU/ml.

The results are presented in Table 3.

Table 3. Relative inhibition of xylanase mutants and a parent xylanase (here wild type B. subtilis enzyme) as a function of xylanase inhibitor concentration, XIU/ml. The activity is expressed as a percentage of the activity at a given inhibitor concentration relative to the activity when XIU/ml =0.

	I	ahibitor co	ncentrati	on, XIU	ml .
Xylanase	0	1,26	3,15	6,3	12,6
Wt	100	76	50	30	23
Mut 1	100	92	73	51	33

-45-

As can be seen from Table 3, the mutations introduced in the parent xylanase changed the sensitivity of the variant xylanases towards the wheat endogenous xylanase inhibitor.

In addition, the xylanase mutant (Mut 2) has was less stable to the wheat endogenous xylanase inhibitor at the concentration 1,26 XIU/ml.

Example 11. Thermostability studies of xylanase mutants

B. subtilis xylanase mutants were obtained by site directed mutagenesis of the wild type enzyme (see example 2). The following variants were used in this example:

Mut 1:

S2A/N8Y/I15M/S22P/N29T/S31Q/T44V/F48N/T50V/V57I/A59E/N61S/S74N/P75A/ D121F

20 Mut 2:

S2A/N8Y/I15M/S22P/N29T/S31Q/T44V/F48N/T50V/V57I/A59E/N61S/S74N/P75A/ T123D

These mutants were expressed in *E. coli* (see Example 2), fermented and purified (meaning no other xylanolytic activity was present in the purified preparation) using a de-salting step and a cation exchange chromatography step.

These xylanase mutant preparations were evaluated for thermostability, using the "thermostability assay" mentioned previously.

30

The results are presented in Tables 4-7.

Table 4. Thermostability of a parent xylanase (here wild type *B. subtilis* xylanase) and variants thereof as a function of incubation time at 50°C. The results are represented

as a percentage of the activity at given incubation time relative to the activity when time = 0 hour.

Time (hr)	wt	Mut 1	Mut 2
0	100	100	100
.0.5	89	106	99
1	91	101	102
2	88	105	100
3	86	103	100
4	87	104	97

Table 5. Thermostability of parent xylanase (here wild type B. subtilis xylanase) and variants thereof as a function of incubation time at 55°C. The results are represented as a percentage of the activity at given incubation time relative to the activity when time = 0 hour.

Time (hr)	wt	Mut 1	Mut 2
0	100	100	100
0.5	60	105	99
1	40	102	92
2	30	101	95
3	23	102	88
4	18	99	86

15

Table 6. Thermostability of a parent xylanase (here wild type *B. subtilis* xylanase) and variants thereof as a function of incubation time at 60°C. The results are represented as a percentage of the activity at given incubation time relative to the activity when time = 0 hour.

Time (hr)	wt	Mut 1	Mut 2
0	100	100	100
0.5	-	92	101
1	-	75	85
2	-	56	68
3	-	44	50
4	-	33	39

Table 7. Thermostability of a parent xylanase (here wild type B. subtilis xylanase) and variants thereof as a function of incubation time at 65°C. The results are represented as a percentage of the activity at given incubation time relative to the activity when time = 0 hour.

10

15

Time (hr)	wt	Mut 1	Mut 2
0	100	100	100
0.5	-	2	4
1	-	•	-
2	•	-	-
3	<u>-</u>	-	-
4	•	•	-

As can be seen from Tables 4–7, the mutations introduced in the parent xylanase changed the sensitivity of the variant xylanases to temperature (thermostability). At approx. 60°C two of the variants are more stable than the parent xylanase (here wild type).

Example 12. Temperature optimum studies of xylanase mutants.

B. subtilis xylanase mutants were obtained by site directed mutagenesis of the wild type enzyme (see example 2). The following variants were used in this example:

-48-

5. Mut 1:

S2A/N8Y/I15M/S22P/N29T/S31Q/T44V/F48N/T50V/V57I/A59E/N61S/S74N/P75A/ D121F

Mut 2:

S2A/N8Y/I15M/S22P/N29T/S31Q/T44V/F48N/T50V/V57I/A59E/N61S/S74N/P75A/

10 T123D

These mutants were expressed in *E. coli* (see Example 2), fermented and purified (meaning no other xylanolytic activity was present in the purified preparation) using a de-salting step and a cation exchange chromatography step.

15

These pure xylanase mutant preparations were evaluated for temperature optimum, using the "temperature optimum assay" mentioned previously.

The results are presented in Table 8.

20

Table 8. Temperature optimum of a parent xylanase (here wild type *B. subtilis* xylanase) and variants thereof. The results are represented as a percentage of the activity at a given temperature relative to the highest activity.

Temp (°C)	wt	Mut 1	Mut 2
30	37	22	27
40	66	46	51
50	100	86	87
60	17	100	100

25

As can be seen from Table 8, the mutations introduced in the parent xylanase changed the temperature optimum profile of the variant xylanases compared to the parent xylanase (here wild type *B. subtilis*). The variants have an approx. 10°C higher optimum than the parent xylanase.

-49-

5 SUMMARY

In summary, the present invention provides a means for altering the inhibitor sensitivity of a xylanase enzyme combined with a means for changing the thermostability and/or the temperature optimum of the enzyme. In this way, the inhibitor sensitivity and the thermosensitivity of the xylanase enzyme can be independently controlled.

All publications mentioned in the above specification are herein incorporated by reference. Various modifications and variations of the described methods and system of the present invention will be apparent to those skilled in the art without departing from the scope and spirit of the present invention. Although the present invention has been described in connection with specific preferred embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention which are obvious to those skilled in biochemistry and biotechnology or related fields are intended to be within the scope of the following claims.

10

15

PCT/IB02/03797

5 References

Debyser, W. and Delcour, J. A. (1998). Inhibitors of cellolytic, xylanolytic and β-glucanolytic enzymes. WO 98/49278.

10

Debyser, W. Peumans, W.J., Van Damme, E.J.M. and Delcour, J. (1999). TAXI, A new class of enzyme inhibitors affecting bread volume. Journal of Cereal Science.

McLauchlan, R., Garcia-Conesa, M. T., Williamson, G., Roza, M., Ravestein, P. and MacGregor, A. W.. (1999a). A novel class of protein from wheat which inhibits xylanases. Biochem.J.. 338. 441-446.

McLauchlan, R, Flatman, R et al (1999b) Poster Presentation from meeting at University of Newcastle (1999) April 11th-April 17th. Xylanase inhibitors, a novel class of proteins from cereals.

Paice, M.G., Bourbonnais, R., Desrochers, M., Jurasek, L. and Yaguchi, M. (1986): A Xylanase Gene from *Bacillus subtilis*: Nucleotide Sequence and Comparison with *B. pumilus* Gene. *Arch. Microbiol.* 144, 201-206.)

Rouau, X. and Surget, A. (1998). Evidence for the presence of a pentosanase inhibitor in wheat flour. Journal of Cereal Science. 28, 63-70.

30

25

Sibbesen, O. and Soerensen, J.F. (1999). Bacterial xylanase. UK A 9828599.2.

SEQUENCE LISTINGS

The amino acid sequence of the mature Bacillus subtilis xylanase (SEQ ID. No. 1).

1 10 11 20 21 30 31 40 41 50 51 60 ASTDYWQNWT DGGGIVNAVN GSGGNYSVNW SNTGNFVVGK GWTTGSPFRT INYNAGVWAP

61 70 71 80 81 90 91 100 101 110 111 120 NGNGYLTLYG WTRSPLIEYY VVDSWGTYRP TGTYKGTVKS DGGTYDIYTT TRYNAPSIDG

121 130 131 140 141 150 151 160 161 170 171 180 DRTTFTQYWS VRQSKRPTGS NATITFSNHV NAWKSHGMNL GSNWAYQVMA TEGYQSSGSS

181 NVTVW

Amino acid sequences derived from wheat flour xylanase inhibitor

A chain of inhibitor

N-terminal:

GAPVARAVEAVAPFGVCYDTKTLGNNLGGYAVPNV (35aa) SEQ ID NO. 2

C-terminal:

KRLGFSRLPHFTGCGGL (17aa) SEQ ID NO. 3

B chain of inhibitor

N-terminal:

LPVPAPVTKDPATSLYTIPFH (21aa) SEQ ID NO. 4

Lys-C digested B Chain:

LLASLPRGSTGVAGLANSGLALPAQVASAQK (31aa) SEQ ID NO. 5
GGSPAHYISARFIEVGDTRVPSVE (24aa) SEQ ID NO. 6
VNVGVLAACAPSK (13aa) SEQ ID NO. 7
VANRFLLCLPTGGPGVAIFGGGPVPWPQFTQSMPYTLVVVK SEQ ID NO. 8

CLAIMS

- 1. A method of altering the sensitivity of a xylanase polypeptide to an inhibitor and of altering the thermo-sensitivity of said xylanase polypeptide, which method comprises modifying a parent xylanase polypeptide to provide a variant xylanase polypeptide, and testing the sensitivity of said variant xylanase polypeptide to a xylanase inhibitor compared with the parent xylanase enzyme and testing the thermosensitivity of said variant xylanase polypeptide compared with the parent xylanase enzyme and selecting a variant xylanase polypeptide having an altered sensitivity to a xylanase inhibitor and an altered thermo-sensitivity compared with the parent xylanase enzyme.
- 2. A method according to claim 1 wherein said variant polypeptide is derived from a family 11 xylanase.
- 3. A method according to claim 1 wherein there are at least two of said amino acid modifications.
- 4. A method according to any one of the preceding claims wherein said amino acid modification is at any one or more of amino acid residues:
 - 2, 8, 11, 12, 13, 15, 17, 22, 29, 31, 32, 34, 44, 48, 50, 57, 59, 61, 74, 75, 90, 93, 99, 111, 113, 114, 119, 120, 121, 122, 123, 124, 126, 128, 142, 143, 147, 154, 156, 163, 169, 175 and 179, or combinations hereof, based on the amino acid numbering of *B. subtilis* xylanase shown as SEQ ID No. 1, or the equivalent residues in other homologous xylanase polypeptides.
 - 5. A method according to any one of the preceding claims wherein the inhibitor is an inhibitor found naturally in plant tissues.

- 6. A method according to any one of the preceding claims wherein the sensitivity to an inhibitor is reduced.
- 7. A variant xylanase polypeptide obtainable by the method according to any one of claims 1 to 6.
- 8. A variant xylanase polypeptide, or fragment thereof having xylanase activity, comprising one or more amino acid modifications such that the polypeptide or fragment thereof has an altered sensitivity to a xylanase inhibitor as compared with a parent xylanase enzyme and has an altered thermo-sensitivity as compared with a parent xylanase enzyme.
- 9. A variant polypeptide according to claim 8 which is derived from a family 11 xylanase.
- 10. A variant xylanase polypeptide, or fragment thereof having xylanase activity, according to any one of claims 8-9 wherein there are at least two of said amino acid modifications.
- 11. A variant xylanase polypeptide, or fragment thereof having xylanase activity according to any one of claims 8-10 wherein said amino acid modification is at any one or more of amino acid residues:
- 2, 8, 11, 12, 13, 15, 17, 22, 29, 31, 32, 34, 44, 48, 50, 57, 59, 61, 74, 75, 90, 93, 99,
 10 111, 113, 114, 119, 120, 121, 122, 123, 124, 126, 128, 142, 143, 147, 154, 156, 163, 169, 175 and 179, or combinations thereof, based on the amino acid numbering of B. subtilis xylanase shown as SEQ ID No. 1, or the equivalent residues in other homologous xylanase polypeptides.
 - 12. A variant xylanase polypeptide according to any one of claims 8-11 wherein the inhibitor is an inhibitor found naturally in plant tissues.

- 13. A variant xylanase polypeptide according to any one of claims 8-12 wherein the sensitivity to an inhibitor is reduced.
- 14. A method of altering the sensitivity of a xylanase polypeptide to an inhibitor and of altering the thermo-sensitivity of said xylanase polypeptide enzyme, which method comprises modifying one or more amino acid residues of said enzyme such that the polypeptide or a fragment thereof has an altered sensitivity to a xylanase inhibitor and has an altered thermo-sensitivity as compared with the parent xylanase enzyme.
- 15. A method according to claim 14 wherein said variant polypeptide is that defined in any one of claims 8 to 13.
- 16. A method according to claim 14 or claim 15 wherein the sensitivity of the enzyme to an inhibitor is reduced.
- 17. A composition comprising a variant polypeptide according to any one of claims 7 to 13.
- 18. A method of degrading or modifying a plant cell wall which method comprises contacting said plant cell wall with a polypeptide according to any one of claims 7 to 13 or a composition according to claim 17.
- 19. A method of processing a plant material which method comprises contacting said plant material with a polypeptide according to any one of claims 7 to 13 or composition according to claim 17.
- 5 20. A nucleotide sequence encoding a variant polypeptide according to any one of claims 7 to 13.

- 5 21. A construct comprising the nucleotide sequence according to claim 20.
 - 22. Use of a variant polypeptide according to any one of claims 7 to 13 in a method of modifying plant materials.
 - 23. Use of a variant polypeptide according to any one of claims 7 to 13 in any one or more of: baking, processing cereals, starch production, in processing wood, enhancing the bleaching of wood pulp.

) r	? .	7 6	35	44	0	20	16	45	54	54	20	53	4	47	47	46	14	47	Ծ	20	46	64	54	55	28	26	57	o .	7 6	2 5		7 5	* ;	2.6	7 0	9 8						41				7	4	4. t
06 90	# 5 K K	ACE OF A	TOTOWN TOTOWN	SAATOT	SAATUI	RONTPNGEGTHNGCF	ROSTPNGEGTHNGCF	RAGIPSSOGIHNGCF	ASGTPSSTGTDGGYY	ROTTPNSEGWHDGYY	ROSTPSAEGYHNGYF	ROSTPSSEGYHNGYF	ROVTPNAEGWHNGYF	ROSTPSSTGRHNGYY	RAGTPSGTGTNNGYF	ROTIOPGTGYNNGYF	ROTIOPGTGYNNGYF	RQTIQPGTGYNNGYF	-QTIGPGTGYSNGYY	ROTIGPGTGFNNGYY	OTLTSSQTGTNNGYY	ERSTPSSTGENNGFY	QTITSSQTGTNNGYY	TTITINGIGYDG-MY	TVITTNOTGTNNGYY	-TITSNOTGTHNGYF	PVITTNOTGTNNGWW	VTSNETGYHDGYF	AAVDSNSTGSSGGYF	RAITSSETGINNGYY	MOMTPRINSCYGGGLY	OTLINNATGTHNGFY	OTLESSNETGINNER Y	KVLINNELGENNGF I			N194		VICAHADHRRACIV	ETTYDNRIGHTSGYD	RTITNNEMGNHSGYD	KTITSNEIGVNGGYD	VVITSNOTGTGGGYN	AAITSNEIGTHDGYD	QTFYNNAGGQIDGLD		QVFTKNARGTSDGYD	MTFTSNATGTYDGYY	ITLISNASGIFDGYY	-AADQQTRGNVGGYD
63							DIVA	ALTA	K	ELEK		LLEK	POTE	DIMR	ELVA	AVEK	AVEK	AVEK			THE PERSON NAMES	HMLS	HDKR		ARAD	ARAD	ATAA	AHAA	4308	ELAK	73	40	WI		; ; ; ; ; ; ; ; ; ; ;				JAN.	AHA	AHA	STOKTYSAFINTOAAP	VRAD	EAE			KDSKNG	¥	S	
9	•						ARAPS	TRSLG			ERDDVNATA	ERDDGNATA	RDNST	NMTG-FPFE	NAO	PVV9	AS	SV		ΛΛΛΛ		L		1111111111111111	L	TT	TI	A	A	Λ			: : : : : : : : : : : : : : : : : : : :	: : : : : : : : : : : : : : : : : : :			1111111111111111				1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	TNINTTESTFSKEVL				1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	SKKSADSAK-ADSN-			
Figure 1	CF # 00 * 00 * 00 * 00 * 00 * 00 * 00 * 0	LSAALMSISLESATA	LSAALMSISLESATA	LLTASMSFGLFGATS	VLAASMSFGVFAATS		VAATGALAAPATDIA	VAATGALAVPVTDLA		LAATGALAFPAGNAT	VATTSVLAAPFDFLR	VATTSVLAAPFDFLR	TAVSSAIAAPFDEVP	VALAGSALAIPAPDG	AGALAFPENVT	AAISGVLAAPAAEVE	AAISGVLAAPAAEVE	PPSR-ASCRPAAEVE		VAVIGVLSAPTETVE	SAAVVAVAAPGELPG	LAVPHDSVAQRS-DA	MAVPG-EYHKR	GTVALATASGLLLPS	GALALATSG-LMLPG	WALALAALAAMMFGG	WAVLLAALAVMLLPG	FAAALVAVVTMIPST	ATVAMVIAGVA	SAVSGALAAPGDSTL	GAISCVSAAPAAS-	LAALFCSALLGVNNT	VRTLMGAVALGAISV	QFLIPVVILCVSLVD		VIAFAAPVPEPVLVS	VIAFAAFEFULVS	ARHSPPLSTELVTRS	MOTOT TOTOGRANIA	MARIOLEFESSON V.	1.TI,TTAVP	VMTSLTIVDNTAFAA	FTVSLTLFPVN	LGIGLLFFSEN	IALFGLIEA		GVLGSCGNSSDKDSS	VVLANPFYAQA	VAVYTQVNAQT	VSALMIASAAPVVAS
						MVSFTSIITAA	MVSFTSIITAA	MVSFTSIFTAA		MVGFTPVALAA	MVSFKSLLLAA		MVSLKSVLAAA	MVSFTSIVTAV	MVSFKALLLGA	MVSFTSLLAGV	MVSFTSLLAGV	MVSFTSLLAAS	* * * * * * * * * * * * * * * * * * * *	MVSFTTLLAGF	MVNFSSLFLAA	LTKNLLLCFAAAKAA	SFIAYLLASVAVTGV	APFSGLSRRGFLGGA	TPIRPVSRRGFIGRA	GRAGGLRLLVRAA	GRRHGRSAPMSPRST	KSRRRFRPRLLIGKA	PPAGGRIARALAAAG	MVSFSSLLLAV	MELTSVVSLVV	MKFPLIGKST	KLPI	E		MKVTAAFAGLL	MKVIAAFAGLL	MKVTAAFAGLL	THOUSE TOWN TOWN	MILKRIBILENMOTE	MNI.RKI.RI.I.FVMCTG	-MLRRKVIFTVLATL	-MKOKLLVTFLILIT	MKOVKIMFLMTMF	EKVICLL		KMRVMAGVAAVICLA	DWWC	MFLKKLSKLLVVLL	MKLSKIKKVLSGT
									111111111111													W	XM	MOODGKRODONOONP	NOTH	OGHATIANHPO	MNAFAHPR	MNHAPASI	MTRTISRAAHR		***************************************		1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1						W. W.	C						1 3 2 4 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	MRNNF		1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	
		B. Subtilis XVIA		B. stearothermophilus xylA		C. carbonum xyll	H. turcicum xyll	A. pist xyl	S. commune xvlA	T. lanuginosus xvlA	C. carbonum xv12	C. sativus xv12	H. insolens xvll	M. grisea xv122	C. gracile cgxa	T. reesel xv12(2)	T. reesei. ALKO2721 Xv12	T. reesei xyll	T. harzianum xylD	T. viride xyl	C. gracile cgxB	A. niger xyl2	Penicillium sp 40 xylA		-	S. thermocyaneoviolaceus xylB		T. fusca xyl		A. oryzae XylGl	C. purpurea xyll		P. fluorescens cellulosa xyl	P. cochleariae xyl	A. Kawachi Xyic	A. niger xyll	A. tubigensis xyli	P. purpurogenum xylB	T your will	I. recort Ayra			C. thermocellum XvlB		P. multivesiculatum xylA	P. multivesiculatum xyl		-	D. thermophilum xynB	R. flavefaciens xylA

GEGGRYSVWING.—NT GNEVVGKGWTTG.———SPRINTINYNAGUA RANGOG—YILLYGW GEGGRYSVWING.—NT GNEVVGKGWTTG.———SPRINTINYNAGUA RANGOG—YILLYGW GEGGSYSVGGA.—NT GNEVVGKGWTTG.———GRARITYSGTY RANGOG—YILLYGW GEGGSYSVGGA.—SG GNEVGGKGWPT.———GRARITYSGTY RANGOG—YILAYGW GEGGSYSVGGA.—GG GNEVGGKGWPP.———GRARITYSGTY RONGOG—YILAYGW GEGGSYSVGGAGNAP———GGARRITYSGTY RONGOG—YILAYGW GEGGSSYVGWG—NG GNEVGGKGWPP———GGARRITYSGTY RONGOG—YILAYGW GEGGSSYVGWG—NG GNEVGGKGWPP———GGARRITYSGTY RONGOG—YILAYGW GEGGSSYVGWG—NG GNEVGGKGWPP———GGARRITYSGTY RONGOG—YILAYGW GEGGSSYVGWG—NG GNEVGGKGWPP———GGARRITYSGTY RONGOG—YILAYGW GEGGSSTVWMS—NS GNEVGGKGWPP———GGARRITYSGTY RONGOG—YILAYGW GGGGSSTVWMS—NS GNEVGGKGWPP———GGARRITYRAYSGTY RONGOG—YILAYGW GGGGSSTVWMG—NS GNEVGGKGWPP———GGARRITYRAYSGTY RONGOG—YILAYGW GGGGSSTVWMG—NS GNEVGGKGWPP———GGARRITYRAYSGTY RONGOG—YILAYGW GGGGSSTVWMG—NS GNEVGGKGWPP————GGARRITYRAYSGTY RONGOG—YILAYGW GGGGSSTVWMG—NS GNEVGGKGWPP————GGARRITYRAYSGTY RONGOG—YILAYGW GGGGSSTVWMG—NS GNEVGGKGWPP————GGARRITYRAYSGTY RONGOG—YILAYGW GGGGSSTVWMG—NS GNEVGC	Figure 1 continued	91 105	120	ß			166 180	;
WORTDOGGENARM GENERALISTYCH—IN GENERALITY GE	lis xylA	WONWIDGGGIVNAVN	_	GNEVVGKGWTTG		APNGNGYLTLYGW	TRS-PLIEYYVVDSW TRS-DITEYYVVDSW	113
SEMPLOGGOVANY GEGISTORMS—IN GIFVOGGORP***	lans xylA	WONWINDGGGIVNAVN		GNEVVGKGWTYG		SPSGNGYLTLYGW	TRN-ALIEYYVVDSW	111
WANDGGGARATITY GAGGSTSVANGEN*********************************		WONWTDGGGTVNAVN	_	GNEVVGKGWTYG	TPNRVVNYNAGVE	APSGNGYLTFYGW	TRN-ALIEYYVDSW	112
YSWANDGGOMANTYN GAGGSTSTUNNER—TG GALUGGGGNN————GAARTITISGTY SPESNS—TLATON MR PLIETIUREN YSWANDGGOADATYN GAGGSTSTUNNER—TG GALUGGGGNN———GAARTITISGTY SPESNS—TLATON MR PLIETIUREN YSWANDGGOADATYN GAGGSTSTUNNER—TG GALUGGGGNN———GAARTITISGTY SPESNS—TLATON MR PLIETIUREN YSWANDGGGAGATTH LEGGRYSTUNNER—TG GALUGGGGNN———GAARTITISGTY SPESNS—TLATON MR PLUETITISSY YSWANDGGGAGATTH GAGGSTSTUNNER—TG GALUGGGGNN———GAARTITISGT SPESNS—TLATON MR PLUETITISSY YSWANDGGGAGATTH GAGGSTSTUNNER—TG GAGGSTSTUNNER——GAARTITISGT SPESNS——TLATON MR PLUETITION MR YSYMNDGGGAGTTH GAGGSTSTUNNER—TG GAGGSTS	11	WSWWSDGGARATYTN	GAGGSYSVSWGSG	GNLVGGKGWNP	GTARTITYSGTY	NYNGNSYLAVYGW	TRN-PLVEYYVENF	122
YSWATOGGOAGNITH GEGENSTURMS—— GENOGGIGNED————GENETINGGEN PROGNE——TLANTOR TRE-PLUZYTURNY YSWATOGGOAGNITH GEGENSTURMS—— GENOGGIGNED———GENETINGGEN PROGNE——TLANTOR TRE-PLUZYTURNY YSWATOGGSACHTH GEGENSTURMS—— GENOGGIGNED———GENETINGGEN PROGNE——TLANTOR TRE-PLUZYTURNY YSWATOGGGOAGNYPH——HG GENOGGIGNED———GTHKKVINISGSY RENGRE——TLANTOR TRE-PLUZYTURNY YSWATOGGGOAGNYPH——HG GENOGGIGNED———GTHKKVINISGSY RENGRE——TLANTOR TRE-PLUZYTURNY YSWATOGGGOAGNYPH——HG GENOGGIGNED———GTHKKVINISGSY RENGRE——TLANTOR TRE-PLUZYTURNY YSWATOGGOAGNYPH GEGES YNNS——HG GENOGGIGNED———GTHKKVINISGSY RENGRE——TLATOGG SHE PLIZYTURNY YSWATOGGOANYPH BAGGOSYNYMS——HG GENOGGIGNED———GTHKKVINISGSY RENGRE——TLATOGG SHE PLIZYTURNY YSWATOGGOANYPH BAGGOSYNYMS——HG GENOGGIGNED———GTHKKVINISGSY RENGRE——TLATOGG SHE PLIZYTURNY YSWATOGGOANYPH BAGGOSYNYMS——HG GENOGGONED———GTHKKVINISGSY RENGRE——TLATOGG SHE PLIZYTURNY YSWATOGGOANYPH BAGGOSYNYMS——HG GENOGGONED———GTHKKVINISGSY RENGRE——TLATOGG SHE PLIZYTURNY YSWATOGGOANYPH BAGGOSYNYMS——HG GENOGGONED———GS-ARITYNYGG PROGNED——TLATOGGOANYPHOLD YSWATOGGOANYPH BAGGOSYNYMS——HG GENOGGONED———GS-ARITYNYGG PROGNED——TLATOGGOANYPHOLD YSWATOGGOANYPHOLD YSWATOGGOAN	lcum xyll	YSWWSDGGARATYTN	GAGGSYSVSWGTG	GNLVGGKGWNP	GTAKTITYSGOY	NPNGNSILALIGM	TRN-FLVEL SVENE	128
YSWANDOGRADYTH LEGGTEESNOYTH AND STRUCKGRANE———GTRANINTERFOY GHARGE—TLANYOR THE PLETETIVESY YSWANDOGRADYTH LEGGTEESNOYTH GERSENSYMEN———GTRANINTERFOY GHARGE—TLANYOR THE PLETETIVESY YSWANDOGRADYTH GERSENSYMEN———GTRANINTERFOR PROGREGULAR THE PLETETIVESY YSWANDOGRADYTH GERSENSYMEN———GTRANINTERFOR PROGREGULAR THE PLETETIVESY YSWANDOGRADYTH GERSENSYMEN———GTRANINTERS PROGREGULAR THE PLETETIVESY YSWANDOGRADYTH GERSENSYMEN———GTRANINTERSON PROGREGULAR THE PLETETIVESY YSWANDOGRADYTH GERSENSYMEN———GTRANINTERSON PROGREGULAR THE PLETETIVEN THE PLETETIVEN THE YSWANDOGRADYTH GERSENSYMEN———GTRANINTERSON PROGREGULAR THE THE PLETETIVEN THE YSWANDOGRADYTH GERSENSYMEN———GTRANINTERSON PROGREGULAR THE THE PLETETIVEN THE YSWANDOGRADYTH GERSENSYMEN——GTRANINTERSON PROGREGULAR THE THE THE THE THE THE THE YSWANDOGRADYTH GERSENSYMEN——GTRANINTERSON PROGREGULAR THE THE THE THE THE THE YSWANDOGRADYTH GERSENSYMEN THE	×yı	YSWWTDGGAOATYTN	CAGGGYSVNWKIG	GNLVGGRGWRFTTT	VIOSTITION OF THE PROPERTY OF	WOYVE SYGNOC	TRS-SLIEYIVESY	96
SAWFDGGGSAQYTH GESSTYGTHE-N CHPUCKGRWNCTGRINGGE WEGGGG-TLANYGR TRN-PLEYTYLESY I SHWFDGGSAQYTH GESSTYGTHE-N** CHPUCKGRWNCTGRINGGES WEGGEN CTLANYGR TRN-PLEYTYLESY I SHWFDGGSTOWN GESSTYGTH CONCESSION CHARACTER TO STATE THE CHARACTER TO STATE THE CHARACTER TO STATE THE CHARACTER THE CH	une xyla zinosus xyla	このは、こののみのなり、このなるのかできない。	DODESTANTOSET	GNLVGGKGWNP	GLNARAIHFEGVY	OPNGNSYLAVYGW	TRN-PLVEYYIVENF	124
VSWATDGGGSNOTH DEGRNOVERS - TO GIVIOGRGAMP	grillosus Ayra	メニュー できることでは、	エスーー 出別しつひく ロップはつ	GNWCWCCKC	GSGRVINYGGAF	NPOGNGYLAVYGW	TRN-PLVEYYVIESY	132
VSTWIDGGGVVQTY LEGISTOWNSH-ST CHANGE CONTOCKENS CONTRINGED TO THE CONTRIBUTION TO THE CHARGE THE CONTRIBUTION	onum xyız	VSWWTDGGGSAOYTM	GEGSRYSVTWRNT	GNFVGGKGWNP	GIGRVINYGGAF	NPOGNGYLAVYGW	TRN-PLVEYYVIESY	132
VERWIDGAGGNIYM GROGSEYSUNG———GERNALINEGGS PROMOGNATIONS TOWN OR GROSSEYSUNG——GERNALINEGGS PROMOGNATIONS GROWNS——SELECTIVENE FROM GROGGSTOWN——SERVED GROWN——SELECTIVENE FROM GROGGSTOWN——SERVED GROWN——SERVED GROWN——	713 X717	YSWWSDGGGOVOYTN	LEGSRYOVRWRNT	GNFVGGKGWNP	GTGRTINYGGYF	NPOGNGYLAVYGW	TRN-PLVEYYVIESY	128
12 YSPWINGHOGTYTYN GROGGSTWWS-NS GNYCGKGWOPCTRNWINTESCS NRNGSLISYVGK SN-PIETYTUSNF YSPWINGHOGTYTYN GROGGSTWWS-NS GNYCGKGWOPCTSNWINTESCS NRNGSLISYVGK SN-PIETYTUSNF YSPWINGHGOTYTYN GAGGSTWWS-NS GNYCGKGWOPCTSNWINTESCS NRNGSLISYVGK SN-PIETYTUSNF YSPWINGHGOTYTYN GAGGSTWWS-NS GNYCGKGWNPGSSARDIYSGS NRNGSLISYVGK SN-PIETYTUSNF YSPWINGHGOTYTYN GAGGSTWWS-NS GNYCGKGWNP	EC.::	YSWWTDGASPVOYON	GNGGSYSVOWQSG	GNFVGGKGWMP		NPVNNGNAYLCIYGW	TON-PLVEYYILENY	133
12 YSYMNOGHIGATYTH GEOGGSTWINGNS GINTGGKGMOPGTRNKUINFSGSY NRNASLISYVGM SNR-PILEYTURNF YSYMNOGHIGATYTH GEOGGSTWING-NS GINFELEYTURNF YSYNNOGHIGATYTH GEOGGSTWING-NS GINFELEYTURNF YSTATIOGGSOVATH GEOGGSTWING-NS GINFELEYTING YSTATIOGGSOVATH GEOGGSTWING-NS GINFELEY GINCH GEOGGSTWING-NS GINFE	ile cqxA	YSFWIDGGGTVNYON	GAGGSYSVQWQNC	GN FVGGKGWNP	GAARTINFSGTF	SPOGNGYLAIYGW	TON-PLVEYYIVESF	122
YSYNNOGHIGGYTYTH GEGGESTWINE-NG GIPTGGKGWOPCTHNKYINESGS NRWARS-YLEYTWR SHP-PLEYTYLENF YSYNNOGHIGGYTYTH GEGGESTWINE-NG GIPTGGKGWOP	et xy12(2)	HSYWNDGHGGVTYTN	7	GNEVGGKGWQP	GTKNKVINFSGSY	NPNGNSYLSVYGW	SRN-PLIEYYIVGNE	126
YSYNNDGHACOTYTY GGGGSTYNNS-NG GIPTOGGGGNAPGGSSRUINEGSY NPROBLE	lei, ALKO2721 Xy12	YSYWNDGHGGVTYTN	GPGGQFSVNWSNS	GNEVGGKGWOP	GTKNKVINFSGSY	NPNGNSYLSVYGW	SKN-PLIEYYIVENE	125
YSTWINGGROUTTH GAGGGSTRYWAA-NS GREVOGKGNNPGS-SRIVINEGGS NEWGSTILOVGW SKW-PLIEYTIVENF YSTWINGGGOVTTH GAGGGSTRYWAA-NS GREVOGKGNNPGS-ARINTHYN NEWGSTILOVGW SKW-PLIEYTIVENF YSFWINGGGOVTTH GAGGGSTRYWAS-NO GREVOGKGNNPGS-ARINTHYN NEWGSTILOVGW TTS-PLUEYTILDN YSFWINGGGOVTTH GAGGGSTRYWAS-NO GREVOGKGNNPGS-ARINTHYN SGF PRSGNAYLLIVGW TTS-PLUEYTILDN YSFWINGGGSVSWIL NGGGSYSTGWT-NC GREVAGKGNS	sei xyll	YSYWNDGHGGVTYTN	GPGGGFSVNWSNS	GNEVGGKGWOP	TOPOLINE NEW TOPOL	NEWGING CITY ON	CNECT TO THE CONT) M
YSTWIDGGONOTH GOGGYSTYRA. YSTWIDGGONOTH GOAGYSTYRAEGG GWWGGKGNNPGS-ARTINYTAN NINGGSYLAVGW TRE-PLIEXYVVERY YSTWIDGGONOTH GOAGYSTYRAEGG GWWGGKGNNPGAADOTYSST PSGGMYLAVGW TIS-PLUEYXIVDBY YSTWIDGGONOTH GOAGYSTYRAEGG GNAVAGKGNNPGAARTVYNSGSF PSGGMYLAVGW TIS-PLUEYXIVDBN YSTWIDGGSCNSTAIL GGGGSTSTOWHNC GNYAGKGNNPGARTVYNSGSF PSGGNYLAVGW TSM-PLUEYXIVDBN YSTWIDGGSCNSTAIL GGGGSTSTOWHNC GNYAGKGNNP	zianum xylD	YSYWNDGHAGVIYIN	CCCCCT VNWO-1NO	GNE VAGAGENDE	GSSSRVINESGSY	WDXJZZI KISVYGW	SKN-PLIEYXIVENE	126
YSEWIDGGGONTYTH GDAGATTURESNV GNFVGGKGNNPGRADITYSCTF TPSGGGYLSYVGW TTD-PLIEVITYESY YSEWIDGGGSVSHIL GDAGGSYSTWHNC GNFVGKGWSGRARITYSCTF NESGNAYLLYGW TNA-PLUEYITYDDNA YSEWIDGGGSVSHIL AGGGSYSTWHNC GNFVGKGWSGRARITYNSCTF NESGNAYLLYGW TNA-PLUEYITYDDNA XSEWIDGGGSVSHIL AGGGSYSTWHNC GNFVGKGWS	Ide xyl	いているのではいるというという	というとは、 というとうとう	GNWVGGKGWNP	GS-ARTINYTANY	NPNGNSYLAVYGW	TRN-PLIEYYVVENF	123
YSEWTWIGGEVOOTTN GAAGEVSUTWE-NC GDTSGAGGWSTGSARDITEECTF NBSGNAYLANGW TAS-PLUDDW YSEWTWIGGEVOOTTN GAGGSYSTWATCARRITWYSGYF NBSGNAYLANGW TAS-PLUDDW YSEWTDGGGSVSTWAT GAGGSYSTWATCARRITWYSGYF NBSGNAYLLYGW TAN-PLUEYITUDNW YSEWTDGGGSVSTWAT GAGGAYGWSTCARRITWYSGYF NBSGNAYLLYGW TAN-PLUEYITUDNW YSEWTDGGGSVSTWAT GAGGAYGWST	cite cyas	YSFWTDGGGDVTYTN		GNFVGGKGWNP	GSAQDITYSGTF	TPSGNGYLSVYGW	TTD-PLIEYYIVESY	128
YSFYTOGGGSVSMTL NGGGSYSTOWT-NG GNEYAGKGWANGGRRTVYSGSF NPSGKA-YLLLYGW TAN-PLUEYYIVDNW YSFWTOGGGSVSMTL ASGGSYGTSWTNC GNEYAGKGWANGGRRTVYSGSF NPSGKA-YLLLYGW TAN-PLUEYYIVDNW YSFWTDAGGTVSMTG AGGSYSTOWS-NT GNEYAGKGWAN	llium sp 40 xvlA	YSFWTNGGGTVQYTN	GAAGEYSVTWENC	GDFTSGKGWST	GSARDITFEGTF	NPSGNAYLAVYGW	TTS-PLVEYYILEDY	124
YSEWTOCGCONSUNLA GAGGNYSTONS—NT GNFVAGKGNAT————GGRRTVTYSGTF NPSGNA—"YILLYGW SQN—PLUEYYIVDNW YSEWTOCGCONSUNLA GAGGNYSTONS—NT GNFVAGKGNAT————GGRRTVTYSGTF NPSGNA—"YILLYGW SQN—PLUEYYIVDNW YSEWTOAGCTVSHALL GAGGNYSTONS—NT GNFVAGKGNAT————GGRRTVTYSGTF NPSGNA—"YILLYGW THG—PLUEYYIVDNW YSEWTOACTGVSHALL GAGGNYSTONS—NT GNFVAGKGNAT————GGRRTVTYSGTF NPSGNA—"YILLYGW THG—PLUEYYIVDSW YSEWTOACGCOVEYTN GAGGNYSTONS—NT GNFVAGKGNAP————GGRRTVTYSGST NPSGNA—"YILLYGW THG—PLUEYYIVDSW YSEWTOACGCOVEYTN GAGGNYSTONS—NG GNVVAGKGNAP————GGRRTVYSGST WONSONSYLALYGW TNA—PLUEYYIVDSW YSEWTOACGCOVEYTN GAGGNYSGWSN—TO MNWYGGKGNNP————GGRRTVYSGST GONSGNA—"YLSVYGM TNA—PLUEYYIVDSW YSEWTOACGCOVEYTN GAGGNYSGWSN—TO MNWYGGKGNNP————GGRRTVYSGST GONSGNA—"YLSVYGM TNA—PLUEYYIVDSW YSEWTOACGCOVEYTN GAGGNYSGWSN—TO MNWYGGKGNNP————GGRRTVYSGST GONSGNA—"YLSVYGM TNA—PLUEYYIVDSW YSTWANGG—DASMTL LSGGRYGGNATT—ST NNWYGGKGNNP————GGRRTYTYSGST GONSGNA—"YLSVYGM TNA—PLUEYYIVDSY YQNYNGNIGDFTYD ESAGTFSWYNEDGY SDEVVGLGATT————GGRRTYTYSGS ASGSS—SYLAYGW WNY—POAEYYIVEDY YQNYNGNIGDFTYD ESAGTFSWYNEDGY SDEVVGLGATT————GGS—SRITYSAEY SASGSS—SYLAYGW WNY—POAEYYIVEDY YQNYNGNIGAFSDRYND ESAGTFSWYNEDGY SDEVVGLGATT————GGS—SRITYSAEY SASGSS—SYLAYGW WNY—POAEYYIVEDY YQNYNGNIGALGDFTYD ESAGTFSWYNEDGY SDEVVGLGATT————GGS—SRITYSAEY SASGSS—SYLAYGW WNY—POAEYYIVEDY YQNYNGNIGALGDFTYD ESAGTFSWYNEDGY SDEVVGLGATT————GGS—SRITYSASY SASGSS—SYLAYGW WNY—POAEYYIVEDY YQNYNGNIGALGDFTYD ESAGTFSWYNEDGY SDEVVGLGATT————GGS—SRITYSASY SASGS—SYLAYGW WNY—POAEYYIVEDY YQNYNGNIGALGOFTYD ESAGTFSWYNGOWS————GGS—SRITYSASY SASGS—SYLAYGW WNY—POAEYYIVEDY YQNYNGNIGALGOFTYD ESAGTFSWYNGOWS————GGS—SRITYSASY SASGS—SYLAYGW WNY—POAEYYIVEDY YQNYNGNIGALGOFTYD ESAGTFSWYNGOWS—————GGS—SRITYSASY SASGS—SYLAYGW WNY—POAEYYIVEDY YQNYNGNIGALGOFTYD ESAGTFSWYNGOWS—————GGS—SRITYSASY SASGS—SYLAYGW WNY—POAEYYIVEDY YQNYNGNIGALGOFTYD MAETHOCKKRPOTT————GGS—SRITYSASY SASGS—SYLAYGW WNY—POAEYYIVEDY YCHNYGNIGALGOFTYNGOWS————————————————————————————————————	omyces sp xyl	YSEWIDGGGSVSMIL	NGGGSYSTOWT NC	GNFVAGKGWGN	GGRRTVRYSGYF	NPSGNGYGCLYGW	TSN-PLVEYYIVDNW	142
SEWTOADGCTVENDI GSGGTVETTOAT GARVAGKGMATGGRRTVTYSGTF NPSGMAYILLYGW TIG-PLIEYTIVDNW YEFWTDAGCTVENDI GSGGTVETTOATGGRRTVTYSGTF NPSGMAYILLYGW TIG-PLIEYTIVDNW YEFWTDAGCTVENDI GSGGTVETTOAT	omyces sp xyll	YSFW	ASGGSYGTSWTNC	GNFVAGKGWAN	GARRTVNYSGSF	NPSGNAYLTLYGW	TAN-PLVEYYIVDNW	132
YSTWINGGOTOWAND GSGCTYSTOWN-UT GNEYAGKGRATGGARITYSASF NESGNAYILLIGH TRN-PLUEXYILESM YSTWINDARGTUSHEL GPGGNYSTSWRNT GNEYAGKGRATGGARITYSASF NESGNAYILLIGH TRN-PLUEXYILDSW YSTWINDARGTUSHEL GPGGNYSTSWRNT GNEYAGKGRAPT	rmocyaneoviolaceus xylB	XS.	GAGGNYSTOWSNT	GNFVAGKGWAT	GGRRIVIYSGIF	NPSGNAYLALYGW	SQN-FLVERILVONS	
YSPWINGEODVEYIN GEGGNYSTENGEN TO NEVROKKOWST	idosporus T7A svxA	YSEWIDAGGIVSMDL	GSGGTYSTOWRNT	GNEVAGKGWST	TIDSINATEDOUT	NO CONTRACTOR OF THE PROPERTY	306010010101010101	
YSEWINGGGOVETH GNGGGYSVKWTNC DNEVAGKGWNP ASPRATVISGEM GNUNGGCOYSVKWTNC DNEVAGKGWNP ASPRATVISGEM GNGGGYSVKWTNC DNEVAGKGWNP ASPRATVISGEM GNGGGYSVKWTNC GNUNGGRGWNP ASPRATVISGEM GNGGGYSVKWTNC GNUNGGRGWNP GAS-BNITYSGEM GNGGGYSTLANG TRS-PLIEXYVLESY YTEWKDSG-DASWIGL GAGGRYSOWSNG-ST NNWVGGKGWNP GAS-SNITYSAEY SASGS-SYLAVGW TRS-PLIEXYVLESY YQRYNGULGDFTYD ESAGTESWYWEDGVS SDEVVGLGWTT GAS-SNITYSAEY SASGS-SYLAVGW WNY-PQAEYIVUEDY YQRYNGULGGFYSW BCAGTESWYWEDGVS SDEVVGLGWTT GAS-SNITYSAEY SASGS-SYLAVGW WNY-PQAEYIVUEDY YQRYNGULGGFYSW BCAGTESWYWEDGVS SDEVVGLGWTT GAS-SNITYSAEY SASGS-SYLAVGW WNY-PQAEYIVUEDY YCHNGUNGORFSON BORGAFSCOWSNINN ALFERGKKFDSTRTH HQ-LGNISINYMAAF NPGGNSYLCVYGW TOS-PLAEYYIVESW YELWKDYG-NTSMT LGGGKFSCWSNINN ALFERGKKFDSTRTH HQ-LGNISINYMAAF NPGNSYLCYYGW TSS-PLUEYYIVDSW YELWKDYG-NTSMT LGGGKFSCWSNINN ALFERGKKFDSTRTH HQ-LGNISINYMAAF NPGNSYLCYYGW TSS-PLUEYYIVESW YELWKDYG-NTSMT UNGGAFSCOWSNINN ALFERGKKFDSTRTH HQ-LGNISVYROVDY RPNGNSYLCYYGW TSS-PLUEYYIVESW YELWKDYG-NTSMT UNGGAFSCOWSNINN ALFERGKKFDSTRTH HQ-LGNISVYROVDY RPNGNSYLCYYGW TSS-PLUEYYIVESW YELWKDYG-NTTMTV YTGGKFSCOWSNINN ALFERGKKFDSTRTH WGNSYLCYYGW TSS-PLUEYYIVESW YELWKDYG-NTTMTV YTGGKFSCOWSNINN ALFERGKKFDSTRY YELNGWONSYLCYYGW TSN-PLUEYYIVESW YELWKDYG-NTTMTW YTGGRFSCOWSNINN ALFERGKKFDSTAW NG-LGYNDYNSYLCYYGW TSN-PLUEYYIVESW YELWKDYG-NTTMTW YTGGRFSCOWSNINN ALFERGKKFDSTAW NGYLCYYGW TSN-	na xyl	YSEWTDAPGTVSMEL	GPGGNYSTSWR-1NI	GNEVAGKGWST	GSARIISYSGTE	NPSGNAYLAVYGW	SHD-PLVEYXIVDSW	
SSYMADYG-NTRYSC GAGGHYDLSWG-NG GNUVAGRGWKP **SYMADYG-NTRYSC GAGGHYDLSWG-NG GNUVAGRGWKP **TEKKDSG-DASMIL LSGGRYGSWGN-GT NNWYGGRGWNP **CGPKKVTYSGSSY NUDNSQNSYLALYGW TRS-PLEYYVLESY **YTEKKDSG-DASMIL LSGGRYGSWGN-ST NNWYGGRGWNP **GRAFTENDS GATFELL ESGGRYAGNWTT-ST NNWYGGRGWNP **GRAFTENDS GATFELL ESGGRYAGNWTT-ST NNWYGGRGWNP **GRAFTENDS GATFENYWEDGVS SDFVVGLGWTT **GSSNAITYSAEY SASGSS-SYLAVGW VNY-PQAEYYIVEDY **YQNYNGNLGDFTYD ESAGTFSMYWEDGVS SDFVVGLGWTT **GSSNAITYSAEY SASGSS-SYLAVGW VNY-PQAEYYIVEDY **YQNYNGNLAGPFSYNWNGN TDFVCGLGWTV **GSSNAITYSAEY SASGSS-SYLAVGW VNY-PQAEYYIVEDY **YQNYNGNLAGPFSYNWNGN TDFVCGLGWTV **GSSNAINTSATL NNGGAFSAGWNNIGN ALFRKGKKFDSTRTH HQ-LGNISINYNBAF NPGGNSYLCVYGW TGS-PLUEYYIVESW **ELWKDYG-NTFWTL KNGGAFSCGWSNINN LIFFKGKKFDSTRTH HQ-LGNISINYNBAF NPGNSYLCVYGW TN-PLUEYYIVESW **ELWKDYG-DTEMTI NEGGFFSCWSNINN ALFRIGKKWDCTKWW QQ-LGNISINYNDY NPNGNSYLCVYGW TRN-PLUEYYIVESW **ELWKDTG-NTFWTL TYGGKFSCCWSNINN ALFRIGKKWDCTKWW QQ-LGTISVANVUDY SPUNGNSYLCYYGW TRN-PLUEYYIVESW **ELWKDTG-NTFWTL YTGGFFSCGWSNINN ALFRIGKKWDCTKWW QQ-LGTISVANVUDY NPNGNSYLCYYGW TRN-PLUEYYIVESW **ELWKDTG-NTFWTU YTGGFFSCGWSNINN ALFRIGKKWDCTKWW QS-LGTNITYTYSATY NPNGNSYLCYYGW TRN-PLUEYYIVESW **ELWKDTG-NTFWTU YTGGFFSCGWSNINN ALFRIGKKWDCTKWW QS-LGTNITYTYSATY NPNGNSYLCYYGW TRN-PLUEYYIVESW **ELWKDTG-NTFWTU YTGGFFSCGWSNINN ALFRIGKKWDCTW-NTFWTU-YNDSW **ELWKDTG-NTFWTO-T-T	modec system	YSEWINGGGDVEYIN	GNGGOYSVKWTNC	DN FVAGKGWNP	GSAKTVTYSGEW	ESNSNSYVSLYGW	TQN-PLVEYYIVDKY	124
YTEWEDSG-DASHGL GAGGRYTSOWSN-GT NNWYGGKGWNPGG-PKVVTYSGSY NUDDSGNSYLALYGW TRS-PLIEYYVIESY YAFWEDSG-DASHTL LSGGRYOSSWGN-ST NNWYGGKGWNPGENSHRYNYSGYS GINETAANSTSLYGW TRS-PLIEYYVIESY YAFWEDSG-DASHTL LSGGRYOSSWGN-ST NNWYGGKGWNPGENSHRYNYSGYS GINETAANSTSLYGW TYN-PLIEYYVUESY YAFWEDSG-SAFTFL ESGGRYAGWHT-ST NNWYGGKGWNPGS-SRAITYSAEY SASGSS-SYLAVYGW VNY-PQAEYYIVEDY YVQNYNGNLGDFTYD ESAGTFSMYWEDGVS SDEVVGLGWTTGS-SRAITYSAEY SASGSS-SYLAVYGW VNY-PQAEYYIVEDY YVQNYNGNLGDFTYD ESAGTFSMYWEDGVS SDEVVGLGWTTGS-SRAITYSAEY SASGSS-SYLAVYGW VNY-PQAEYYIVEDY YVQNYNGNLGDFTYD ESAGTFSMYWEDGVS SDEVVGLGWTTGS-SRAITYSAEY SASGSS-SYLAVYGW VNY-PQAEYYIVEDY YVQNYNGNLGDFTYD ESAGTFSMYWGGVS SDEVVGLGWTTGS-SRAITYSAEY SASGSS-SYLAVYGW VNY-PQAEYYIVEDY YVQNYNGNLGAFSY EGAGTFSMYWGGVS SDEVVGLGWTTGS-SRAITYSAEY SASGSS-SYLAVYGW VNY-PQAEYYIVEDY YVQNYNGNLGAFSY EGAGTFSMYWGGVS SDEVVGLGWTTGS-SRAITYSAEY SASGS-SYLAVYGW VNY-PQAEYYIVEDY YVQNYNGNLGAFSY EGAGTFSMYWGGVS SDEVVGLGWTYGS-SRAITYSAEY SASGS-SYLAVYGW VNY-PQAEYYIVEDY YVQNYNGNYANGRAFSASNNNIGA ALFRKGKKFFDSTRTH HQ-LGNISINYNAAF NPGGNSYLCVYGW TOS-PLAEYYIVDSW YELWKDYG-NTSWTL NNGGAFSAGWNIGN ALFRKGKKFDSTRTH HQ-LGNISINYNDAY QPYGNSYLCVYGW TOS-PLAEYYIVDSW YELWKDYG-NTSWTL NGGAFSAGWNINN LLFRKGKKFDSTRTH DQ-LGYITVTYSCNY QPNGNSYLCVYGW TSO-PLAEYYIVDSW YELWKDYG-NTSWTL NGGAFSAGWNINN ALFRIGKKWDCTYTYY KE-LGNISVKYGVDY QPNGNSYLCVYGW TNO-PLUEYYIVDSW YELWKDYG-DTEMTI NEGGTFSAGWSNINN ALFRIGKKFDS-TTAM NQ-LGTIEVYNNUSSYMCVYGW TRN-PLUEYYIVESW YELWKDYG-DTEMTI NEGGTFSAGWSNINN ALFRIGKKFFS-TAM NQ-LGTIEVYNNUSSYLCIYGW STN-PLUEYYIVESW YELWKDYG-DTEMTI NEGGTFSAGWSNINN ALFRIGKKFFS-TAM NQ-LGTIEVYNYDYN YNDGNSYLCIYGW STN-PLUEYYIVESW YELWKDYG-DTEMTI NTGAFFSCOWSNINN ALFRIGKKFFS-TAM NG-LGTIEVYNYDYN YNDGNSYLCIYGW STN-PLUEYYIVESW YELWKDYG-NTTHYNY DTGGRFSCOWSNINN ALFRIGKKFSTAM NG-LGTIEVYNYSCNY NDRONSYLCIYGW STN-PLUEYYIVESW YELWKDYG-NTTHYNY DTGGRFSCOWSNINN ALFRIGKKYFSTAM NG-LGTIEVYNYSCNY NDRONSYLCIYGW STN-PLUEYYIVESW YELWKDYG-NTHTHYN STAGRFSCOWSNINN ALFRIGKKYN	ourea xyll	SSYWADYG-NTRYSC	GAGGHYDLSWGNG	GNVVAGRGWKP	ASPRAVTYSGSW	OCNGNCYLSVYGW	TIN-PLVEYYIVENY	119
YTEWROSG-DASHTI ISGGRYQSSWGN-ST NNWWCGKGWNPGNUNSKVISYGGSY GYDSSGNSYTALYGW TRS-PLIEYYVUESY YAFWROSG-BATFTL ESGGRYAGWWT-ST NNWWCGKGWNPGNSWRTVNSGYY GINEYANSYLSLYGW TYN-POAEYYVUESY YOUNYNGLODFTYD ESAGTFSMYWEDGVS SDFVVGLGWTTGS-SRAITYSAEY SASGSS-SYLAVYGW VNY-PQAEYYVUEDY YVQNYNGNLGDFTYD ESAGTFSMYWEDGVS SDFVVGLGWTTGS-SRAITYSAEY SASGSS-SYLAVYGW VNY-PQAEYYVUEDY YVQNYNGNLGDFTYD ESAGTFSMYWEDGVS SDFVVGLGWTTGS-SRAITYSAEY SASGS-SYLAVYGW VNY-PQAEYYVUEDY YVQNYNGNLGDFTYD ESAGTFSMYWEDGVS SDFVVGLGWTTGS-SRAITYSAEY SASGS-SYLAVYGW VNY-PQAEYYVUEDY YVQNYNGNLGDFTYD ESAGTFSMYWEDGVS NDFVVGLGWTTGS-SRAITYSAEY SASGS-SYLAVYGW VNY-PQAEYYVUEDY YVQNYNGNLGAFSYN EGAFFSWYWDGGVS NDFVVGLGWTTGS-SRAITYSAEY SASGS-SYLAVYGW VNY-PQAEYYVUEDY YVQNYNGNLGAFSYN EGAFFSWYWDGGVS NDFVVGLGWTTGS-SRAITYSAEY SASGG-SYLAVYGW VNY-PQAEYYVUEDY YVQNYNGNLGAFSYN EGAFFSWYWDGGVS NDFVVGLGWTTGS-SRAITYSAEY SASGG-SYLAVYGW VNY-PQAEYYVUEDY YVQNYNGNLGAFSAGWNNIGN ALFRKGKKFDSTRTH HQ-LGNISINYNAAF NPGGNSYLCVYGW TGS-PLAEYYVUENY YELWKDYG-NTSMTL NNGGAFSAGWNNIGN ALFRKGKKFDSTRTH HQ-LGNISINYNAAF NPGGNSYLCVYGW TSS-PLUEYYIVESW YELWKDYG-NTSMTL KNGGAFSCCWSNINN ILFRKGKKFDSTRTH HQ-LGNISINYNAAF NPGGNSYLCVYGW TSS-PLUEYYIVESW YELWKDYG-NTSMTL KNGGAFSCCWSNINN ALFRIGKKWDCTKTW QQ-LGTISVAYNUDY RPNGNSYLCVYGW TSS-PLUEYYIVESW YELWKDYG-TTSWTL LGGGKFSCCWSNINN ALFRIGKKWDCTKTW QQ-LGTISVAXNUDY RPNGNSYLCTYGW TNS-PLUEYYIVESW YELWKDG-DTEMTI NEGGTFSCCWSNINN ALFRIGKKWDCTKTW QQ-LGTISVAXNUDY RPNGNSYLCTYGW TNS-PLUEYYIVESW YELWKDG-DTEMTI V DTGGRFSCOWSNINN ALFRIGKKWDCTKTW QQ-LGTISVAXNUDY NPUGNSYLCTYGW TNS-PLUEYYIVESW YELWKDG-NTTMTV TOGGRFSCOWSNINN ALFRIGKKYRFTAM NQ-LGTYVDVYCWYGW TNN-PLUEYYLVEW YELWKDG-NTTMTV TOGGRFSCOWSNINN ALFRIGKKYRFTAM NQ-LGTYVDVYCW NSYLCTYGW SNNPLUEYYLVEW YELWKDG-NTTMTV TOGGRFSCOWSNINN ALFRIGKKYRFTAM NQ-LGTYVDVYCW TNNYLCTYGW SNN	tus xyl	YTFWKDSG-DASMGL	QAGGRYTSQWSN-GT	NNWVGGKGWNP	GG-PKVVTYSGSY	NVDNSQNSYLALYGW	TRS-PLIEYYVIESY	122
YAFWKOSG-SAFFTL ESGERYAGNWIT-ST NNWYGEKGWNPGES-SRAITYSAEY SASGSS-SYLAVYGW VNY-PLAEYIVEDY YUQNYNGNLEDFTYD ESAGTFSWYWEDGVS SDEVVGLGWITGS-SKAITYSAEY SASGSS-SYLAVYGW VNY-PQAEYYIVEDY YUQNYNGNLEDFTYD ESAGTFSWYWEDGVS SDEVVGLGWITGS-SKAITYSAEY SASGSS-SYLAVYGW VNY-PQAEYYIVEDY YUQNYNGNLEDFTYD ESAGTFSWYWEDGVS SDEVVGLGWITGS-SKAITYSAEY SASGSS-SYLAVYGW VNY-PQAEYYIVEDY YUQNYNGNLGAFSYN EGAGTFSWYWEDGVS NDFVVGLGWITGS-SKAITYSASY SASGS-SYLAVYGW VNS-PQAEYYIVEDY YUQNYNGNLGAFSYN EGAGTFSWYWEDGVS NDFVVGLGWITGS-SKAITYSASY SASGS-SYLAVYGW VNS-PQAEYYIVEDY YUQNYNGNLGAFSYN EGAGTFSWYWNGG-N TOFVVGLGWITGS-SKAITYSASY SASGS-SYLAVYGW VNS-PQAEYYIVEDY YUQNYNGNLGAFSYN EGAGTFSWYWNGGVS NDFVVGLGWITGS-SKAITYSASY NGGYSG-SYLAVYGW NNS-PQAEYYIVEDY YUQNYNGNLGAFSYN EGAGTFSWYWNGGVS DEFKCKKFDFTHH HO-LGNISINYNAAF NPGGNSYLCVYGW TGGS-ESEYYIDNY YELWKDYG-NTSMIL KNGGAFSCOMSNIGN ALFRKGKKFDSTRTHH HO-LGNISINYNAAF NPGGNSYLCVYGW TOS-PLAEYYIVDSW YELWKDYG-NTSMIL KNGGAFSCOMSNIGN ALFRKGKKFDSTRTHH HO-LGNISINYNAAF NPGGNSYLCVYGW TOS-PLAEYYIVDSW YELWKDYG-NTSMIL KNGGAFSCOWSNIGN ALFRKGKKFDSTRTHH QO-LGNISINYNDAYD NPUGNSYLCVYGW TSN-PLUEYYIVDSW YELWKDYG-NTSMIL LGGGKFSCOWSNINN ALFRIGKKWDCTYTW QO-LGTISVAYNUDY RPUGNSYLCYYGW TND-PLUEYYIVDSW YELWKDYG-DTEMTI NEGGTFSCOWSNINN ALFRIGKKWDCTYTW QO-LGTISVAXVODY NPUGNSYLCYYGW TRS-PLIEYYIVDSW YELWKDYG-DTEMTI NEGGTFSCOWSNINN ALFRIGKKWDCTYTW QO-LGTISVAXVODY NPUGNSYLCIYGW SRN-PLUEYYIVESW YELWKDYG-DTEMTI NEGGTFSCOWSNINN ALFRIGKKWTO-TTYY NEW-YNDYNSYLCIYGW SRN-PLUEYYIVESW YELWKDYG-DTEMTI DTOGRFSCOWSNINN ALFRIGKKWTO-TTYY NEW-YNDYNSYMCVYGW TRN-PLUEYYIVEGW YELWKDYG-DTEMTI NFGGAFSCOWSNINN ALFRIGKKYR	prescens cellulosa xyl	YTEWKDSG-DASMTL	LSGGRYQSSWGN-ST	NNWVGGKGWNP	GNNSRVISYSGSY	GVDSSQNSYLALYGW	TRS-PLIEYYVIESY	123
YVQNYNGNLGDFTYD ESAGTESWYWEDGVS SUEVUCLGWITGS-SKAITYSAEY SASGSS-SYLAVYGW VNY-PQAEYIVEDY YVQNYNGNLGDFTYD ESAGTESWYWEDGVS SDEVUCLGWITGS-SKAITYSAEY SASGSS-SYLAVYGW VNY-PQAEYIVEDY YVQNYNGNLGAFFYD ESAGTFSWYWEDGVS SDEVUCLGWITGS-SKAITYSAEY SASGSS-SYLAVYGW VNY-PQAEYIVEDY YVQNYNGNLGAFFYD ESAGTFSWYWEDGVS NDFVUCLGWITGS-SKAITYSASY SASGS-SYLAVYGW VNY-PQAEYYIVEDY YVQNYNGNLGAFFYD TO	leariae xyl	YAFWKDSG-SATFTL	ESGGRYAGNWTT-ST	NNWVGGKGWNP	GNSWRTVNYSGYY	GINEYANSYLSLYGW	TTN-PLIETYVVEST	
YVQNYKGNIGDETYD ESACTEMYWQQCVS NDFVVCLGWTTGS-SNPITYSASY SASGA-SYLAVYGW VNY-PQAEYYYVEDY YVQNYKGNIGDETYD ESACTEMYWQQCVS NDFVVCLGWTTGS-SNPITYSASY SASGA-SYLAVYGW VNY-PQAEYYVEDY YVQNYKGNIGDETSYN EGAGTEMYWQQCVS NDFVVCLGWTTGS-SAPINFGGSF SVASGA-SYLAVYGW VNS-PQAEYYVEDY YVQNYKGNIGDETSYN NGGAFSASWNNIG-N DFVVCLGWTTGS-SAPINFGGSF SVASGG-SYLAVYGW VNS-PQAEYYVEDY YDQNYQC-GGQVSYS PSNTGFSVWNNTQ DDFVVCGLGWTTGS-SAPINFGGSF SVASGG-SYLAVYGW TOG-PLAEYYYDDNY YELWKDYG-GGQVSYS PSNTGFSVWNNIGN ALFRKGKKFDSTRTH HQ-LGNISINYNAAF NPGGNSYLCVYGW TOS-PLAEYYYUDSW YELWKDYG-NTSWTL NNGGAFSAGWNNIGN ALFRKGKKFDSTRTH HQ-LGNISINYNAAF NPGGNSYLCVYGW TOS-PLAEYYYUDSW YELWKDYG-NTSWTL KNGGAFSCGWSNIGN ALFRKGKKFDSTRTH HQ-LGNISINYNAAF NPGNSYLCVYGW TOS-PLAEYYIUDSW YELWKDYG-NTSWTL LGGGKFSCGWSNINN ILFRKGKKFDSTRTH MQ-LGTISVYYDDYN YNDWDN NPGNSYLCYYGW TYN-PLUEYYIUDSW YELWKDTG-TTSWTL LGGGKFSCGWSNINN ALFRIGKKWDCTYTW QQ-LGTISVANYDDYN RPNGNSYLCTYGW TNN-PLUEYYIUDSW YELWKDG-DTEMTI NEGGTFSCRWSNINN ALFRIGKKWDCTYTW QQ-LGTISVANYDDY RPNGNSYLCIYGW TNN-PLUEYYIUDSW YELWKDTG-NTTMTV DTGGRFSCQWSNINN ALFRIGKKWDCTYTW KAFGNILTYYSATY NPNGNSYLCIYGW SRN-PLUEYYIUESW YELWKDTG-NTTMTV DTGGRFSCQWSNINN ALFRIGKKYS-TAW NQ-LGTYKTTYSATY NPNGNSYLCIYGW SRN-PLUEYYIUESW YELWKDTG-NTTMTV DTGGRFSCQWSNINN ALFRIGKKYS-TAW NQ-LGTYTYDYSYST NPNGNSYLCIYGW SRN-PLUEYYIUESW YELWKDTG-NTTMTV DTGGRFSCQWSNINN ALFRIGKKYSTAW NQ-LGTYTYDYSYST NPNGNSYLCIYGW SRN-PLUEYYIUESW YELWKDTG-NTTMTV DTGGRFSCQWSNINN ALFRIGKKYSTAW NG-LGTYTYDYSYST NPNGNSYLCIYGW STN-PLUEYYIUESW YELWKDTG-NTTMTV DTGGRFSCQWSNINN ALFRIGKKYSTAW NG-LGTYTYDYSYST NPNGNSYLCIYGW STN-PLUEYYIUESW YELWKDTG-NTTMTV DTGGRFSCQWSNINN ALFRIGKKYN	achi xyic	YVQNYNGNEGDFTYD	ESAGTESENT WEDGVS	SOFT SELECTION		SASGSS-SILAVIGN	VNY-POAEYYIVEDY	
YVONYNGNIGARESTA GGGTFSMYWQQGVS NDFVVGLGRSTGS-SNPITYSASY SASGGSYLAVYGW VNS-PQABYYVVEAY YVONYNGNIGARESTA GGGTFSWWWQGVS NDFVVGLGWTVGT-GRTITYSGSY NPGYSG-SYQAIYGW TGGSLSEYYVIDNY YDQNYQG-GGQVSYS PSWTGFSVNNNT DFVVGGLGWTVGS-SAPINFGGSF SVNSGT-GLLSVYGW STN-PLVEYYINEDN FELWKDYG-GGQVSYS PSWTGFSVNNNTGN ALFRKGKKFDSTRTH HQ-LGNISINYNAFR NPGGNSYLCVYGW TGS-PLAEYYIVESW YELWKDYG-NTSWTL NNGGAFSAGWNNIGN ALFRKGKKFDSTRTH HQ-LGNISINYNAFR NPGGNSYLCVYGW TGS-PLAEYYIVESW YELWKDYG-NTSWTL KNGGAFSCGWSNIGN ALFRKGKKFDSTRTH HQ-LGNISINYNAFR NPGGNSYLCVYGW TSS-PLVEYYIVESW YELWKDTG-NTSWTL KNGGAFSCGWSNIGN ILFRKGKKFDSTRTH DQ-LGYIYVTYSCNY QPYGNSYLCVYGW TSS-PLVEYYIVESW YELWKDTG-NTSWTL LGGGKFSCGWSNINN ILFRKGKKFDETQTH QQ-LGTISVNYDDVD NBNGNSYLCYYGW TNN-PLVEFYIVESW YELWKDTG-TTSWTL LGGGKFSCGWSNINN ALFRIGKKWDCTYFW QQ-LGTISVAXNVDY RPNGNSYLCIYGW TNN-PLVEFYIVESW YELWKDTG-TTSWTL LGGGKFSCGWSNINN ALFRIGKKFDCTKTY KE-LGNISVKYGVDY QPDGNSYLCIYGW TNN-PLVEFYIVESW YELWKDTG-TTSWTT DTGGRFSCGWSNINN ALFRIGKKFS-TAM NQ-LGTISVAXNVDY RPNGNSYLCIYGW SRN-PLVEFYIVESW YELWKDTG-TTSWTT DTGGRFSCGWSNINN ALFRIGKKFS-TAM NQ-LGTISVAXTNYDWY NPNGNSYLCIYGW SRN-PLVEFYIVESW YELWKDTG-NTTMTV DTGGRFSCGWSNINN ALFRIGKKFS-TAM NQ-LGTISVAXTNYDWY NPNGNSYLCIYGW SRN-PLVEFYIVESW YELWKDTG-NTTMTV TTGGRFSCGWSNINN ALFRIGKKFS-TAM NQ-LGTIXTYDVEY NPNGNSYLCIYGW STN-PLVEFYIVESW YELWKDTG-NTTMTV TTGGRFSCGWSNINN ALFRIGKKYNSTAM NQ-LGTIYDVEYT NPNGNSYLCIYGW STN-PLVEFYIVESW YELWKDTG-NTTMTV PTGGRFSCGWSNINN ALFRIGKKYNSTAM NG-LGTITYTYDVEY TNPNGNSYLCIYGW STN-PLVEFYIVESW YELWKDTG-NTTMTV PTGGRFSCGWSNINN ALFRIGKKYNSTAM NG-LGTITYTYDVEY TNPNGNSYLCIYGW STN-PLVEFYIVESW YELWKDTG-NTTMTV PTGGRFSCGWSNINN ALFRIGKKYNSTAM NG-LGTITYTYDVEY TNPNGNSYLCIYGW STN-PLUEYYTVEGW YELWKDTG-NTGWSTAM NG-LGGAFSCGWSNINN ALFRIGKKYNSTAMCYGW TNPNGNSTAMCYGW TNN-PLLIEYYVVDSW YELWKDTG-NTGWSTAMCYGW TNPNGNSTAMCYGW TNN-PLLIEYYVVDSW	er Xyıı igenete voll	YVONYNGNIGDETYD	ESAGIFSMYWEDGVS	SDFVVGLGWTT	GSSTITYSAEY	SASGSA-SYLAVYGW	VNY-POAEYYIVEDY	112
YVQNYNGNVANFEYS QYDGTFSVNWNGN TDFVCGLGWTVGS-SAPINFGGSF SVACSG-SYQAIYGW TGQGSLSEYYVIDNY YDQNYQT-GGQVSYS PSNTGFSVNWNTQ DDFVVCGUGWTVGS-SAPINFGGSF SVNSGT-GLLSYYGW STR-PLVEYYMEDN FELWKDYG-NTSWTL NNGGAFSAGWNNIGN ALFRKCKKFDSTRTH HQ-LGNISINYNAAF NPGGNSYLCVYGW TQS-PLAEYYIVESW YELWKDYG-NTSWTL NNGGAFSAGWNNIGN ALFRKCKKFDSTRTH HQ-LGNISINYNAAF NPGGNSYLCVYGW TQS-PLAEYYIVDSW YELWKDYG-NTSWTL KNGGAFSCGMSNIGN ALFRKCKKFDSTRTH HQ-LGNISINYNAF NPGNSYLCVYGW TOS-PLAEYYIVDSW YELWKDTG-NGTWYL KNGGAFSCGMSNINN ILFRKGKKFDETOTH QQ-LGYTTVYSCNY QPYGNSYLCVYGW TSS-PLVEYYIVDSW YELWKDTG-TTSWTL LGGGKFSCSWSNINN LLFRKGKKFDETOTH QQ-LGTISVANVDVD NPNGNSYLCYYGW TVD-PLVEFYIVDSW YELWKDTG-TTSWTL LGGGKFSCSWSNINN ALFRIGKKWDCTYTW GQ-LGTISVXNYDVD NPNGNSYLCIYGW TRS-PLLEYYIVDSW YELWKDTG-DTEMTI NEGGTFSCKWSNINN ALFRIGKKWDCTYTW (QC-LGTISVXNYDVD QPDGNSYLCIYGW TRS-PLVEYYIVESW YELWKDTG-DTEMTI NEGGTFSCGWSNINN ALFRIGKKFDS-TAM NQ-LGTIXYNYDVD QPDGNSYLCIYGW SRN-PLVEFYIVESW YELWKDTG-DTEMTI NEGGTFSCGWSNINN ALFRIGKKFS-TAM NQ-LGTIXTYDYSTY NPNGNSYLCIYGW STN-PLVEFYIVESW YELWKDTG-NTTMTV TTGGRFSCGWSNINN ALFRIGKKFS-TAM NQ-LGTIXTYDVST NPNGNSYLCIYGW STN-PLVEFYIVESW YEMKDTG-NTTMTV TTGGRFSCGWSNINN ALFRIGKKFNTAM NG-LGTITIYSATY NPNGNSYLCIYGW STN-PLVEFYIVESW YEMKDTG-NTTMTV PTGGRFSCGWSNINN ALFRIGKKFNTAM NG-LGTITIYDVST NPNGNSYLCIYGW STN-PLVEFYIVESW YEMKDTG-NTTMTV PTGGRFSCGWSNINN ALFRIGKKNYTAMCYGW TRS-LLIEXYVVDSW YEMKDTG-NTTMTV PTGGRFSCGWSNINN ALFRIGKKNYTAMCYGW TRS-LLIEXYVVDSW YEMKDTG-NTGATS-TAMCYGW GS-LGTIRITYSATY NPNGNSYLCIYGW STN-PLVEFYIVESW YEMKDTG-NTGATS-TAMCYGWTG-NTTWTW TRAFGGWSTAMCYGW TRS-LLIEXYVVDSW	ourogenum xvlB	YVONYNGNLGAFSYN	EGAGTESMYWOOGVS	NDFVVGLGRST	GS-SNPITYSASY	SASGGSYLAVYGW	VNS-POAEYYVVEAY	108
YDQNYQT-GGQUSYS PSNTGFSVNWNTQ DDFVVGVGWTTGS-SAPINFGGSF SVNSGT-GILSGYGW STN-PLUBTYIMEDN FELMKDVG-NTSWTL NNGGAFSASNNNIGN ALFRKGKKFDSTRTH HQ-LGNISINYNAAF NPGGNSYLCVYGW TQS-PLAEYYIVESW YELWKDYG-NTSWTL NNGGAFSAGWNNIGN ALFRKGKKFDSTRTH HQ-LGNISINYNAAF NPGGNSYLCVYGW TQS-PLAEYYIVDSW YELWKDYG-NTSWTL NNGGAFSCQMSNIGN ALFRKGKKFDSTRTH HQ-LGNISINYNDCNY QPYGNSYLCVYGW TOS-PLAEYYIVDSW YELWKDYG-NGTWYL KNGGAFSCQMSNIGN ALFRKGKKFDETOTH QQ-LGNISINYNDCNY QPNGNSYLCVYGW TSS-PLUEYYIVDSW YELWKDTG-NGTWYL KNGGAFSCQMSNINN ILFRKGKKFDETOTH QQ-LGNISVNYDCNY QPNGNSYLCVYGW TSN-PLUEYYIVDSW YELWKDTG-TTSWTL LGGGKFSCQMSNINN ALFRIGKKWDCTYTW QQ-LGTISVNYDV NPNGNSYLCVYGW TNO-PLUEYYIVDSW YELWKDTG-DTEMTI NEGGTFSCQMSNINN ALFRIGKKFDCTYTY KE-LGNISVKYGVDY QPDGNSYMCVYGW TNO-PLUEYYIVESW YELWKDTG-DTEMTI NEGGTFSCQMSNINN ALFRIGKKFS-TAM QQ-LGTISVKYGVDY QPDGNSYMCVYGW TNO-PLUEFYIVESW YELWKDTG-NTTMTV DTGGRFSCQWSNINN ALFRIGKKFS-TAM QQ-LGTISVKTYSATY NPNGNSYMCVYGW STN-PLUEFYIVESW YEMWDTG-NTTMTV TYGGRFSCQWSNINN ALFRIGKKFNTAM QQ-LGTIRTYSATY NPNGNSYLCIYGW STN-PLUEFYIVESW YEMWDTG-NTTMTV TYGGRFSCQWSNINN ALFRIGKKFNTAM VYGWGNNSYLCIYGW STN-PLUEFYIVESW YEMWDTG-NTTMTV STAGGSFTCSWSNINN ALFRIGKKFNTAM VYGWGNNSYLCIYGW STN-PLUEFYIVESW YEMWDTG-NTTMTV STAGGSFTCSWSNINN ALFRIGKKNNTAW YKAFGNILTYDVEY TYBGNSYMCVYGW TNA-PLUEYYUESW YEMWDTG-NTTMTV STAGGNSLATVYGW TNSPLLIEYYVUDSW	coccus sp S-2 xyl-CS2	YVQNYNGNVANFEYS	QYDGTFSVNWNGN	TDFVCGLGWTV	GT-GRTITYSGSY	NPGYSG-SYQAIYGW	TGGGSLSEYYVIDNY	108
FELWKDYG-NTSWIL NNGGAFSASWNNIGN ALFRKGKKFDSTRTH HQ-LGNISINYNAAF NPGGNSYLCVYGW TQS-PLARYYIVESW YELWKDYG-NTSWIL NNGGAFSAGWNNIGN ALFRKGKKFDSTRTH HQ-LGNISINYNASF NPGGNSYLCVYGW TOS-PLARYYIVDSW YELWKDYG-NTSWIL NNGGAFSCGWSNIGN ALFRKGKKFDSTRTH HQ-LGNISINYNASF NPGGNSYLCVYGW TSS-PLVEYYIVDSW YELWKDYG-NTSWIL KNGGAFSCGWSNIGN ALFRKGKKFDTTH DQ-LGTISVNYGNSYLCVYGW TSS-PLVEYYIVDSW YELWKDGG-GTFSAGWSNINN ILFRKGKKFDETOTH QQ-LGNISINYGATY NPNGNSYLCYYGW TNN-PLVEYYIVDSW YELWKDGG-TTSWIL LGGGKFSCGWSNINN ALFRIGKKWNCQYEW WE-LGTVLVNYDVDY NPNGNSYLCIYGW TNN-PLVEYYIVDSW YELWKDGG-TTSWIL NGGTFSCRNSNINN ALFRIGKKWNCGYEW WE-LGTVLVNYDVDY RPNGNSYLCIYGW TRN-PLVEYYIVDSW YELWKDGG-DTEWTI NEGGTFSCRNSNINN ALFRIGKKWNCGYEW WG-LGTISVXYVDY RPNGNSYLCIYGW SRN-PLVEFYIVESW YELWKDTG-NTTMTV DTGGRFSCGWSNINN ALFRIGKKFSTAW NQ-LGTIKITYSATY NPNGNSYLCIYGW SRN-PLVEFYIVESW YELWKDTG-NTTMTV YTGGRFSCGWSNINN ALFRIGKKFSTAW NQ-LGTIKITYSATY NPNGNSYLCIYGW SRN-PLVEFYIVESW YELWMONGGQASKN PGAGSFTCSWSNINN ALFRIGKKFSTAW NG-LGTIKITYSATY NPNGNSYLCIYGW SRN-PLNEYYIVEGW YERWMONGGQASKN PGAGSFTCSWSNINN ALFRIGKKYDSOKKN YKAFGNIVLITYDVEY TPRGNSYLCIYGW TRN-PLMEYYIVEGW YERWMONGGQASKN PGAGSFTCSWSNINN ALFRIGKKNJDSOKKN YKAFGNIVLITYDVEY TPRGNSYLCIYGW TRN-PLMEYYIVEGW YERWMOLVGELEVRE LKHVWSHRTYSLCDL SCSTVLDSNS	sei xyl2	YDQNYQT-GGQVSYS	PSNTGFSVNWNTQ	DDFVVGVGWTT	GS-SAPINFGGSF	SVNSGT-GLLSVYGW	STN-PLVEYYIMEDN	133
YELWKDYG-NTSMTL NNGGAFSAGWNNIGN ALFRKGKKFDSTRTH HQ-LGNISINYNASF NPGGNSYLCVYGW TOS-PLARYIVUDSW YELWKDYG-NTSMTL KNGGAFSCQMSNIGN ALFRKGKKFDDTQTY KQ-LGNISYNYDCNY QPYGNSYLCVYGW TSS-PLVEYYIVDSW YELWKDYG-NGTWYL KNGGAFSCEWSNINN ILFRKGKKFDDTHYTY KQ-LGNISVNYDCNY QPNGNSYLGVYGW TSN-PLVEYYINESW YEFWKDSGGSGRTL NSGGTFSAQMSNNNN ILFRKGKKFDSTOTH QQ-LGNISVNYGAY NPNGNSYLTVYGW TVD-PLVEYYIVESW YELWKDYG-TTSMTL LGGGKFSCNRSNINN CLFRIGKKWNCQYEW WE-LGTVLVNYDVDY RPNGNSYLCTYGW TRN-PLVEYYIVESW YELWKDG-DTEMTI NEGGTFSCRRSNINN ALFRIGKKWDCTKTY KE-LGNISVKYGVDY QPDGNSYMCVYGW TRN-PLVEYYIVESW YELWKDG-DTEMTI NEGGTFSCRRSNINN ALFRIGKKFSTAM NQ-LGTVKTTYSATY NPNGNSYLCTYGW SRN-PLVEYYIVESW YELWKDTG-NTTMTV DTGGRFSCQWSNINN ALFRIGKKYSTAM NQ-LGTVKTTYSATY NPNGNSYLCTYGW SRN-PLVEFYIVESW YELWKDTG-NTTMTV YTGGRFSCQWSNINN ALFRIGKKYNQNW QS-LGTINITYSATY NPNGNSYLCTYGW SRN-PLVEFYIVESW YEMWNDNGOGQASYNN PGAGSFTCSMSNINN ALFRIGKKYNQNW QS-LGTINITYSATY NPNGNSYLCTYGW TRN-PLMEYYIVEGW YERWMDDLVGELEVRE LKHVMSHRTYSLCDL SCSTVLDSNSATVYGW TRSPLLIEYYVVDSW	ilus xylA(1)	FELWKDYG-NTSMTL		ALFRKGKKFDSTKTH	HQ-LGNISINYNAAF	NPGGNSYLCVYGW	TOS-PLAEYYIVESW	
YELWKDYG-NTSMTL KNGGAFSCQMSNIGN ALFRKGKKFNDTQTY KQ-LGNISVNYDCNY QPYGNSYLCYYGW TSS-PLVEYYIDSW FEYWRDG-NGTWYL KNGGAFSCEWSNINN ILFRKGFKYDETKTH DQ-LGYITYTYSCNY QPNGNSYLGYYGW TSN-PLVEYYIESW YEFWKDSGGSGSTU NSGGTFSAQMSNNNN ILFRKGFKFDETKTH DQ-LGNMSINYDDYN NPNGNSYLGYYGW TYN-PLVEYYIDSSW YELWKDTG-TSSTWIL LGGGKFSCRWSNINN ALFRIGKKWDCTFTW QQ-LGTISVAYNVDY RPNGNSYLCIYGW TRN-PLVEYYIVESW YELWKDTG-DTEMTI NEGGTFSCRWSNINN ALFRAGKKFDCTKTY KG-LGNISVKYGVDY QPDGNSYMCYYGW TRS-PLIEYYIVDSW YELWKDTG-NTTMTV DTGGRFSCQWSNINN ALFRAGKKFST-TRW NQ-LGTVKTTYSATY NPNGNSYLCIYGW SRN-PLVEFYIVESW YELWKDTG-NTTMTV YTGGRFSCQWSNINN ALFRAGKKFS-TRW QS-LGTINITYSATY NPNGNSYLCIYGW SRN-PLVEFYIVESW YEMWNDNGGGASKN PGAGSFTCSWSNINN ALFRAGKKYNOWW QS-LGTINITYSDVEY TPRGNSYRCYYGW TRN-PLMEYYIVEGW YEMWNDNGGGASKN PGAGSFTCSWSNINN ALFRAGKKYNOWW SS-LGTINITYSDVEY TPRGNSYRCYYGW TRN-PLMEYYIVEGW YERWNDLVGELEVRE LKHVMSHRTYSLCDL SCSTVLDSNSFFSLGKGWQAIS SRQGVGATVYGW TRSPLLIEYYVVDSW	ilus xylA(2)	YELWKDYG-NTSMTL	_	ALFRKGKKFDSTRTH	HQ-LGNISINYNASF	NPGGNSYLCVYGW	TOS-PLAEYYIVDSW	127
FEYWKUTG-NGTWVL KOGGAFSCEWSNINN ILFRKGFKYDETKTH DO-LGYTTVTYSCNY QPNGNSYLGGYYGW TSN-PLVEFYILESW YEFWKDGGSGSMTL NSGGFFSAQMSNVNN ILFRKGFKFDETQTH QQ-LGYTRYDATY NPNGNSYLTVYGW TVD-PLVEFYIVDSW YELWKDTG-TISMIL LGGGKFSCSWSNINN CLFRICKKWNCOYEW WE-LGTVLVYDVDV NNGNSSYLCIYGW TRN-PLVEYYIVDSW YELWKDTG-TISMIL LGGGKFSCSWSNINN ALFRIGKKFDCTKTW QQ-LGTISVAXNVDY RPNGNSYMCVYGW TRS-PLIEYYIVDSW YELWKDTG-DTEMTI NEGGTFSCCWSNINN ALFRIGKKFS-TAW NQ-LGTVKTTYSATY NPNGNSYMCVYGW TID-PLVEFYIVESW YELWKDTG-NTTMTV DTGGRFSCOWSNINN ALFRIGKKFS-TAW NQ-LGTVKTTYSATY NPNGNSYLCIYGW STN-PLVEFYIVESW YELWKDTG-NTTMTV TYGGRFSCOWSNINN ALFRIGKKYNOWW QS-LGTIRITYSATY NPNGNSYLCIYGW STN-PLVEFYIVESW YELWKDTG-NTTMTV PGGRFSCOWSNINN ALFRIGKKYNOWW QS-LGTIRITYSATY NPNGNSYLCIYGW STN-PLVEFYIVEGW YELWKDTG-NTTMTV TYGGRFSCOWSNINN ALFRIGKKYNOWW QS-LGTIRITYSATY NPNGNSYLCIYGW TNA-PLWEYYIVEGW YELWKDTG-NTWTV TYGGRFSCOWSNINN ALFRIGKKYNOWW QS-LGTIRITYSATY NPNGNSYLCIYGW TNA-PLWEYYIVEGW YERWKDTG-NTWTV TYGGRFSCOWSNINN ALFRIGKKYNOWW GS-LGTIRITYSATY NPNGNSYLCIYGW TNA-PLWEYYIVEGW YERWKDTG-NTWTV TYGGRFSCOWSNINN ALFRIGKKNSYRCYYGW TNA-PLWEYYIVEGW	cobutylicum XylB	YELWKDYG-NTSMTL		ALFRKGKKFNDTQTY	KO-LGNISVNYDCNY	QPYGNSYLCVYGW	TSS-PLVEYYIVDSW	159
YEFWKDGGGGGSWTL NGGFFSAQNSNVNN ILFRKGKKFDETOTH QQ-IGTMSINYGATY NPNGNSYLTVYGW TVO-PLUEFTIVDSW YELWKDGG-TISMTL LGGGKFSCSWSNINN CLFRIGKKWDCYKTW QQ-LGTISVNVDVN NPNGNSYLCIYGW TRN-PLUEYYLVESW YELWKDGG-TTSMTL LGGGKFSCKWSNINN ALFRACKKFDCTKTY KE-LGNISVKYGVDY QPDGNSYMCVYGW TRS-PLIEYYIVESW XELWKDGG-DTEMTI NEGGTFSCCKWSNINN ALFRACKKFSTAW NQ-LGTISVKYGVDY QPDGNSYMCVYGW TID-PLUEYYIVESW YELWKDTG-NTTWTV DTGGRFSCOWSNINN ALFRACKKFSTAW NQ-LGTIKTYSATY NPNGNSYLCIYGW STN-PLUEFYIVESW YELWKDTG-NTTWTV YTGGRFSCOWSNINN ALFRACKKFNOWW QS-LGTIRITYSMTY NPNGNSYLCIYGW STN-PLUEFYIVESW YEMWATOLVGELEVRE LKHVMSHRTYSLCDL SCSTVLDSNSFFSLGKGWQAIS SRQGVGATVYGW TRSPLLIEYYVUSSW	rmocellum XylB	FEYWKDIG-NGTMVL	KDGGAFSCEWSNINN	ILFRKGFKYDETKTH	DQ-LGYITVTYSCNY	QPNGNSYLGVYGW	TSN-PLVEYYIIESW	129
YLJA YELWKUTG-TYSMTL LGGGKESCUMSNIGN ALFRIGKKWNGQIEW WE-LGTULVNIDVDI NENGNS-TICLIGW INN-ELVELITYESM YLMIL LGGGKESCUMSNIGN ALFRIGKKWDCTKTW QQ-LGTISVARVNDY RPNGNSYMCVYGW TRS-PLIEYYIVDSW YELWKDTG-DTEMTI NEGGTESCKWSNINN ALFRIGKKFDCTKTY KE-LGHISVYKGONS-YMCVYGW TID-PLUSEYIVESW YELWKDTG-NTTMTV DTGGRESCOWSNINN ALFRIGKKFSTAW NQ-LGTVKITYSATY NPNGNSYLCIYGW SNN-PLVEFYIVESW YELWKDTG-NTTMTV YTQGRESCOWSNINN ALFRIGKKYNQNW QS-LGTIRITYSATY NPNGNSYLCIYGW STN-PLVEFYIVESW YEMWNQNGQGASMN PGAGSFTCSWSNIEN FLARMGKNYDSQKKN YKAFGNIVLTYDVEY TPRGNSYMCVYGW TRN-PLMEYYIVEGW YDRWTDLVGELEVRE LKHVMSHRTYSLCDL SCSTVLDSNSMFSLGKGWQAIS SRQGVGATVYGW TRSPLLIEYYVVDSW	is sp 41M-1 xyld	YEFWKDSGGSGSMTI		ILFRKGKKFDETQTH	QQ-IGNMSINYGATY	NPNGNSYLTVYGW	TVD-PLVEFYIVDSW	126
YOI YELWENCE-DIEMIL DEGERESCHWENION ALFREGKRUNDCININ QUIDISVRINVED RENGRAS-INCYGN IN FILE FILESTATORY OF CALLEY ON GARDON GARDON OF THE PROCESS OF XYLO YELWENGE OF THE PROCESS OF XYLO YELWEND YOUR OF THE YELWEND OF THE YOUR OF THE YOUR YELWEST OF YELVE OF THE YOUR OF THE YOUR YELVE OF THE YOUR OF THE YOU OF THE YOUR OF T	ivesiculatum xylA	YELWKOTG-TTSMTL		CLEKIGKKWNCQYEW	ME-LGTVLVNYDVDY	DENCINO - TECH IGH	TAN TELVELLEVEUM	74
sp xyld yelwrdg-nythyt digeresconsninn alfirekres-tha no-letykitysaty nydgnsylciygw san-pluefyivesw yelwrdg-nythyt ytogrescowsninn alfrekrynonw os-letiritysaty npugnsylciygw stn-pluefyivesw yemwuongogasmn peagsfycswsnien flarmcknydsokkn ykafgnivliydvey tprgnsymcvygw tru-plmeyyivegw ydrwydlvgelevre ikhvmshrtyslcdl scstvldsnsmfslgkgwqais srqcgatvygw trspllieyyvudsw	ilvesiculatum xyl	T.W	とうているのというないとのできないというないというないというないというないというないというというというというというというというというというというというというという	ALF KIGKKWDCIKIW	KE-LGNISVAINVDI	MPROCES - TRICK IGN	+ [-	154
YELWKDIG-NITMIV YIQGRESCQMSNINN ALFRIGKKYNQNW QS-LGTIRITYSATY NPNGNSYLCIYGW STN-PLVEFYIVESW YEMWNQNGQGQASMN PGAGSFICSWSNIEN FLARMGKNYDSQKKN YKAFGNIVLIYDVEY IPRGNSYMCVYGW TRN-PLMEYYIVEGW YDRWIDLVGELEVRE LKHVMSHRIYSLCDL SCSTVLDSNSMFSLGKGWQAIS SRQGVGATVYGW TRSPLLIEYYVVDSW		YELWKOTG-NITMIV		ALFRIGKKESTAW	NO-LGTVKITYSATY	NPNGNSYLCIYGW		112
YEMWNQNGQGQASMN PGAGSFTCSWSNIEN FLARMGKNYDSQKKN YKAFGNIVLTYDVEY TPRGNSYMCVYGW TRN-PLMEYYIVEGW 12 YDRWTDLVGELEVRE LKHVMSHRTYSLCDL SCSTVLDSNSMFSLGKGWQAIS SRQGVGATVYGW TRSPLLIEYYVDSW 15		YELWKDIG-NITMIV		ALFRIGKKYNQNW	QS-LGTIRITYSATY	NPNGNSYLCIYGW		125
YDRWIDLVGELEVRE LKHVMSHRTYSLCDL SCSTVLDSNSMFSLGKGWQAIS SRQGVGATVYGW TRSPLLIEYYVVDSW 15	refaciens xylA	YEMWNONGOGOASMI		FLARMGKNYDSQKKN	YKAFGNIVLTYDVEY	TPRGNSYMCVYGW	TRN-PLMEYYIVEGW	129
	pitis xyla	YDRWTDLVGELEVRE		SCSTVLDSNS	MFSLGKGWQAIS	•	TRSPLLIEYYVVDSW	151

B	Figure 1 continued							
GTTREFGINGS——TWESTGGTTDITTIT KINNESIDDHTTTO OFFSVEGRERTS——SWATTTE SHIVMARKSIGNIG GTTREFGINGS——TWESTGGTTDITTIT KINNESIDDHTTTO OFFSVEGRERTS——SWATTTE SHIVMARKSIGNIG GTTREFGINGS—TWESTGGTTDITTIT KINNESID CTOTE OFFSVEGRERTS——SWATTTE SHIVMARRSIGNIG GTTREFGINGS—TWESTGGTTDITTIT KINNESID CTOTE OFFSVEGRERTS——SWATTTE SHIVMARRSIGNIG GTTREFGINGS—WERE TYPGGGTTDITTH KINNESID—THTE OFFSVEGRERTS——SWATTTE SHIVMARRSIGNIG GTTREFGINGS—WERE TYPGGGTTDITTH KINNESID—THTE OFFSVEGRERTS——SWATTTE SHIVMARRSIGNIG GTTREFGINGS—ARE TYPGGGTTDITTH KINNESID—THTE OFFSVEGRERTS——SWATTTE SHIVMARRSIGNIG GTTREFGINGS—ARE TYPGGGTTDITTH KINNESID—THTE OFFSVEGRERTS——SWATTTE SHIVMARRSIGNIG GTTREFGINGS——WERE TYPGGGTTDITTH KINNESID—THTE OFFSVEGRERGS——SWATTTE SHIVMARRSIGNIG GTTREFGINGS——KALE STEDGGTTDITTH KINNESID—THTE OFFSVEGRERGS——SWATTTE SHIVMARRSIGNIG GTTREFGINGS——KALE STEDGGTTDITTH KINNESID—THTE OFFSVEGRERGS——SWATTTE SHIVMARRSIGNIG GTTREFGINGSO—WERE TYPGGGTTDITTH KINNESID—THTE OFFSVEGRERGS——SWATTTE SHIVMARRSIGNIG GTTREFGINGSO—WERE TYPGGGTTDITTH KINNESID—THTE OFFSVEGRERGS——SWATTTE SHIVMARRSIGNIG GTTREFGINGSO—WERE TYPGGGTTDITTH CHANGE TO DESIGNED SHIPS SHIPMARRSIGNIG GTTREFGINGSO—WERE TYPGGGTTDITTH KINNESID—THTE OWNSVEGRERG——SWATTHENANCE CONTRICTION CHIPMARAGET CONTRICTION CHIPMARAGE		1	196 210	- 1	9		256 270	
CITIONS SQLWING STREAM AND STRE	LIS XYLA		TVKSDGGTYDIYTT	RYNAPSIDGDRITFI	QYWSVRQSKRPTG	SNATITE	SNHVNAWKSHGMNLG	183
CTURESSON-WIRE UTSGESSURINGS RINGERS CHETCO OMESSONERSSONESSONESSONESSONESSONESSONESSO	tans xylk	GTYRPTGTYKG	TVKSDGGTYDIYTT	RYNAPSIDGDRITFT	QYWSVRQSKRPTG	SNATITE	TNHVNAWKSHGMNLG	183
GTUNESTAGE——1978 TOOGSTRIANGE HERE OF THE OF OWNSTORERS GENERAL STREET HERE SHARMARDES GENERAL	othermophilus xylA	GTYRATGNYESG	TVNSDGGTYDIYTTM	RYNAPSIDG-TOTFO	QFWSVRQSKRPTG	SNASITE	SNHVNAWRSKGMNLG	187
GTODSSOR—OWG TYTSDGSSYTANGST RINGPEDGE—THIRO OWSVIGNRENSGE———————————————————————————————————	e xyla	GTYRPIGTYKG	TVNSDGGTYDIYTTM	RYNAPSIDG-TQTFP	QYWSVRQSKRPTG	JLILSNA	SNHVNAWPSKGMYLG	187
GTUDSSGATHKG TYTOGOSTYTIAL THROPELOG-THTTO QUENTIVORNERSGE	TTAX WING	GTYDPSSQSQNKG	TVTSDGSSYKIAQST	RINGPSIDG-TRIFO	OYWSVRONKRSSG	WNAS	KTHFDAWASKGMNLG	196
GTTPPSSGA—THG STORGGYTVANGSTELLAND OWNSKIRSGG———————————————————————————————————		GTYDPSSQAQNKG		RINGPSIDG-TRIFQ	OYWSVRONKRSSG	WNAS	KTHFDAWASKGMNLG	202
GYDPSSGA-TOLG TWOOGSTYLEATY WINNESIG-TOTE OWNSYRONGESTOWN ORTHWASKILLING GYNPSSGA-OWG STOTOGGTWANNYS TRYDESIG-TRYEQ OWNSYRONGES		GTYDPSSQATVKG		RINGPSIDG-TOTFO	QYWSVRQNKRSSG	WNASSANW	KTHFDAWAAKGMKLG	202
GTYPPSSGA—QTKG STOTOGGTYNAVAUST RYNDSSIG—TRTO OFWARDORNINGS———————————————————————————————————		GSYDPSSAASHKG		RYNAPSIDG-TOTFE	OFWSVRNPKKAPGG-	SISGIVDV	QCHFDAWKGLGMNLG	175
GTYNBSGG,—OWG SPODGGTYNVANST RYNGESIG—TREG OWGUNGROUGG————SYNN GHRENARRYLLLLG GTYNBSGG,—OWG SPODGGTYNVANST RYNGESIG—TREG OWGUNGROUGGGENGE GTYNBSGG,—OWG SPODGGTYLLAKT RYNGESIG—TREG OWGUNGROUGGGENGE GTYNBSGG,—OWG STOTOGGCTYLLAKT RYNGESIG—TREG OWGUNGROUGGGENGE GTYNBSTGG,—TREG EVTSDGGVYDIYRT RYNGESIG—TREG OWGUNGROUGGGENGE GTYNBSTGG,—TREG EVTSDGGVYDIYRT RYNGESIG—TREG OWGUNGROUGGGENGENGEGGGGGGGGGGGGGGGGGGGGGGGGGGGG	yla	GTYDPSSGATDLG		RVNAPSIDG-TQTFD	OYWSVRQDKRTSG		GCHFDAWARAGLNVN	198
GTYNBESGA,—CYNG SPUDGOCOTINAVST RYNOPSIDG-TREFO OWNSTRANKROGG——SYND OHNEPAMODHERLE GTYNBESGA,—CYNG GTYNBEGSA,—CYNG GTYNBEGSA,—CYNG GTYNBEGSA,—CYNG GTYDBEGG,—SYND ANEPAMODAGALL GTYNBERS,—CSTACL DYNDSSGA,—SKT STOODGSTYTLAGT RYNOPSIGG-TREFO OWNSTRANKROGG—SYND ANEPAMOGACLL GTYNBETGA,—TRLE EVYSDGSVYDIYTO RYNOPSIGG-TREFY OWNSTRANKROGG—SYND ANEPAMOGACLL GTYNBETGA,—TRLE EVYSDGSVYDIYTO RYNOPSIGG-TREFY OWNSTRANKSGG——SYND ANEPAMAGACLL GTYNBETGA,—TRLE EVYSDGSVYDIYTO RYNOPSIGG-TREFY OWNSTRANKROGG—SYND ANEPAMAGACLL GTYNBETGA,—TRLE EVYSDGSVYDIYTO RYNOPSIGG-TREFY OWNSTRANKROGG—SYND ANEPAMAGACLL GTYNBETGA,—TRLE EVYSDGSVYDIYTO RYNOPSIGG-TREFY OWNSTRANKROGG——SYND ANEPAMAGACLL GTYNBETGA,—TRLE EVYSDGSVYDIYTO RYNOPSIGG-TREFY OWNSTRANKROGG——SYND ANEPAMAGACLL GTYNBETGA,—TRLE EVYSDGSVYDIYTO RYNOPSIGG-TREFY OWNSTRANKROGG——SYND ANEPAMAGACLL GTYNBETGA,—TRLE EVYSDGSVYDIYTO RYNOPSIGG-TREFY OWNSTRANKROGG——GTYN RYNOPSIGG-TREFY OWNSTRANKROGG—TREFY OWNSTRANKROGG——TREFY OWNSTRANKROGG—TREFY OWNSTRANKROGG—TREFY OWNSTRANKROGG——TREFY OWNSTRANKROGG—TREFY OWNSTRANKROGG—TREFY OWNSTRANKROGG—TREFY OWNSTRANKROGG——TREFY OWNSTRANKROGG—TREFY OWNSTRANKROGG——TREFY OWNSTRANKROGG—TREFY OWNSTRANKROGGG—TREFY OWNSTRANKROGGG—TREFY OWNSTRANKROGGGNS OWNSTRANKROGGNS OWNSTRANKROGGN		GTYNPSSGAQIKG		RYNQPSIDG-TRTFQ	OYWSVRTOKRVGG	WNAS	ONHENAWSRYGLNLG	206
GTYNBEGGA.—CORG TICLOMACTYTLHEST RYNGPSIDG-TRYED GYMSIRROGGE———TYND GEFDAMERAGENEG GTYNBEGGA.—CORG TICLOMACTYTLHEST RYNGPSIGG-TRYED GYMSIRROGGES——TYND GEFDAMERAGENEG GTYNBEGGA.—TYLE EVYSDGSYTLHEST RYNGPSIGG-TRYET OF GYMSIRROGGES——SYND AMFRAMADGELLIC GTYNBETGA.—TYLE EVYSDGSYTLHYOD RYNGPSIGG-TRYET OYBSYNBRINSGG——SYND AMFRAMADGELLIC GTYNBETGA.—TYLE EVYSDGSYTLHYOD RYNGPSIGG-TRYET OYBSYNBRINSGG——SYND AMFRAMADGELLIC GTYNBETGA.—TYLE EVYSDGSYTLHYOD RYNGPSIGG-TRYET OYBSYNBRANGGGLLIC GTYNBETGA.—THE OYBSYNBRANGGGRNB. GTYNBETGA.—THE OYBSYNBRANGGRANGGRNB.—THE OYBSYNBRANGGRNB.—THE OYBS		GTYNPSSGAQVKG	SFQTDGGTYNVAVST	RYNQPSIDG-TRIFQ	OYWSVROOKRVGG	WNAS	ONHENAWSRYGINLG	206
GYMPSTGA.—YEAR TIOQUESTYTIAKTY RUNDSYSIG—TATTO OFFWAYRORHESG——SWY ANHYMAROGITLE CYTYPSTGA.—YEAR TIOQUESTYTIAKTY RUNDSYSIG—TATTO OFFWAYROHESG——SWY ANHYMAROGITLE CYTYPSTGA.—YEAR EVYDGGYVDIYRTO RUNDSYSIG—TATTO OFFWAYROHESG——SWY ANHYMARAGICLE CYTYPSTGA—THE CYT		GTYNPGSQAQYKG	TFYTDGDQYDIFVST	RYNOPSIDG-TRTFO	OYWSI RKNKRVGG	WNAS	ONHENAWOOHGMPLG	202
GTVPBSTGA.—TKLG EVTSDGSVUITKITQ NUNDSSIGG-TATEY OWSVRANHSSG——SVAN ANHENANAGGLILG GTVPBSTGA.—TKLG EVTSDGSVUITKITQ NUNDSSIGG-TATEY OWSVRANHSSG——SVAN ANHENANAGGLILG GTVPPSTGA.—TKLG EVTSDGSVUITKATA NUNDSSIGG-TATEY OWSVRANKSGG——SVAN ANHENANAGGLILG GTVPPSTGA.—TKLG EVTSDGSVUITKATA NUNDSSIGG-TATEY OWSVRANKSGG——GVATT SHEPRANAKLGADLG GTVPPSTGGA—TKLG SYTDGGSVUITKATA NUNDSSIGG-TATEY OWSVRANKSGG——GTVT SHEPRANAKLGADLG GTVPPSTGGA—TKLG SYTDGGSVUITKATA NUNDSSIGG-TATEY OWSVRANKSGGA—TKLG STATEGATA GHEPRANAKLGADLG GTVPPSTGGA—TKLG SYTDGGSVUITKATA NUNDSSIGG-TATEY OWSVRANKSGGA—TKLG STATEGATA GHEPRANAKLGADLG GTVPPSTGA.—TKLG SYTDGGSVUITKATA NUNDSSIGG-TATEY OWSVRANKSGGA—TKTG OWSVRANKSGGA TKGGGA TKGGG TKGGGA TKGGGA TKGGGA TKGGGA TKGGGA TKGGGA TKGGGA TKGGGA TKGGGA T		GEYNPGNSAOSRG		RVNOPSIEG-TRIFO	OYWAIROOKRNSG	TNAT	GEFFOAWERAGMRMG	207
GTWRPSTGATKLG EVTSDGSVDIYRTQ RUNDESIIG-TATE? OWGSVRANHSSGSWY ANHENAAGGGLIGGTUNG GTWRPSTGATKLG EVTSDGSVDIYRTQ RUNDESIIG-TATE? OWGSVRANHSSGSWY ANHENAAGGGLIGGTUNG GTWRPSTGATKLG EVTSDGSVDIYRTQ RUNDESIIG-TATE? OWGSVRANHSSGSWY ANHENAAGGGLIGGTUNG GTWRPSTGATKLG EVTSDGSVDIYRTQ RUNDESIIG-TATE? OWGSVRANHSSG		GTYDPSSOASKFG	TICODGSTYTIAKTT	RVNOPSIEG-TSTED	OFWSVRONHRSSG	ANAS	AAHFNAWAOAGLKLG	196
GTYMPSTGA-TILLE EVISOSEVUDITATO RNUQPSIIG-TATEY OTWSVRRNHRSSGSUNT ANHENAMAGGGILLG GTYMPSTGA-TILLE EVISOSEVUDITATO RNUQPSIIG-TATEY OTWSVRRNHRSSGSUNT ANHENAMASHGLILLG GTYMPSTGA-TILLE EVISOSEVUDITATO RNUQPSIIG-TATEY OTWSVRRNHRSSGSUNT ANHENAMASHGLILLG GTYMPSTGA-TILLE SVITOSESVUDITATO RNUQPSIIG-TATEY OTWSVRRNHRSGSUNT ANHENAMALGGANG GTYMPSTGA-TILLE SVITOSESVUDITATO RNUGPSIIG-TATEY OTWSVRRNHRSGSUNT ANHENAMALGGANG GTYMPSTGA-TILLE SVITOSESVUDITATO RTHORAD RANGESTG		GTYNPSTGATKLG	EVTSDGSVYDIYRTO	RVNOPSIIG-TATEY	OYWSVRRNHRSSG	TNVS	ANHENAWACOGLITEG	200
GTWNBSTGA-TRLE EVTSGSVUDTRTO RNNOPSIIG-TATEY OYMSVRANHRSSGSUNT ANHFNAMASHGLIGGE GTWNBSTGA-TRLE EVTSDGSVUDIRTO RNNOPSIIG-TATEY OYMSVRANHRSSGSUN AHHFNAMASHGLIGGE GTWNBSTGA-TRLE EVTSDGSVUDIRTO RNNOPSIIG-TATEY OYMSVRANKAGGSUN AHHFNAMASHGLIGGE GTWNBSTGA-TRLE EVTSDGSVUDIRTO RNNOPSIIG-TATEY OYMSVRANKAGG	721 Xy12	GTYNPSTGATKLG	EVTSDGSVYDIYRTO	RVNOPSIIG-TATEY	OYWSVRRNHRSSG	TNVS	ANHENAWACOGLILG	200
GTYNPSTCA-TKLG EVISDGSVIDITRTQ RINNOPSIIG-TATET QUESURANHESSGSINN ANHFNAMASHGILLIG GTYNPSTCA-TKLG EVISDGSVIDITRTQ RINNOPSIIG-TATET QUESURGESCASINN AAHFNAMASHGILLIG GTYNPSTCATKLG EVISDGSVIDITRTQ RINNOPSIIG-TATET QUESURGESCA		GTYNPSTGATKLG	EVISDGSVYDIYRTO	RVNOPSIIG-TATEY	OYWSVRBNHRSSG	TNVS	CIT. ISOCAWANTHNA	6
GTYNPSTGATRLG SUTDGGSUDITRIQ RUNGESIG-GATTY OWNSTRANDAAD—————————————————————————————————		GTYNPSTGATKLG	EVTSDGSVYDIYRTO	RVNOPSIIG-TATEY	OYWSVRRNHRSSG	TNVS	ANHENAWASHGLILIG	167
GUNNEGSGG-TYKE SYTDGSCYDDYRTO RYNOESIGG-TATET OWSVRORRESGG		GTYNPSTGTTKLG	EVISDGSVYDIYRIO	RVNOPSIIG-TATEY	OYWSVRNHAPAA	RSRL	RTTSNAWRNLGLTLG	200
CDYNEGSGGTYKG TYTSGCSVYDIYTA RTNAASIGG-TATFT DYWSVRQNKRVG		GTYNPSTGATRLG	SVTTDGSCYDIYRTO	RVNOPSIEG-TSTEY	OFWSVRONKRSGG	WNAS	AAHFNAWAAAGLOLG	197
GDYNPCHSHTYKG TUYSDGSTYDIYEHO QUNOPSISC-TATEN QUMSTRESS	: xylž	GDYNPGSGGTYKG	TVTSDGSVYDIYTAT	RINAASIOG-TATET	OYWSVRONKRVG	TTVTD	SNHENAWAKLGMNLG	202
GYNEPTGTYKG TVYSDGGTYDIYKTT RYNAPSYBG-TKTFD QYWSVRQSKTG	tum sp 40 xylA	GDYNPGNSMTYKG	TVTSDGSVYDIYEHO	OVNOPSISG-TATEN	OYWSIRONTRSS	TTVTD	ANHFNAWAKLGMNLG	198
GTYRPTGTYKG TVYSDGGTYDIYGTT RVAMPSYEG-TKTEN GYWSVRGKRTG	yces sp xyl	GSYRPTGEYRG	TVYSDGGTYDIYKTT	RYNAPSVEG-TRIFD	OYWSVROSKVIGS	GTITT	GNHFDAWARAGMNLG	215
GTYRPTGTYKG TVYSDGGTYDIYKTT RYNAPSIEG-TKTFD OYWSVRGKRTGGTITT GNHFDAWAAHGMPLG GTYRPTGTYKG TVYSDGGTYDIYKTT RYNAPSIEG-TKTFD OYWSVRGKRTGGTITT GNHFDAWAAHGMPLG GTYRPTGTYKG TVYSDGGTYDIYKTT RYNAPSIEG-TATFT OYWSVRGKRTGGTITT GNHFDAWAAHGMPLG GTYRPTGTYG TVYTDGGTYDIYKTT RYNAPSIEG-TATFT OYWSVRGKRTGGTITT ANHFWAARGMLLG GTYRPTGTEG TVYSDGGTYDIYKTT RYNAPSIEG-TATFT OYWSVRGKRTGGTITT ANHFWAARGMLLG GTYRPAGTEG TVYSDGGTYDIYKTT RYNAPSIEG-TNTFY OYWSVRGKRTGGTITT ANHFWAARGLLGLG GSYNPAGCSGTDYG SFOSDGATYWYRACO RVOOPSIDG-TOYFY OYFSVRRKKGGTSGTITT ANHFWAARGLLGLG GSYNPAGCSGTDYG SFOSDGATYWYRACO RVOOPSIDG-TOYFY OYFSVRRKKGGTSGTITT ANHFWAARGLLGLG GSYNPAGCSGTDYG SFOSDGATYWYRACO RVOOPSIDG-TOYFY OYFSVRRKKGGTYGT OYH-WANABAGCLLG GSYNPAGCSS-ATSLG TVYSDGSTYOVCTDT RYNBPSITG-TOSFY OYFSVRRSTRTGGTTYT ANHFWAARGLGLNG GDYNPCSSATSLG TVYSDGSTYOVCTDT RYNBPSITG-TSFT OYFSVRRSTRTGGTTYT ANHFWAARGLGNS GDYNPCSSATSLG TVYSDGSTYOVCTDT RYNBPSITG-TSFT OYFSVRRSTRTGGTTYT ANHFWAARGLGNS GNYNPCSSATSLG TVYSDGSTYOVCTDT RYNBPSITG-TSFT OYFSVRRSTRTGGTTYT ANHFWAARGLGNS GNYNPCSSATSLG TVYSDGSTYOVCTDT RYNBPSITG-TSFT OYFSVRRSTRTGGTTYT ANHFWAARGLGNS GNYNPCSSATSLG TVYSDGSTYOVCTDT RYNBPSITG-TSFT OYFSVRRSTRTG	yces sp xyll	YRPTG	TVTSDGGTYDVYQTT	RVNAPSVEG-TKTFN	OYWSVROSKRIG	ATISS	GNHFDAWARYGMPLG	204
GTYRPIG	ocyaneoviolaceus xylB	YRPTG	TVYSDGGTYDIYMTT	RYNAPSIEG-TKTFN	OYWSVRONKRIG	TTILD	GNHFDAWAAHGMPLG	205
GTYRPTGTYMG TVITOGGTYDIXKTT RYNARSIEG-TRTPD OYWSVRQSKRTS GTYRPTGTYMG TVITOGGTYDIXKTT RINAPSIEG-TRTPD OYWSVRQSKRTG	osporus T7A svxA	!	TVTSDGGTYDIYKTT	RYNAPSIEG-TKTFD	QYWSVRQSKRTG	GTITS	GNHFDAWARNGMNLG	208
GTYRPTGTRIG TUNS DGGTYDTYKTT RTNAPSIEG-TATET QYMSURGSKRVGGTITA ANHFNAMASHGANLG GNUPPSGGAGTIAG TUNS DGGTYNDTYKTT RTNAPSIEG-TSTEV QYMSURGSKRVGGTITA GNUPDAMASHGANLG GNUPPSGGAGREG GVTADGGIYDTYTST QHOPESILG-TOTEY QYESURSKRGGGGTITA ANHWNEWASKGLNLG GSYNPASCSGTDYG SFQSDGATYNVRRCQ RVQPESILG-TQTEY QYESURSKRGFGQTVST GVHFNAMASHGANLG GSYNPASCSGTDYG SFQSDGATYNVRRCQ RVQPESILG-TQTEY QYESURSKRGFGQSGGTTTF ANHWNEWASKGLNLG GSYNPASCSGTDYG SFQSDGATYNVRRCQ RVQPESILG-TQTEY QYESURSKRGFGQSGGTTTF ANHWNEWASKGLNLG GSYNPASCSGTDYG SFGSGATYQVRCR RTNAPSILG-TQTEY QYESURSTRTSG	×yl	GTYRPIGTYMG	TVTTDGGTYDIYKTT	RYNAPSIEG-TRIFD	QYWSV.RQSKRTS	GTITA	GNHFDAWARHGMHLG	206
GDYDPSTGATELG TVESOGGTYKIYKT RENAPSIEG-TSTEN OYWSVROSGRVG	odae xylllA	GTYRPIGTFMG	TVNSDGGTYDIYKTT	RINAPSIEG-TATFT	QYWSVRQSKRVG	GTITT	ANHFNAWASHGMNLG	207
GENTRASCSGEDORG GVARDGSIYDIYET GYRSINGRENGGTUST GYRFRANKENGG GENTRASCSGEDORG GYRGATYUVRACO RVQOPSIDG-TOTFY QYESVRENKENGG GENTRASCSGEDORG SFOSGGATYUVRACO RVQOPSIDG-TOTFY QYESVRENKENGG GENTRASCSGEDORG SFOSGGATYUVRACO RVQOPSIDG-TOTFY QYESVRENKENGG GENTRASCSGETORG SFOSGGATYUVRACO RVQOPSIDG-TOTFY QYESVRENKENGG GENTRACSS	•	GDYDPSTGATELG	TVESDGGTYKIYKTT	RENAPSIEG-TSTFN	QYWSVRQSGRVG	GTITA	Onhedawanvglqlg	198
GSYNPACSGGTOYG SFOGDGATYWNRCQ RVQDPRIDG-TOTFY QYESVRSPKKGFG QISGTITT ANHENFWASKGLNLG GSYNPASCSGGTOYG SFOGDGATYWNRCQ RVWQPSIDG-TQTFY QYESVRDRKKGFG QISGTITF ANHENFWADRGEDLG GSYSPLOFGGGTOYG STGSGGATYWNRCQ RVWQPSIDG-TQTFY QYESVRDRKKGFG GSYNPASCSGGTOYG STGSGGATYWNRCQ RVWQPSIDG-TGTFT QYESVRDRKGFG		GNYNPSAGAORRG	OVTADGSIYDIYIST	CHNOPSILG-TNTFH	QYWSIRRNKRVGG	TSAL	GVHFNAWRSLGMPLG	193
GSYPENCEGGTOYG SEQSDGATYWORKCO RUNOPPIDG-TOTFY OFFSURNPRKGFG NISCTITF ANHUNEWASKGINLG GSYSPLNCPGGTDEG SFISGGATYWORKCR RINAPSIIG-TOSFY OFFSURPRKGFG N		GSYNPASCSGGTDYG	SFOSDGATYNVRRCQ	RVQQPSIDG-TQTFY	QYFSVRSPKKGFG	QISGILTL	ANHFNFWASKGLNLG	202
GSYSPINGEGIDEG SETGGGATYOVECR RINAPPIIG-TOSED OTESURESTREGE	lulosa xyl	GSYNPASCSGGTDYG	SFOSDGATYNVRRCO	RVNQPSIDG-TQTFY	QYFSVRNPKKGFG	NISGIILE	ANHVNEWASKGLNLG	203
GDYNPCSSATSIG TVYSDGSTYQVCTDT RINEPEITG-TSTFT QYFSVRESTRISGTVTV ANHFNEWAGHGFGNS GDYNPCSSATSIG TVYSDGSTYQVCTDT RINEPEITG-TSTFT QYFSVRESTRISGTVTV ANHFNEWAGHGFGNS GDYNPCSSATSIG TVSDGSTYQVCTDT RINEPEITG-TSTFT QYFSVRGSRTSG	earlae xyl	GSYSPLNCPGGTDEG	SFTSGGATYQVRKCR	RINAPSIIG-TQSFD	QYFSVRTPKKGFG	QDSGSVNF	ADHVQYWASKGLPLG	194
GUNPCSSATSLG TVYSDGSTYQVCTDI KINEPSITG-TSTET QYESVRESTRISGTVTV ANHENFWAHGFGNS GNYPCSS-ATSLG TVYSDGSTYQVCTDI RINEPSITG-TSTET QYESVRESTRISGTVTV ANHENFWAHGFGNS GNYPCSS-ATSLG TVSDGSTYQVCTDI RINEPSITG-TSTET QYESVROKRSSGTVTV ANHENFWANDGFGNS GNYPCSSCATHLG TVSSDGSTYQVCTDI RINGPSIGG-TATEN QYESVRONKRSSG	nı xyıc	GDYNPCSSATSLG	TVYSDGSTYQVCTDT	RINEPSITG-ISTET	QYFSVRESTRISG	TVTV	anhenewaqhgegns	159
GUNPCSSCATULG TYSEDGSTIQUCIDI KINEPEIIG-TSTET QFESVRESERIEGGTVTV ANHENEWANDGFGNS GRINDCSSCATULG TYSEDGSTIQUCCTDI KINEPEIIG-TSTET QFESVRESERIEGGTVTI ANHENEWANDGFGNS GGYNPCTGSGVIDG SLYSEDGSTYQUCCTHI QYNQPSIIG-TTFP QYESVRQURRSSGSVNM QNHENYWAQHGFPNR HNYPAGGTVKG TVISDGATYIIWENI RVNEPSIGG-TATFN QYISVRNSPRISG	Xytt	GDYNPCSSATSLG	TVYSDGSTYQVCTDT	RINEPSITG-TSTFT	OYFSVRESTRISG	VIVI	ANHENEWAQHGEGNS	187
GTYRPTGSGYTOLG SIVEDGSTIOUCTUI KNUGPEIGG-TATEP QYESVRQGSRTSG	Gilata Aytt	GUINFUSSATSLG	TVISDGSTYQVCTDI	KINEPSITG-ISTET	OYFSVRESTRISG	OTOT	ANHENEWAHHGEGNS	186
GUNEVIOLS SIZED SIZED SIZED CHILD GIVE SURVENERS SG	togenda Ayta	GNINECOSCOATNEC	TVSSDGGTTQVCTDT	KVNQPSITG-TSTFT	ا بد	ILAL	ANHENEWANDGEGNS	184
THINTAGOIVY ONHERNAMBLIGHLIG THINTAGOIVY ONHERNAMBLIGHLIG THINTAGOIVY ONHERNAMBLIGHLIG THINTAGOIVY ONHERNAMBLIGHLIG GTYRPIGAYKG SEYADGGTYDIYETL RVNOPSIIG-DATEK QYMSVRQTKRTSGTASV SEHFKWESLGMPMG GTYRPIGAYKG SEYADGGTYDIYETT RVNOPSIIG-DATEK QYMSVRTKRTSGTISV SKHFAAMESKGMPLG GTWRPPGGTEKG TITVDGGTYDIYETT RVNOPSIKG-TATEQ QYMSVRTKRTSGTISV SKHFAAMESLGMPMG GTWRPPGGTEKG TITVDGGTYDIYETT RVNOPSIKG-TATEQ QYMSVRTSKRTSGTISV SEHFRAMESLGMNMG GWRPPGGSTEKG TINVDGGTYDIYETT RVNOPSIKG-TATEQ QYMSVRTSKRTS	ccus sp 3-2 xy1-c32	GGINFCIGSGVIQUE	SLISDESSIOVCIAL	OXNOPSI VG-TTTTE	OYFSVRONKRSSG	WNAS	ONHENYWAOHGFPNR	18
GTWRPIGING SFYADGITOLIET NVORSILG-INTER QYWSVRQTRITSGTASV SHERKRWESLGMPMG GTWRPIGTSKG TIVUDGGIYDIYETT RINQPSILG-INTER QYWSVRQTRRTSGTASV SHEPRWESLGMPMG GSWRPPGGTSKG TIVUDGGIYDIYETT RINQPSILG-INTER QYWSVRTSKRTSGTISV SHEPRAWESLGMPMG GTWRPPGGTPKG TIVUDGGIYDIYETT RVNQPSIKG-INTEQ QYWSVRTSKRTSGTISV SHEPRAWESLGMNMG GTWRPPGGSTPKG TIVUDGGIYDIYETT RVNQPSIKG-INTEQ QYWSVRTSKRTSGTISV SHEPRAWESLGMNMG GSWRPPGGSPM TWVDDGGIYDIYUTD RINQPSIDG-INTER QYWSVRTGKKT		DYALDOWNING	c	RVNEPSIQG-TATEN	QYISVRNSPRTSG	VIVI	ONHENAWASLGLHLG	202
GSWRPEGGTEKG TITVOGGIVELT RUNDESIGG-NTTFR QYWSVRRTRISGTISV SKHFAAWESKGAPLG GSWRPEGGTEKG TITVOGGIVETT RUNDESIGG-NTTFR QYWSVRRTRIS		9411	'n	KVNQPSIIG-DATEK	CYMSVROTKRTS	GTASV	SEHFKKWESLGMPMG	199
GTWRPPGAISSU ILLUGITIELE INVORPINGENCE OF ANY CONSTRUCTORS SKHPAMESKMPLG GTWRPPGAISSU ILLUGITIELE INVORPINGE TATEQ QYMSVKRIKKISGTISV TEHFRAMESKMPLG GTWRPPGGTPKG TINVDGGTYQIYETT RYNQPSIKG-TATEQ QYMSVRISKRTSGTISV TEHFRAMESLGMNMG GTWRPPGGSP-MN TMYVDDGQYDVYUD RINQPSING-NTHFK QYMSVRIQKKTGTISV SKHFEAWTSKGLNLG GSWRPPGSNS-MG TINVDGGTYQIYYUD RINQPSIDG-TKTFD QYWSVRIQKKT				KVNQPSIIG-IATFK	OYWSVROTKRTS	ASALD	SAHFRKWESLGMPMG	199
GTWRPEGGITEM TINVOEGIVETI NYOPELATEQ QYMSVRISKRISGTISV TEHRRAMERGARMG GAMPPEGGTEM TINVOEGIVETI NYOPELGETATEQ QYMSVRISKRISGTISV SEHFRAMESLGANMG GSWRPPGGSP-NN TMYVDDGQYDVYUD RINQPSING-NTFR QYMSVRICKTI			TIELIO COCCUENTA	KINGPOIGENITER	OYWSVRKTKRTS	GTISV	SKHFAAWESKGMPLG	232
GSWRPEGSINTOWODGOYOVVID INTOREDIDG-NTWING QYWSVRIGKISGGTISV SEHRAMESLERNMG GSWRPEGS			TINDOCTELIET	RVNQPSIRG-TATED	OYMSVRTSKRTS	GTISV	TEHFKAWERLGMKMG	202
GSWRRPGSNS-MG TINVOGGTYDIYYD RINGESIDG-TITER GLASSKILGANI	A	DV-ISUDGEMSU	THANDOCTION TELL	DINOPOLNG-INIEG	CIWOVKTOKKTO	ASTIS	SEHFRAMESLGMNMG	200
GSWRPPGAAESIG TVTVDGGTYDIYKTT RYEOPSIDG-TYTTD GYWSVRODRFGDGT KEGTISI SKHFDAWEGVGLTLG sp xyld GSWRPPGAESIG TVTVDGGTYDIYKTT RYNOPSIEG-TRTFD GYWSVRORFRTS	:	GSWRPPGSNS-MG		RINORSIDG-PHPPK	OF STANDARD STANDARD	VAVIOR	NAMETAWOEMGLAVG	7 6
sp xyld GSWRPPG-ATSLG TVTIDGATYDIXKTT RVNOPSIEG-TRIFD OYWSVRTSKRIS		GSWRPPGAAESLG		RYEOPSIDG-TRIED	OVWSVB TOTAL	>01>901-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-	SKHE EAWISKGLNLG	7 6 7
GNWRPPG-ATSLG QVIDGGTYDIYRTT RVNQPSIVG-TATFD QYWSVRTSRRTSGTVTV TDHFRAWARGLNLG GDWRPPGND-GEVKG TVSANGNTYDIRKTM RYNQPSLDG-TATFP QYWSVRQTSGSANNQ TNYMKGTIDV TKHFDAWSAAGLDMS GSYHPSNTIT-GTFV TVKCDGGTYDIYTAV RVNAPSIEGTŤFT QYWSVRQSATIQLAV IKPLTLQNATITFTF SNHFDAWKTWTLEAT	sp xylD	GSWRPPG-ATSLG		RVNOPSIEG-TRIFD	OYWSVRTSKRTS	ALALD	TOHFKAWAAKGLNLG	185
GDWRPPGND-GEVKG TVSANGNTYDIRKTM RYNQPSLDG-TATFP QYWSVRQTSGSANNQ TNYMKGTIDV TKHFDAWSAAGLDMS GSYHPSNTIT-GTFV TVKCDGGTYDIYTAV RVNAPSIEGTŤFT QYWSVRQSATIQLAV IKPLTLQNATITFTF SNHFDAWKTWTLEAT		GNWRPPG-ATSLG	QVTIDGGTYDIYRTT	RVNQPSIVG-TATED	QYWSVRTSKRTS	GIVIV	TOHERAWANRGLNLG	198
GSYHPSNIIT-GIFV TVKCDGGTYDIXTAV RVNAPSIEGTİFT QYMSVRQSATIQLAV IKPLTLQNATITFTF SNHFDAWKTMTLEAT	faciens xylA	GDWRPPGND-GEVKG	TVSANGNTYDIRKTM	RYNQPSLDG-TATFP	QYWSVRQTSGSANNQ	- }	TKHFDAWSAAGLDMS	212
	cis xylA	GSYHPSNTIT-GTFV	TVKCDGGTYDIYTAV	RVNAPSIEGTṛFT	QYWSVRQSATIQLAV	IKPLTLONATITETE	SNHFDAWKTMTLEAT	238

11		360 213	213	211	221	227	227	102	577	231	722	233	219	223	223	777	223	241	225	221	240	228	267	295	293	221	216	290	292	182	211	210	208	229	227	228	261	772	268	717	303	274	273	25.5
SYALA SYALALDEGYOS SCISSINTWA— SYALA SHANYOWALEGYOS SCISSINTWA— SHANYOWALEGYOS SCISSINTWA— SHANYOWALEGYOS SCISSINTWA— OHYTOTIVATEGYOS SCISSINTWA— OHYTOTIVATEGYOS SCISSINTWA— OHYTOTIVATEGYOS SCINSITIVATE— OHYTOTIVATEGYOS SCINSITIVATE— OHYTOTIVATEGYOS SCINSITIVATE— OHYTOTIVATEGYOS SCISSITIVATE— OHYTOTIVATEGYOS SCISSITIVATE— OHYTOTIVATEGYOS SCISSITIVATEGYOS SCISSITICATEGYOS SCISSITI		46					; ; ; ; ; ; ; ; ;																									,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,							5 1 3 1 1 2 4 8 1					
SYAIA SYAI	!	345		***************************************							************																																	
SYATA		330											- 14124-1414-141																															
SNWAYQWATEGYQS SGSSNVTVW SNWAYQWATEGYQS SGSSNVTVW SSWAYQVLATEGYQS SGSSNVTVW SSWAYQVLATEGYGS SGRSNVTVW	.00												;					TGGGSTGGGSTNVSF						PGGGNNDBBG	GSGGG		TGGGU	GTSSV									APS	0	,			SSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSS		・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・
s xyla xyl2 xyl2 xyl2 svxA losa xyl losa xyl svxA xyl-CS2 ly cylA cylA sylA cylA cylA cylA cylA	v	SSNVTVW	SGRSNVTVW	SGNANVTVW	TGNAQITVNCP	SGSAOTTVNCF	SGTATITVIAS	SGYARITVADVG	SGSSDIYVQTQ	SGSSDIYVQTQ	SGESDIYVQTH	AGNSNINVOTPA	SGSSS TVS	SGSASITUS	SGSASITVS		SGNANINVS	SGSATVNVGASSDGS	OCCUPATION OF THE PROPERTY OF		SGSSISVS	SGSSNITVGDSGGDN	SGSSTITVSESGSGG	SGSSNVTLGTSGGGN	SGSSNITIGSTSGGG	SGSATTVENTOR	RGSSDITVSEGTGGT	RGSSDITVSEGTSGG	SGFADITVS	AGSASVTIS	AGSASVTISS	TGTASVTVSA	SGNANMKLISG	SGSASQSVSN	NGSANVMINQLMIR-	SGKADVNSMSINIGK			AGSATVNKNEVVQT-	SGSATVNQNDVTGG-	NGOATIYENELTVDG	SCOUNT TONIETICS		
s xylA xyl2 xyl2 svxA losa xyl losa xyl tyl-CS2 xyl-CS2 xyl-S xyl-S sylA sylA sylA	271 285	SNWAYQVMATEGYOS SNWAYOVMATEGYOS	SSWAYQVLATEGYOS	NSWSYQVMATEGYQS	-SHYYOTVATEGYES	-THNYOIVATEGYES				-OHYYQIVATEGYQS		-NHNYMIVATEGYRS	-TMOVOTVAVEGYES	-TMDYQIVAVEGYES	-TMDYQIVAVEGYFS	-TMDYQIVAVEGYFS	-TLDYQIIAVEGYFS	TUNINGIVATEGYYS			SFNYYMIMATEGYOS	H	NHN-YMIMATEGYOS	THD-YMIMATEGYOS	TAN-VATI ATECTOS	-TYDYMIVATEGERS			-THAHOI FATEGYOS	DEN-YOUMAVEAWSG	DEN-YOUNDAVEANSO	NFN-YOVVAVEAWSG	NFN-YOVLAVEGFSG	OMN-YOVVAVEGWGG	-KMYETAETVEGYKS	-KMHETAFNIEGYOS	-KMYEVALVVEGYOS	-NMYEVALTVEGYOS	-KVYEASLNIEGYQS	-LMYEASLTIEGYOS	-NMYEVALNIEGYQS		GTLYEVSINIEGYRS):::
	Figure 1 continued	subtilis xylA circulans xylA	stearothermophilus xylA	lae xyla	cicum xvll	pist xyl	commune xylA	uginosus xylA	bonum xy12	ivus xyl2	olens xyll	sea xylzz	circ cyxa sei xv12(2)	reesei, ALKO2721 Xy12	reesei xyll	zianum xylD	rde xyl	cite cyas	llium sp 40 xvlk	omyces sp xyl	Streptomyces sp xyll		idosporus T7A svxA	ca xyr bnodae xvllla	zae XvlGl	purea xy11	mixtus xyl	orescens cellulosa xyl	hleariae xyl	acni xylc ar xvll		xylB	S-2 xyl-cs2			81					מניא מפ	1		

INTERNATIONAL SEARCH REPORT

Internation Application No PCT/IB 02/03797

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C12N9/24 C12N9/42

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols) IPC 7 C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, MEDLINE, BIOSIS, SEQUENCE SEARCH

Category *	Citation of document, with indication, where appropriate, of the	relevant passages	Relevant to claim No.
 X Y	US 5 306 633 A (SCHUSTER ERWIN 26 April 1994 (1994-04-26) the whole document	7-13,17, 20-23 1-23	
(WO 00 39289 A (SOERENSEN JENS F); DANISCO (DK); SIBBESEN OLE (DK 6 July 2000 (2000-07-06)	7-13,17, 20-23	
Y	page 19, line 13 page 63, line 25 - line 28; cla figure 20; table 14	1-23	
X	US 5 736 384 A (FUKUNAGA NOBUYU 7 April 1998 (1998-04-07) column 3 -column 20; claim 3; f	7-13, 17-23	
X	WO 00 68396 A (XENCOR INC) 16 November 2000 (2000-11-16) examples 2-5	-/	7-13,17, 20,21
X Furt	her documents are listed in the continuation of box C.	Patent family members are listed	in annex.
"A" docume consider earlier of filing of the docume which citation other the docume of the	ent which may throw doubts on priority claim(s) or is cited to establish the publication date of another n or other special reason (as specified) ent referring to an oral disclosure, use, exhibition or	"Y" later document published after the inter- or priority date and not in conflict with cited to understand the principle or the invention "X" document of particular relevance; the cannot be considered novel or cannot involve an inventive step when the document of particular relevance; the cannot be considered to involve an involve an involve and involve an involve and involve an involve and invo	the application but ony underlying the lairned invention be considered to cument is taken alone lairned invention rentive step when the re other such docu- is to a person skilled
	actual completion of the international search	Date of mailing of the international sea	

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tet, (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016 Authorized officer

Stoyanov, B

INTERNATIONAL SEARCH REPORT

PCT/IB 02/03797

0.40===	WALL DOOUNEARS CONCINEDED TO BE DELEVANT	101/18 02/03/9/		
C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT Category • Citation of document, with indication, where appropriate, of the relevant passages		Relevant to claim No.		
Category *	ованов от оодинень, яви виссанов, явее сарроровае, от постои в раззадез			
P,X	WO 01 66711 A (SOERENSEN JENS FRISBAEK; DANISCO (DK); SIBBESEN OLE (DK)) 13 September 2001 (2001-09-13) page 45 -page 46; table 10		7-13,17, 20- 2 3	
	·			
			_	

INTERNATIONAL SEARCH REPORT

Information on patent family members

PCT/IB 02/03797

Patent document cited in search report		Publication date		Patent family member(s)	Publication date
US 5306633	. A	26-04-1994	DE	4226528 A1	17-02-1994
			ΑT	159295 T	15-11-1997
			DE	59307538 D1	20-11-1997
			DK	585617 T3	02-02-1998
			EP	0585617 A2	09-03-1994
			ES	2110035 T3	01-02-1998
			FI	933519 A	12-02-1994
WO 0039289	A	06-07-2000	AU	1676600 A	31-07-2000
	•		BR -	9916507 A	02-10-2001
			CN	1342197 T	27-03-2002
			EP	1141254 A1	10-10-2001
			FR	2788781 A1	28-07-2000
			GB	2362386 A	21-11-2001
			WO	0039289 A2	06-07-2000
			JP	2002533121 T	08-10-2002
US 5736384	Α	07-04-1998	JP	8224081 A	03-09-1996
			CA	2165839 A1	22-06-1996
			JP	2001231585 A	28-08-2001
			JP	2001288687 A	19-10-2001
			JP	2002095470 A	02-04-2002
			US	5888802 A	30-03-1999
			US	5916795 A	29-06-1999
WO 0068396	Α	16-11-2000	AU	5132700 A	21-11-2000
			EP	1179 07 5 A2	13-02-2002
			WO	0068396 A2	16-11-2000
WO 0166711	Α	13-09-2001	AU	4098401 A	17-09-2001
			BR	0108750 A	24-12-2002
			EP	1263941 A1	11-12-2002
			WO	0166711 A1	13-09-2001